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Atrial fibrillation and sudden cardiac death are two burgeoning cardiac disorders caused by 
arrhythmic events in the heart. Patients with atrial fibrillation are at an increased risk of 
severe cardiovascular complications, hospitalisation, thromboembolic events, clinical 
morbidity, and mortality. Premature death resulting from sudden cardiac death is a significant 
cause of cardiovascular mortality, often occurring in patients without apparent high-risk 
conditions and with normal heart functions. The emergence of obesity epidemic in the 
community is implicated in the rising burdens of atrial fibrillation and sudden cardiac death, 
but this has not been well characterised. More recently, the ectopic cardiac fat depot 
“epicardial adipose tissue” is postulated to mediate the pro-arrhythmic sequalae of obesity. In 
this thesis, investigations were undertaken to characterise these relations in a meta-analysis; 
and to evaluate the cardiac electrophysiological and structural substrates due to epicardial fat 
in ovine sheep models of chronic weight gain and weight fluctuations.   
 In chapter 2, a comprehensive systematic review of the literature and a meta-analysis 
were conducted to define the association of the fibrotic biomarker galectin-3 and atrial 
fibrillation. The findings demonstrated significant associations of high serum galectin-3 and 
risk and severity of atrial fibrillation. 
In chapter 3, a comprehensive systematic review of the literature and a meta-analysis 
were conducted to define the clinical associations of epicardial fat and atrial fibrillation, 
arrhythmia progression, recurrent atrial fibrillation following curative catheter ablation, and 
post-operative atrial fibrillation after cardiac surgery. The findings demonstrated significant 
associations of increased expansions of total cardiac and peri-atrial epicardial adipose tissue 
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with greater risk of atrial fibrillation; severity of atrial fibrillation; atrial fibrillation 
recurrence post-ablation; and de novo incidence after cardiac surgery.  
Next, the underlying mechanisms were explored in chronic ovine models and 
presented in chapters 4 & 5. The results demonstrated that obesity induces expansion of 
epicardial fat and fibro-fatty replacement of atrial myocytes and deterioration of myocyte 
contractile apparatus, which may drive impairments of atrial electrical properties. Despite 
having comparable epicardial fat quantity with reference controls, weight fluctuation, 
induced similar abnormalities, albeit less severe, with stable obesity, thus highlighting an 
explanation for the increased atrial arrhythmias risks often seen with periodic fluxes in 
weight.  
Chapter 6 reports findings from a systematic review and meta-analysis undertaken to 
define the association between obesity and sudden cardiac death. The pooled analyses 
involving over 1.4 million patients demonstrated that, after correcting for traditional high-risk 
risk factors: underweight body mass index (<18.5 kg.m-2) associates with an increased risk of 
sudden cardiac death; overweight shows no significant association with sudden cardiac death; 
obesity (BMI: ≥30 kg.m-2) predicts an exaggerated risk for sudden cardiac death. Similarly, 
unit increment in body mass index was shown to demonstrate a greater risk for sudden 
cardiac death, further implicating the role of increased adiposity in the risk of sudden cardiac 
death. 
   In chapter 7, the molecular and structural substrates for ventricular arrhythmias that 
lead to sudden cardiac death in a model of chronic obesity are presented. Obesity 
demonstrated two-and-half-fold expanded ventricular epicardial fat depot with a consequent 
extensive and severe fat cell infiltrations; significant reduction in ventricular desmosomal 
cadherin desmoglein-2, which demonstrated significant negative correlation with the degree 
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of fatty infiltration; and induction of diffuse ventricular interstitial fibrosis. The findings 
further demonstrated that obesity results in significant abnormal modulation of fibrotic 
pathways, including an alternative component of the central transforming growth factor-beta 
1 pathway, angiotensin II, endothelin and aldosterone signalling pathways.  
The observations of epicardial fat expansion and subsequent fibro-fatty infiltrations 
are particularly noteworthy. Epicardial fat adds an important extra layer to the stratification 
of patients at risk of atrial fibrillation and sudden cardiac death. Fibro-fatty infiltrates alone 
are sufficient to induce re-entrant tachyarrhythmias, leading to atrial fibrillation and sudden 
cardiac death. Clinical assessment of fibro-fatty infiltrates could help improve sudden cardiac 
death risk profiling of patients in the low-risk communities, who paradoxically have high 
absolute mortality rates. More importantly, the fibro-fatty deposits could form a key element 
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1.1 OBESITY – Scaling an epidemic 
Obesity is a burgeoning condition associated with increased multi-morbid state in affected 
individuals.1 More worryingly, the obesity epidemic is shown to lead to increased public 
health burden and associated social costs to communities.1  
Data looking at trends in weight gain from the 80s through present times have 
consistently shown significant increment in the prevalence of obesity. In a recent Global 
Burden of Disease data, obesity was found among over 107 million children and 603 million 
adults, indicating a prevalence of 5.0% in children and 12.0% in adult population.1 
Conversely, the prevalence of underweight has tremendously decreased globally. According 
to data from the Non-Communicable Disease Risk Factor Collaborators, the global age-
standardized prevalence of underweight decreased from 13.8% in 1975 to 8.8% in 2014, 
highlighting the overall shift in body mass index (BMI), which is defined as weight divided 
by height squared [kg.m-2].2  
Furthermore, future projections of obesity epidemic show increasing disease burden at 
alarming rates. Data from the Australian Department of Health puts yearly increase between 
0.4% and 0.8%, meaning that by 2025, 83% of adult males and 75% of adult females will 
become either overweight or obese.3 Similarly, over a third of children under the age of 20 
years will become overweight or obese.3 Taken together, approximately 7 million additional 
Australians will be impacted by 2025 as compared to 2005 figures.3  
 
1.2 Obesity as a Cardiovascular Risk Determinant 
Although it is known that obese individuals are at increased risk of developing adverse health 
conditions, its impact on cardiovascular health is recently being appreciated. Nonetheless, 
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obesity is shown to be associated with cardiovascular (CV) risk factors, such as diabetes4, 5, 
hypertension5, sleep apnoea6, dyslipidaemia5, and metabolic syndrome7. For example, sleep 
apnoea was reported to be prevalent in 18.9% patients with BMI <25 kg.m-2 rising to 82.85% 
in patients with BMI ≥40 kg.m-2, and in the HypnoLaus study, both overweight (defined as 
BMI: 25 kg.m-2 to 29.9 kg.m-2) and obesity (defined as BMI: ≥30 kg.m-2) independently 
associated with 1.74- to 4-fold increased risk of sleep-disordered breathing in both men and 
women.8 Interestingly, in the same study, adjustment for BMI resulted in marked reduction in 
the association of sleep apnoea with hypertension, type 2 diabetes and metabolic syndrome.8  
When cardiac diseases are investigated, obesity is shown to significantly associate 
with increased risks, incidence, and disease prevalence. The risks of non-arrhythmogenic 
cardiac disease are greater in obese patients compared to normal weight counterparts. Even 
after correcting for advancing age and sex, the cumulative life-time risk of heart failure 
increases with increase in BMI classes, such that it doubles from 9 at BMI <25 kg.m-2 to 19 
at BMI ≥30 kg.m-2.9 This situation is compounded further by evidence implicating obesity 
and overweight in the development of cardiometabolic multimorbid states in affected 
individuals. Using data from 16 prospective cohort studies across Europe and USA, Kivimäki 
et al10 demonstrated that overweight increases the odds of cardiometabolic multimorbidity 
(characterized by type 2 diabetes, coronary artery disease and stroke) to twice those in 
healthy weight groups. In the same study, class I obesity (BMI: 30 to 34.9 kg.m-2) resulted in 
5-fold increased odds of developing multimorbid state, which increased to fifteenfold with 
severe obesity (classes II & III; BMI ≥35 kg.m-2).10  
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1.3 Obesity and Atrial Fibrillation 
1.3.1 Atrial fibrillation – Setting the scene  
Atrial fibrillation (AF) is a rhythm disorder characterized by very rapid, chaotic electrical 
activities in the atria, culminating in accelerated and irregular ventricular activity, and loss of 
atrial mechanical function.11 AF is the most common sustained arrhythmia present in the 
clinical setting, with a wide range of clinical presentations.12-15  
AF is increasingly being recognised as a global clinical conundrum, and according to 
more recent epidemiological data, the occurrence of AF is predicted to surpass traditional 
cardiac conditions like ischaemic heart disease and heart failure.12, 13 Importantly, patients 
with AF have increased risk of significant morbidity, with potentially deleterious outcomes.13 
The disease confers greater risk for stroke and systemic thromboembolism in affected 
patients16, 17, such that a third of stroke events are caused by AF18-20. Interestingly, 
cardiogenic strokes due AF are more severe than other types of strokes; and a significant 
proportion of embolic strokes of unexplained source, termed “ESUS”, are attributed to 
asymptomatic episodes of AF or subclinical AF.18-21 Additionally, there are exaggerated risks 
of all-cause mortality and cardiovascular complications, such as CVD hospitalizations, and 
impairments of quality of life (QOL).22, 23  
 
1.3.2 The Epidemiological Quandary of Atrial Fibrillation 
AF is prevalent in 1% to 4% of the adult population in western countries, such as Australia, 
USA, and the European Economic Area, and is shown to rise above 13% by the 9th decade of 
life.12, 13, 22 According to US population-based figures, the annual prevalence of AF in 2010 
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was estimated at 5.2 million from the 2.3 million reported in the ATRIA study by the end of 
the 20th century.24 Additionally, in an age- and sex-adjusted meta-analysis, AF was found to 
be prevalent among 2.8% of adults.12 Similarly, the global estimates show a growing pattern 
of AF prevalence. The 2010 Global Burden of Disease Study puts the age-adjusted AF 
prevalence rates at 596 per 100,000 males and 373 per 100,000 females, up from 569.5 in 
men and 359.9 in women in 1990, representing a 5% increase.13 Consequently, AF is 
prevalent in staggering 33.5 million adult individuals, which, in fact, compares very well with 
global epidemics like cancers and HIV/AIDS, both, of which, are currently at 32 million and 
36.7 million, respectively.13  
A major contributor to the increased regional and global prevalence of AF is high 
incidence of new disease cases. In the Manitoba Follow-Up Study involving 3,983 
participants, AF developed in 7.5% (299) during 154,131 person-years of observation.25 In 
another study looking at community-based trends in AF incidence, Miyasaka et al22 found 
12.6% relative increase in AF incidence rate over 21 follow-up years, up from the age- and 
sex-adjusted incidence rate of 3.04 new AF cases per 1000 person-years at the end of first 
year to 3.68 by the end of the 21-year follow-up period. These are even higher when patients 
are stratified according to age, with up to 68.9 incident AF cases reported per 1000 persons 
per year by the 10th decade of life.26  
The high lifetime risk of developing AF is another major cause for concern. Previous 
data reported sex-adjusted lifetime risk of AF ≥40 years of age at 25% and was shown to 
remain as high as 16% even after correcting for comorbidities, such as myocardial infarction 
(MI) or congestive heart failure (CHF).27 More recently, modelling data by investigators from 
the Framingham cohort projected a 37% overall lifetime risk of the arrhythmia after 55 
years.28 Moreover, with the increasing risk factors like obesity, this is estimated to be even 
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higher. In fact, the presence of at least one risk factor was associated with 38.4% greater 
lifetime risk of AF compared to 23.4% in the absence of a risk factor.28 Further, with the 
combination of rising ageing population, increasing incidence and high lifetime risks of the 
rhythm disorder, future projections show AF will be prevalent in a significant portion of the 
general population. This was very evident in the 2010 report by Chugh et al13, entailing 5 
million new cases of AF annually. Correspondingly, the US Census Bureau projected AF to 
be prevalent among 15.9 million by 2050, given that the increasing incidence is maintained.13 
Similarly, European-based models have projected 18 million patients to have AF, more than 
doubling the current rate at 8.8 million.29 Most importantly, AF incidence and projection are, 
in most part, to be underestimated because of high rate of subclinical AF, which is rarely 
detected. 
 
1.3.3 Risk Factors for AF 
It is increasingly being accepted that AF is not a disease that occurs in isolation, or the so 
called “lone AF”. It is understood that multiple important clinical conditions, 
electrocardiographic and echocardiographic, and biomarkers predispose to episodes of AF, 
including increasing age, hypertension, heart failure, type II diabetes, valvular heart disease, 
obstructive sleep apnoea. Interestingly, data also show AF symptomatic burden increases 
with increasing number of these concomitant conditions in patients is associated with the 
chronicity of the rhythm disorder. 
 
 




Hypertension (HTN) is a well-established cardiovascular risk factor. HTN is highly 
associated with increased incidence of AF. Indeed, HTN is very prevalent among individuals 
with AF – this was initially demonstrated in a Framingham Heart Disease study over a 
decade ago and is well corroborated by a large body of data till date, ranging from 50% to 
90% of AF patients.28, 30-32 Data show that HTN independently predicts new-onset AF, with 
future risk of AF increasing from 28% to 2.7-fold for every 10 mm Hg of systolic blood 
pressure (BP).31 Independent long-term prediction of incident AF has also been noted for 
upper normal BP’s (defined as systolic BP: 128-138 mm Hg and diastolic BP: ≥80 mm Hg), 
and at 50% and 79% increased risk, respectively.33  
Hypertension is implicated in mechanisms driving AF. Both short- and long-term 
experimental models of hypertension have demonstrated increased inducibility and duration 
of atrial tachycardia and conduction abnormalities.34-36 HTN promotes abnormal atrial 
cardiomyopathy, haemodynamic changes and release of neuro-humoral factors, all of which 
lead to formation of AF substrate. For example, the renin-angiotensin-aldosterone system, 
which is activated in HTN, is a predictor of cardiac arrhythmias.37 Additionally, mechanical 
overload in hypertensive heart disease promotes chronic stretch causing structural 
remodelling of the atria, including myocardial fibrosis, left atrial (LA) hypertrophy, atrial 
inflammation and ion channel remodelling.38 Interestingly, pharmacological control of BP in 
hypertension has shown promise in substrate regression and lower risk of new-onset AF.39  
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1.3.3.2 Obstructive Sleep Apnoea 
Obstructive sleep apnoea (OSA) and central sleep apnoea (CSA) are the most common sleep-
disordered breathing syndromes associated with worsening of health outcomes in adult 
individuals and shown to affect more than a quarter of these subjects globally.6 The 
association of OSA with cardiovascular outcomes is well researched, with data supporting 
more than a triple prevalence rate of heart failure in OSA patients than in non-OSA 
patients.40 Both OSA and CSA are shown to strongly predict AF, demonstrating 2- to 3-fold 
higher risk of developing future AF when compared to healthy cohorts.41, 42 In untreated 
patients, OSA associates with higher recurrence of AF after DC cardioversion43 and catheter 
ablation44 and new-onset post-operative AF.45 Moreover, patients in AF are more likely to 
present with OSA than do those in sinus rhythm.46 Interestingly, treatment of OSA by 
continuous positive airway pressure is associated with reduction in AF recurrence rate and 
post-op AF after cardiac surgery, symptomatic burden and hospitalization.47  
Obstructive sleep apnoea (OSA) is characterized by recurrent episodes of upper 
airway collapse during sleep caused by failure of the neuromuscular system to maintain 
airway patency. These repetitive cycles are what increase susceptibility to AF, wherein they 
lead to oxyhaemoglobin desaturation, sympathetic overdrive and vagal output, and excess 
generation of reactive oxygen species and intracardiac pressures.48 Obstructive disordered 
breathing is associated with enlargement of intra-atrial area, intracardiac electromechanical 
delay, conduction delays, and development of low voltage.49 OSA is also shown to promote 
AF maintenance, as typified by increased prevalence of right atrial rotors.50  
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1.3.3.3 Diabetes Mellitus 
Diabetes mellitus is a well-known cardiovascular risk factor caused by autoimmune-mediated 
reduction of insulin in type 1 DM or insulin insensitivity in type 2 DM (T2DM). Surmounting 
body of evidence shows that diabetes increases the risk of AF, and more than 2-fold 
incidence rate ratios of AF is seen in patients with T2DM.51, 52 In fact, hyperglycaemia and 
elevated glycated haemoglobin A1C are positively correlated with increased mortality, 
recurrence of atrial tachyarrhythmias after catheter ablation53, and AF pre- and post-CABG. 
Data on diabetes-mediated atrial remodelling are very limited. Streptozotocin-induced 
diabetic models show reduced connexin 43 phosphorylation and sinus node conduction 
delay.54, 55 Diabetic rats also display induction of myocardial fibrosis with generation of atrial 
reactive oxygen species, such as advanced glycation end products (AGE).56 Interestingly, 
development of fibrosis was halted in this model via blockade of AGE receptors, indicating 
potential of ROS in diabetic CMP-mediated atrial remodelling.56  
 
1.3.3.4 Heart Failure 
Heart failure (HF) and AF have interesting and complex relationships, often sharing similar 
risk factors and pathophysiological mechanisms. HF independently predicts future AF, 
increases PV reconnections after ablation57 and thus predisposing to recurrent atrial 
arrhythmias58, and AF progression59. AF is more prevalent in HF with preserved ejection 
fraction (HFpEF)60, 61, but the prognostic severity is debatable62. The coexistence of both 
conditions is also noted and reported in more than 30% of patients by several prospective 
studies.59, 63 Notably, incident HF is associated with worsening of outcomes in patients with 
AF, including higher risk of all-cause mortality63, hospitalization, and bleeding. It seems that 
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the substrate for AF in HF is uniquely different from non-HF, often involving myocardial 
fibrosis and distinct remodelling of Ca2+-handling but not increased refractoriness or 
conduction slowing.64, 65   
 
1.3.3.5 Alcohol Excess 
There has always been long suspicion of a link between excess alcohol intake and cardiac 
arrhythmias; however, this has not been thoroughly investigated.66 In 1978, Ettinger et al67 
reported high prevalence of arrhythmias among patients with a history of heave alcohol 
consumption. Interestingly, positive correlation was seen between the months of high 
arrhythmia incidence and months of high occurrence of alcohol-related diseases, thus, leading 
the authors to coin the term “Holiday Heart.”67 During a long-term follow-up of 34,715 
patients (>50 years), heavier drinking defined as >2 standard drinks per day was associated 
with 60% increased hazard of incident AF (HR: 1.60).68 Conflicting evidence exists for the 
association between mild to moderate drinking and AF, with some studies to showing 
significant associations after multivariable adjustment68, while others show no association69. 
At a mechanistic level, conduction disturbances (due to left atrial dilatation and reduction in 
conduction velocity)70, 71 and impaired autonomic tone (reduced respiratory sinus arrhythmia 
after acute alcohol ingestion)72 have been suggested as possible mediators of alcohol induced 
arrhythmogenesis. More recently, data from isolated human and murine atrial myocytes have 
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1.3.3.6 Valvular Heart Disease 
Changes in the heart valves are associated with abnormal remodelling of the myocardial 
walls and shown to predispose to arrhythmia.75-77 Indeed, increased risk of AF is 
demonstrated in patients with valvular diseases, such as mitral stenosis and regurgitation, 
aortic stenosis and regurgitation78, and tricuspid regurgitation79. AF was even suggested as a 
marker of more severe or long-standing mitral stenosis, and, in patients undergoing mitral 
balloon valvuloplasty, the presence of AF was associated with reduced procedural success, 
both short-term and long-term survivals, and event-free survival.80 Moreover, the presence of 
AF has been shown to underlie comorbid valvular disease; coexistence of AF and mitral 
valve disease was recently associated with progression of tricuspid regurgitation and right-
sided heart remodelling, which were both eliminated by surgical ablation of AF.81  
 
1.3.3.7 Coronary Artery Disease 
AF is a common finding reported in patients with coronary artery disease (CAD) and both 
conditions are known to coexist. In fact, up to 40% of AF patients are diagnosed with CAD82, 
83 and 74% have preclinical CAD84. Preclinical CAD is also reported to independently 
promote AF; thus, multivariate adjusted analysis shows independent association between 
coronary artery calcium score (CACS) and AF, with up to 3.2-fold greater hazards.85 The 
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1.3.3.8 Sinus Node Disease 
The frequent occurrence of atrial arrhythmias in the patients with SND is long established, 
often owing to tachycardia-bradycardia syndrome or sick sinus syndrome.87, 88 The incidence 
of AF is 10 times higher in SND patients than in the general population, which equates to 125 
per 1000 person-years. In SND patients requiring pacemaker implantation, new AF diagnosis 
occurs in up to 68%, with permanent AF reaching 15% over the long term. Additionally, sick 
sinus syndrome is associated with 5.75- and 4.25-fold greater hazards of both prevalent and 
incident forms of AF.89 Moreover, bradycardia due to SND is known to complicate AF 
management and is often the indication for pacemakers in 83% of SND patients.89, 90   
There is evidence to suggest that this relation is also bidirectional, with AF predisposing 
to sinus node dysfunction and, subsequently, SND. Both of these conditions share similar 
pathophysiological substrates. In a study by Sanders et al88, the authors demonstrated 
widespread atrial electro-structural abnormalities in SND patients, including left atrial 
enlargement, areas of low voltage and scarring, functional conduction delay, increased right 
atrial effective refractory period and loss of rate adaptation to ERP. Similarly, atrial 
tachyarrhythmias have been shown to cause reversible changes in the atrial tissue 
predisposing to SND.91 In pre-clinical models, SND substrates due to AF have been mapped 
to: prolongation of sinoatrial node recovery time and reductions in intrinsic heart rates 
(induced by >2 weeks of rapid atrial pacing) in dogs92; calcium clock malfunction as typified 
by unresponsiveness to isoproterenol and repression of ryanodine type 2 receptors93. Taken 
together, these data suggest that AF is both a consequence and cause of SND. More 
importantly, sinus node dysfunction can create a self-perpetuating substrate for both SND and 
AF. 
 




1.3.3.9 Chronic Stretch 
The role of chronic stretch in abnormal atrial remodelling is well documented in reports from 
both pre-clinical and clinical studies over the last few decades. One example of chronic atrial 
stretch and volume overload in humans is the presence of an atrial septal defect (ASD) which 
is associated with atrial volume overload, increased atrial pressure and higher vulnerability to 
AF as compared to normal control subjects.94, 95 Electro-anatomical mapping has 
demonstrated that ASD patients display atrial enlargement, an increase in low voltage areas 
suggestive of myocardial and electrical scar, an increase in electrogram fractionation and 
local conduction slowing.94, 95 However, no change or an increase in ERP was observed.94, 95 
Further, mitral stenosis (MS) in patients leads to chronic atrial stretch with atrial enlargement 
and MS patients show a greater propensity for sustained AF without any changes in ERP.96 
Electro- anatomical mapping in MS patients revealed changes comparable to ASD patients.96 
Interestingly, in patients with MS, the atrial remodeling exacerbates greater physiological 
direction-dependent conduction characteristics compared to patients without chronic atrial 
stretch.97 In another study, vulnerability and heterogeneity in ERP and conduction delay 
correlated with left atrial pressure in patients with MS.98 Epicardial mapping of local 
electrograms and activation times in patients with mitral regurgitation and left atrial 
enlargement showed more extensive regions of conduction slowing during pacing and an 
increase in fractionated electrograms in the posterior left atrium.99 Taken together, chronic 
stretch constitutes a major clinical correlate contributing to AF substrate formation. 
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1.3.4  Genetics of AF 
Although AF is a very multifactorial in nature, it has become a common knowledge that 
individuals with the same number of risk factors do not have the same level of risk.28, 30 In 
2004, Fox et al100, in Framingham cohort, demonstrated that AF status in parents was an 
independent predictor of future AF risk in offspring and was more exaggerated in the 
younger cohort; thus, indicating that the high variability in AF susceptibility might have 
some genetic component. Numerous other studies have also looked at the heritability of AF, 
often reporting similar findings.101-105 It is interesting to note that the gene-attributable risk of 
AF tends to be higher in healthy patients with no known heart condition101, 104 and younger 
individuals100, 102, 103. In a population-based national registry study involving over 4 million 
participants, Øyen et al104 showed higher incidence rate ratios (IRR) of AF in patients who 
had familial AF in younger 1st-relatives; IRR of 5.42 patients ≤39 years old with familial AF 
in ≤39-year-old 1st-degree relative versus IRR 3.28 in patients ≤39 years with 1st-degree 
relative 40-59 years of age. More recently, there have also been heightened interests in gene 
variants modifying AF risk, AF substrate and circuits, and catheter ablation outcome, which 
are further explored below. 
Evidence for a gene locus associated with AF was first reported by Brudaga et al106 in 
1997, where they mapped AF susceptibility gene to locus 10 by linkage analysis. Ever since, 
using linkage analysis, different authors have been able to identify gene variants that might 
precipitate heritable AF, such as: gain-of-function (GOF) mutation in potassium (K+) channel 
a-subunit (KCNQ1)107; GOF mutation of sodium (Na+) channel causing conduction 
disturbances and increased excitability (SCN5A)108, 109; natriuretic peptide precursor A 
associated with shortened APD110. Other reports have focused on single candidate genes to 
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see potential AF predisposing mutations. For example, A single-gene association study 
identified AF-associated variant in the slow component of the delayed rectifier K+ current 
(IKs, R14C); with the authors concluding that, though by itself, R14C was insufficient to 
cause AF, it could precipitates higher risk of AF in the presence a “second hit” like 
hypertension.111 Additionally, a heterozygous mutation (E375X) in the KCNA5 gene 
encoding Kv1.5 (IKur) was identified in only AF patients but not in 540 unrelated controls.112 
The LOF mutation, which introduces a premature stop codon in the primary amino acid 
sequence and loss of the S4-S6 voltage sensor, pore-forming region, and C-terminus, 
associated with APD prolongation, early after-depolarisation, and increased vulnerability to 
triggered activity.112 Interestingly, the authors were able to recapitulate the findings in a 
murine model.  
As a legacy of the human genome project, it is now possible to search within a large 
expanse of the entire genome to find regions or loci that might associate with AF. Techniques 
like the genome-wide association studies (GWAS) have allowed the identification of several 
common variants or single-nucleotide polymorphisms (SNP) associated with AF, with the 
added advantage that they do not require multigenerational family cohorts as is the case in 
linkage analysis studies. Using an analysis of 316,515 SNPs in an Icelandic population (550 
AF/AFlut patients and 4,476 patients), Gudbjartsson et al113 identified rs2200733T and 
rs10033464T as AF-susceptibility variants on chromosome 4q25 and showed that for each 
additional copy an individual has, the risk of AF increases by 1.72 and 1.39, respectively. 
Notably, more than 30 AF-risk loci have been identified as of today, including at least 24 loci 
in people of European decent and at least 6 in Japanese populations. 
Determining the mechanisms mediating these putative AF-risk conferring loci has 
remained a major difficult. To address this, Ritchie et al. looked at 33 AF patients and 17 
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controls and showed that the presence of two common variants in the locus of 4q25 
(rs2200733 and rs10033464) determines clinical expressions of rare mutations in the ion 
channels and signalling molecules: SCN5A, NPPA, KCNQ1, KCNA5, and NKX2.5.114 
Similarly, increased inflammation115, disruption of nucleocytoplasmic transport116, non-
pulmonary vein foci117, and calcium handling- and extracellular matrix-receptor pathways118 
have been implicated in the causal link between genetic risk and AF. In summary, the 
discovery of genetic basis for atrial fibrillation has vast refined our understanding of the 
pathogenesis of the arrhythmia, and further characterisation of the associated loci will 
potentially improve the management of AF. 
 
1.3.5 Mechanisms Driving AF – towards an understanding 
of the atrial substrate 
AF is believed to require both an initiating spontaneous electrical activity and a permissive 
substrate for its development and progression.11, 119, 120 The permissive atrial substrate 
consists in an enabling environment for the pathogenesis of AF and is characterised by the 
shortening of atrial refractoriness and re-entrant wavelength or by local conduction 
heterogeneities caused by disruption of electrical interconnections between muscle bundles; 
thus, AF substrate is created by both structural and electrophysiological atrial remodelling.11, 
120  
 
1.3.5.1 Structural Substrate for AF 
The association of atrial structural remodelling with the pathogenesis of AF is well studied 
and has been reproduced in several animal models. Indeed, data from models of mitral-valve 
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regurgitation121, right atrial pacing122, and congestive heart failure (induced by 5 weeks of 
right ventricular pacing)123 have shown that atrial changes promoting AF may range from 
gross tissue structural alterations (e.g. atrial fibrosis, myocyte hypertrophy and necrosis) to 
ultrastructural changes occurring at cellular levels of myocytes, such as accumulating 
glycogen and collagen. Abnormal morphological changes in the atria are also seen in clinical 
models. For example, Frustaci et al124 demonstrated diverse changes in the atria, involving, 
hypertrophy, inflammatory infiltrates with myocyte necrosis, areas of patchy fibrosis and 
myofibrillolysis, in patients with lone AF.  
Structural substrate for AF takes several weeks to months to develop. It is proposed 
that remodelling of atrial structure starts with ultrastructural changes progressing to more 
visible gross structural changes, thus stabilizing AF circuitry.122 Of note, atrial fibrosis, 
myocyte hypertrophy, loss of contractile structures, and atrial inflammation are implicated as 
the most important factors causing structural remodelling. 
 
1.3.5.1.1 The Atrial Fibrotic Story 
Fibrosis is a key element in the formation and perpetuation of AF and is considered as the 
histological hallmark of structural remodelling.64, 123 Induction of atrial fibrosis during 
formation of AF substrate is well reported in animal models. For example, 1 week of 
ventricular tachypacing-induced heart failure (tachycardiomyopathy) in dogs and resulted in 
extensive atrial interstitial fibrosis formation.64 This has since been corroborated by work in 
transgenic mice overexpressing the pro-fibrotic transforming growth factor-beta 1 (TGF-
b1)125; Zucker diabetic fatty rats126; experimental sleep apnoea in rats127; ventricular pacing-
induced congestive heart failure64, 123; chronically instrumented sheep and rat models of 
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hypertension35, 36; and doxorubicin-induced non-ischaemic cardiomyopathy128. Involvement 
of atrial fibrosis in structural remodelling is also seen in human models of AF as well as risk 
factors, such as advanced age129, mitral valve disease121, dilated and hypertrophic 
cardiomyopathy130.  
Interstitial fibrosis contributes to atrial remodelling by altering muscle bundle 
architecture.120, 131 Cardiac muscle cells are exquisitely arranged from end-to-end into 
contractile units of myofibres, which are further arranged into “bundles” of “fibres”. Within 
each myofibre, myocytes are separated by thin layers of endomysial collagen tissue; in 
muscle bundles, myofibres are separated by perimysial fibrous tissue. Consequently, as 
fibrosis amount increases, myofibres may lose myocyte-to-myocyte connections arising from 
increased transverse separations. In a simulation work by Spach and Boineau, it was shown 
that such loss of side-to-side coupling of myocytes or myofibres can cause “non-uniform 
anisotropy”, a discontinuous electrical conduction.132 Interestingly, Lau et al35 found 
significant negative correlation between atrial fibrosis with conduction velocity, and strong 
positive association with conduction heterogeneity index. So far, this has also been 
corroborated by several others demonstrating: significant correlation between increased 
endomysial fibrosis and complexity of fibrillatory conduction pathways and higher incidence 
of epicardial breakthrough; and higher atrial arrhythmia inducibility and longer AF durations 
with atrial fibrotic changes.133, 134  
 
1.3.5.1.2 Myocyte hypertrophy – becoming too big is a bad idea! 
Structural remodelling can also result from increase in myocyte size. Ausma et al135 
demonstrated up to 195% hypertrophy in atrial myocytes following chronic instrumentation 
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of goats by right atrial pacing. This is further demonstrated upon atrial dilatation (produced 
by right atriotomy and constriction of pulmonary artery)136; chronic atrial dilation (AF goats 
induced by 48-h burst pacing)137; in models of CHF; and during hypertension in chronically 
instrumented ovine and rats (produced by One Kidney - One Clip nephrectomy model)35. 
Though the precise contribution of atrial cellular hypertrophy to substrate formation is not 
quite well defined, it is likely to be due to increased conduction pathway in the ensuing 
enlarged myocytes. To this end, Spach et al138 analysed microscopic propagations in two-
dimensional (2D) neonatal and adult cellular models, showing that increased cell size 
contributes to pronounced propagation delays during transverse propagation, and may be 
more important than patterns of gap junction distribution. It is also shown that conduction 
abnormalities maintaining AF circuits can be produced solely by myocyte hypertrophy 
without involvement of myocardial fibrosis.137 
 
1.3.5.1.3 Gap junction remodelling – abnormal myocyte-myocyte 
connectivity 
The heart muscle cells are lined by highly specialized, low-resistance channels, the gap 
junctions, for exchange of ions and small molecular weight (<1.5 kilodalton, kDa) molecules, 
such as adenosine triphosphate (ATP), cyclic-adenosine monophosphate (cAMP), inositol 
1,3,5-trisphosphate (IP3); and thus, allow for intercellular communication between 
neighbouring cardiomyocytes.139 These junctions are formed by head-to-head joining of 
connexon hemichannels, made up of six four-transmembrane-spanning connexin (Cx) 
proteins, of which three are expressed in the atria (Cx40, 43 & 45).140 Changes in quantitative 
expression of connexin proteins, distribution, location or composition have been implicated 
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in connexin-based atrial remodelling.141-143 It should be noted that the evidence behind 
changes in the amount of Cx proteins has been rather conflicting, with some showing 
increased levels while others show reduced expression in AF.141, 144  
 Alteration in connexin proteins and ultimately gap junctions can cause abnormal 
electrical coupling of myocytes leading to conduction disturbances. Cx40 is particularly 
associated with conduction heterogeneity and is shown that partial or complete loss of Cx40 
eliminates anisotropic conduction.145 This suggests that, under conditions causing increased 
expression of Cx40, development of AF substrate will be favoured. Interestingly, 
Polontchouk et al showed significant association between Cx40 with chronic AF, such that 
2.7-fold increased expression of Cx40 was noted in patients with chronic AF compared to 
SR, which was replicated with pacing-induced AF in rats.141 Similarly, inhibition and 
ablation of Cx43 expression significantly decreases electrical coupling and increases 
inducibility of arrhythmias.146 Cx43 can also promote remodelling by altering partner 
connexins and membrane currents.146 
Further, Cx40 and Cx43 proteins and gap junction redistribution on myocytes may 
cause structural remodelling. Concomitant lateralisations of Cx40 and Cx43 have been 
observed in AF patients undergoing Maze procedure, in chronic AF and experimental AF 
model following rapid atrial pacing.141, 144 The involvement of lateral gap junction 
remodelling in AF substrate is likely to be caused by reduced electrical coupling at 
intercalated disks and increased transverse conduction.141 
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1.3.5.1.4 Remodelling of ultrastructural architecture 
Accumulating body of evidence shows that changes at subcellular levels, occurring early on 
before overt structural remodelling (1 to 3 weeks), may contribute to AF pathogenesis.122 For 
example, Ausma et al135 found marked subcellular changes, including loss of myofibrils, 
accumulation of glycogen granules, changes in mitochondrial shape and size, fragmentation 
of sarcoplasmic reticulum, and dispersion of nuclear chromatin, in over 92% of portion 
myocytes in goats with pacing induced AF. It is shown that mitochondria are smaller, greater 
in number (demonstrating elevated mitochondrial fission) and more elongated in chronic 
AF.135 Mitochondrial dysfunction, typified by decreased adenosine diphosphate-stimulated 
respiration supported by palmitoyl-L-carnitine and mitochondrial permeability transition pore 
opening (indicative of increased Ca2+ sensitivity), was recently shown to predict post-
operative AF.147 Furthermore, there have been observations of ultrastructural changes 
involving amyloid deposition; dedifferentiation of myocytes by molecular switch to foetal 
phenotypes, such as re-expression of a-smooth muscle actin, abnormal distribution of titin 
and decrease in cardiotin; and loss of contractile fibres (myolysis) in AF conditions.135, 148 
 
1.3.5.2 Electrophysiological remodelling 
1.3.5.2.1 Abbreviation of action potential duration and refractoriness 
Electrical remodelling leading to shortening of action potential duration (APD) and atrial 
effective refractory period (AERP) are well documented to increase AF vulnerability and 
stability.149, 150 In goat and dog models of chronic AF, arrhythmia vulnerability was 
associated with decreased AERP (~50%; 150 ms to <80 ms), and heterogeneity in AERP 
reported as an independent predictor of AF.149, 151 In clinical data, AF is associated with 
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reduction in rate adaptation to AERP and increased dispersion in refractoriness.152 Similar to 
changes seen with refractoriness, APD is shown to be shorter in AF than in SR in both 
clinical and experimental models.151 Changes in both AERP and APD occur very early on in 
the course of AF (first 3 days), much before the start of structural remodelling, and they are 
likely to precipitate decrease in atrial contractility seen during short AF episodes.149  
 Adaptation of atrial myocytes to rate changes in AF is proposed as a fundamental 
mechanism driving shortening of APD and AERP. This is reflected by modulations of ion 
channels which lead to pro-arrhythmic changes in membrane currents. In a model of heart 
failure induced by ventricular tachypacing for 4 months, there were significant shortening of 
atrial APD at 90% repolarization (APD90, ~40%), APD50 (~60%), AERP; prolongation of the 
transient outward rectifier K+ ionic current (Ito); and decreases in the ultra-rapid delayed 
(IKur), inward rectifier (IK1) and slow-conductance (IKs) current densities; but, no change was 
found for the rapid component of the delayed rectifier current (IKr).153 The involvement of 
late-sodium current (INa-Late) is also reported to impact atrial APD; it was shown to be 
markedly increased in castrated mice and was correlated with AF burden, rate and duration, 
which was ameliorated by inhibition of INa-L with ranolazine, eleclazine or GS967.154 Further, 
the repolarizing K2P3.1 K+ current (IK2P) has been reported to modify atrial APD in chronic 
AF and pAF with advanced left ventricular dysfunction; inhibition of K2P3.1 was reported to 
cause APD prolongation.155  
 
1.3.5.2.2 Complex Fractionated Atrial Electrograms 
Areas of complex fractionated atrial electrograms, known as CFAEs, have attracted much 
enthusiasm in the electrophysiology field as sites that may harbour substrates for perpetuating 
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fibrillatory circuits. Indeed, CFAEs have shown to represent areas of wave collisions, 
inhomogeneous tissue activations, slow conduction, and localised rotors.156-159 In 1994, using 
right atrial (RA) high-density mapping in 25 patients with Wolff-Parkinson-White syndrome, 
Konings et al160 made the seminal observation of fragmented wavefronts in the free wall of 
the RA. In some patients, activation was shown to be highly fragmented by arcs of intra-atrial 
conduction block producing multiple wavelets.160  
These important findings have led to the development of the novel technique of CFAE 
ablation to treat PAF and persistent AF (PerAF). In 2004, Nademanee et al156 demonstrated 
this in human AF (121 patients; 57 PAF and 64 permanent AF, PeAF) as a first-in-man 
modality. The authors defined CFAEs as ≥2 deflections on atrial electrograms (EGMs), and 
atrial EMGs of cycle lengths (CL) ≤120 ms. Using biatrial three-dimensional (3-D) 
electroanatomic mapping, the authors were able characterise AF by the regional distribution 
of AF, namely: 
1. Type I (23 patients) – CFAEs are localised to one area and the rest of the atria have 
organised EGMs. Applied radiofrequency energy eliminated all CFAEs and 
terminated AF. 
2. Type II (less organised, 43 patients) – CFAEs localised to two areas and ablation in 
both areas to terminate AF. 
3. Type III – CFAEs localised in ≥3 areas (83% in interatrial septum) and was 
associated with multiple unsuccessful pharmacological cardioversions. 
With the aid of CARTO 3D map, the investigators observed organisations of tachycardia 
EGMs following CFAE ablation, which ultimately led to elimination of AF.156 Notably, the 
therapy was associated with high success rate at 1-year post-ablation follow up, 
demonstrating 91% freedom from both arrhythmia and long-term complications.156 The 
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findings were further confirmed in subsequent publication by the investigators.161 However, 
the hypes around CFAE ablation for AF treatment have not yielded much success in other 
trials.158, 159, 162, 163  
Accurate characterisation if CFAEs remains a major challenge, an argument 
highlighted by proponents of CFAE-based ablation of AF. It is worth nothing that over 
eleven definitions of CFAEs have been adopted since research into EGM fractionations 
began about 50 years ago. For instance, the deflection threshold was defined as ≥3 
deflections over the mapping area by Lee et al164; ≥2 deflections and/or continuous 
deflections of a prolonged activity perturbing the baseline, and waveform of cycle length 
≤120 ms or shorter by Nademanee et al156; and just as CL of ≤120 ms or shorter than 
coronary sinus in the report by Oral et al158. The variation in software algorithms have also 
been noted. Over the decades, three software have been used in CFAE detection, including 
interval confidence level (ICL), complex fractionated electrogram (CFE) mean, and 
automated programs calculating CFAE percentage.  
 
1.3.5.2.3 Dominant Frequencies 
The concept of there been localised high-frequency sources of triggers for AF was put fort 
more than half a century ago. In 1931, using dog heart preparations, Brams and Katz165 tested 
the concept of the presence of mother waves traveling in circus that would solely explain AF 
and ventricular fibrillations (VF). The authors made an important observation that fibrillatory 
waves continue even after functional and/or anatomical separation the atrial chambers, thus 
highlighting role of local activity in AF.165 Almost 60 years later, Schuessler and 
colleagues166 showed, in canine RA preparation, multiple re-entrant circuits that tended to 
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convert to small, relatively stable and high-frequency dominant activation with increasing 
concentration of acetylcholine treatment. Two subsequent experimental reports further 
confirmed these finding by demonstration of: focus of very short AF CL in the posterior LA 
wall of halothane-anaesthetised dog, which were successfully cryoablated167; and successful 
ablation (62% to 67%) of dominant focus with short CL in the Bachmann’s bundle in sterile 
pericarditis canine model168. Clinical evidence for DFs was initially reported in nine patients 
with PAF, wherein the authors observed dominant focal and rapidly firing activity source that 
associated with AF and was successfully eliminated with RF ablation.  
DF substrate tends to exhibit heterogeneities depending on the type of AF (PAF or 
PerAF). In an acute canine model, Sih et al169 demonstrated shorter mean AFCL in the LA 
than RA, with DF originating from the posterior and medial portion of the LA. In the chronic 
model, the LA-RA AFCL gradient exhibited greater severity and 25% increased 
disorganisation of LA activation, but no change in the RA. The existence of DF gradients has 
been confirmed in multiple preclinical investigations170, 171. Moreover, ablation of sites 
exhibiting left-to-right gradients is associated high long-term ablation success rate.172 
Furthermore, a single DF was identified in 94% acute AF dogs and 57% in PerAF dogs173. 
Also, in human, high DF sites were reported to be higher in the LA-PV junction than in 
coronary sinus (intermediate) and posterior RA (lowest) in PAF, but no difference was 
observed in PerAF174. Using spectral analysis and frequency mapping modalities, Sanders et 
al157 showed that, in patients with PAF, high DF sites are more localised around the PV, 
whereas, in PerAF patients, DFs are more widely distributed. There reports showing that 
combination of DF- and CFAE-based CA ablations results in high success rates, thus 
indicating that DF mapping may revolutionise substrate-based AF ablation.157 Moreover, a 
recent report using the automated CARTOFINDER system and PentaRay recordings, DF and 
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CFAE demonstrated comparable correlations with low voltage zones in predicting focal and 
rotational AF drivers.175 
 
1.3.5.2.4 Conduction Slowing and Conduction Heterogeneity 
Abnormalities of atrial conduction are known to be important for electrical substrate 
formation. One of the first demonstration for abnormal conduction patterns comes from 
periprocedural induction of AF in Wolff-Parkinson-White (WPW) syndrome patients 
undergoing surgery.160 Whereas, homogenous conduction is usually observed in the right 
atrium of WPW patients in sinus rhythm, AF was associated with complex conduction along 
plenty arcs of block.160 In patients with PeAF, rapid repetitive patterns of conduction were 
reported, implying that increasing heterogeneity in conduction can serve as self-perpetuating 
substrate for more chronic forms of AF. Correspondingly, Allesie et al176 performed 
epicardial mapping in 24 patients undergoing cardiac surgery to characterise fibrillatory 
conductions. The authors found more significantly impaired conduction in PerAF compared 
to acute AF, with the former having 6-fold higher lines of blocks than the latter.176 They also 
found electrical dissociation between neighbouring muscle fibres, which were more severe in 
the PVs than in the free wall of the RA.176 In a parallel report by the same authors, they 
demonstrated that these dissociated fibrillatory wavelets are epicardial breakthrough waves. 
The authors concluded that epi-endocardial dissociation and longitudinal dissociation of atrial 
muscle fibres constitute the second most important substrate for PerAF177.  
 In preclinical models, conduction disturbances have also been demonstrated. Earlier 
reported showed both increased and reduced conduction velocities (CVs) following 
tachycardia induced by rapid atrial pacing.167, 178-180 However, in these studies, there was no 
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change in CV heterogeneity (CHI). More recently, impaired conduction has been 
demonstrated in: rat model of hypertension and ageing36; hypertension in chronically 
instrumented ovine model35; ovine models of overweight and short- and long-term obesity181, 
182; goats with short- and long-term AF134. Notably, Verheule et al134 made the important 
finding that presence of endomysial fibrosis, characterised by separation between muscles 
within bundles, in occur more frequently in chronic AF. intriguingly, the goats with chronic 
AF had slower wavefront expansion and more anisotropy during high-resolution optical 
mapping.134 
 
1.3.5.2.5 Sinus Node Dysfunction 
Sinoatrial (SA) node disease (SND) and AF are known to have bidirectional relation. 
Numerous studies show that AF predispose to SA dysfunction and, subsequently, SND. 
Atrial tachyarrhythmias promote left atrial enlargement, areas of low voltage and scarring, 
functional conduction delay, increased right atrial effective refractory period and loss of rate 
adaptation to ERP. Similarly, atrial tachyarrhythmias have been shown to cause reversible 
changes in the atrial tissue predisposing to SND.91 In pre-clinical models, SND substrates due 
to AF have been mapped to: prolongation of sinoatrial node recovery time and reductions in 
intrinsic heart rates (induced by >2 weeks of rapid atrial pacing) in dogs92; calcium clock 
malfunction as typified by unresponsiveness to isoproterenol and repression of ryanodine 
type 2 receptors93. Tachycardia-induced SA node remodelling does not occur very quickly. 
Manios et al183 observed the recovery of AF induced remodelling occurred over 24 hours. In 
a study of patients with paroxysmal and chronic atrial flutter, Sparks et al91 noted that 
prolongation of SA node recovery time reversed in 5 min for paroxysmal flutter. However, 
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even after termination of flutter, reversal of SA node remodelling did not occur till after 3 
weeks.91 Taken together, these data suggest that AF is both a consequence and cause of SND. 
More importantly, sinus node dysfunction can create a self-perpetuating substrate for both 
SND and AF. 
 
1.3.5.2.6 Abnormal calcium-handling and sensing  
As a conceptual framework, excitation-contraction coupling is initiated by the entry of Ca2+ 
into the cells via the L-type Cav1.2 channel during phase 2 of action potential, leading to 
increased subsarcolemmal [Ca2+]i that activates and causes opening of type 2 ryanodine 
receptor (RyR2) that allows for the surge in systolic Ca2+ levels (Figure 1).184, 185 Diastolic 
Ca2+ level is maintained via the activities of the ATP-dependent sarco/endoplasmic reticulum 
Ca2+-ATPase type-2a (SERCA2a)186, Na+/ Ca2+-exchanger (NCX)187, plasmalemmal Ca2+-
ATPase (PMCA)188-190. Interestingly, [Ca2+]i is highly regulated, such that dysfunction in any 
of its regulating arm can lead to a pro-arrhythmic state. Increased [Ca2+]i is associated with 
increased activation of NCX resulting in influx of Na+ (producing transient inward current), 
which leads to afterdepolarisations (known contributors to APD alternans); ion channel 
remodelling; contractile dysfunction. Yeh et al191 reported, in congestive heart failure induced 
by 2 weeks of ventricular tachypacing in dogs, significant increases in atrial diastolic [Ca2+]i, 
[Ca2+]i transient amplitude, and sarcoplasmic reticulum (SR) Ca2+ overload. The authors 
correlated these events with spontaneous Ca2+ transient events and triggered activity, which 
were suppressed by RyR2 or NCX blockade.191  
Abnormal Ca2+ handling can occur as dysfunctions in L-type Ca2+ Channel (Cav1.2, 
LTCC), RyR2, SERCA2a or calsequestrin-2 (CASQ2). RyR2 controls Ca2+-induced Ca2+ 
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release (CICR) from the SR, and RyR2 remodelling is implicated as the most important Ca2+-
handling factor in AF pathogenesis.191-193 In a canine model of CHF, Kubalova et al194 
detected increased sensitivity of RyR2 to luminal [Ca2+]i and reduced receptor content, which 
correlated with increased Ca2+ sparks. This increased open probability of RyR2 has been 
attributed to hyperphosphorylation of the receptor by protein kinase A (PKA) or Ca2+-
Calmodulin-dependent protein kinase II (CaMKII) in human atrial myocytes.193, 195 
Regulation of important interacting partners of RyR2 may impact CICR; for example, 
arrhythmia-promoting mutation has been noted in junctophilin-2 (JPH2), the protein 
responsible for maintaining the junctional membrane complex for ECC; and increased open 
probability of RyR2 in transgenic mice caused by reduced expression of protein phosphatase 
1 (PP1) is also seen.196 Further, luminal Ca2+ [Ca2+]i is tightly regulated by SERCA2a, 
CASQ2 and phospholamban (PLB), such that reduction in SERCA2a is correlated with AF 
persistence.197 Ca2+-handling abnormality involving LTCC is seen as decreased peak ICa-L 
noted in an ageing model of Welsh Mountain sheep198; significantly reduced mRNA 
expression levels in AF patients199; or decreased a1C subunit with consequently increased 
Ca2+ transients in aged spontaneously hypertensive rats200.  
 
1.3.5.3 AF triggers 
Events originating as ectopic or focal discharges and re-entrant circuits are thought to serve 
as initiating mechanisms for AF.11, 119, 120 These can be organized as “hierarchical” 
propagations, wherein the AF drivers are from localized sources, or in an “anarchical” 
fashion, involving firing from multiple non-localised sources.11  
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Ectopic activity is promoted by abnormality in atrial cellular electrophysiology. 
Figure 2 shows an illustration of the normal AP generation, involving 5 phases, AP upstroke 
by the depolarizing current of Na+ currents (INa, phase 0), the initial extrusion of Na+ (phase 
1), plateau phase due to both opening of LTCC and CICR by RyR2 activation (phase 2), 
early repolarization by outward currents (phase 3) and late repolarization by IKACh and IK1 
(phase 4). Abnormal or enhanced automaticity can be caused by the presence of AF-
promoting conditions that cause membrane potentials to become more positive, thus allowing 
for spontaneous AP generation.201 It should be noted that enhanced automaticity is not easily 
demonstrated as a mechanism of AF.  
Afterdepolarisations, including early and delayed afterdepolarisations (EADs & 
DADs), producing triggered activity are thought to be the main drivers of focal arrhythmias. 
EADs are due to mechanisms causing prolongation of AP and are responsible for 
tachyarrhythmias associated with long QT syndrome.202 These mechanisms may occur as 
potentiation of late non-activating Na+ current, INa,L, or reduction in repolarizing K+ currents; 
the ensuing APD prolongation is able to allow recovery of LTCC from Ca2+-mediated 
inactivation leading to Ca2+ influx and AP in phase 2 or 3 (Figure 2).202, 203 DADs are caused 
by mainly Ca2+-handling abnormalities that allow for spontaneous SR Ca2+ leak and diastolic 
SR Ca2+ release events.195 Diastolic SR Ca2+ release leads to cytoplasmic Ca2+ overload that 
activates the electrogenic NCX, which is able to exchange Ca2+ for influx of depolarizing INa 
(1:3 stoichiometry) and trigger AP.204  
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1.3.5.4 Mechanisms Sustaining AF 
Re-entrant mechanisms are currently understood as the main drivers of persistent forms of 
AF. Both functional and structural remodelling contributes to the formation of re-entrant 
circuitry. Several theories have been postulated over the years to explain the functional 
determinants of re-entry, such as: 
1. The circus movement,  
2. Leading circle,  
3. Spiral circus, and  
4. Multiple wavelets hypotheses (Figure 3).11, 120, 205-207  
 
1.3.5.4.1 Anatomical Re-entry 
In circus movement re-entry, re-entry occurs in the presence of a unidirectional block 
wherein an activation travels along the anatomical block or pathway to re-excite a previously 
excited region.208-210 It follows that this mechanism requires full recovery of a previously 
excited tissue before the activation arrives.211  
 
1.3.5.4.2 Functional Re-entry 
The leading-circle concept posits that re-entry is through a central region constantly being 
activated by rotating waves. It was first postulated by Garrey207 in 1924 and experimentally 
demonstrated by Allessie et al208 in 1973 in isolated rabbit left atrial tissue as requiring no 
anatomical obstacle. The dimension of this re-entrant circuit is equivalent to wavelength 
(defined as product of refractory period and conduction velocity) and adapts to the smallest-
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sized loop to maintain re-entry. The short wavelength of the leading-circle means the chance 
of spontaneous termination is low, thus higher likelihood of AF sustenance.  
As a limitation of the leading-circle model, it fails to account for some observations 
made, such as; the anti-arrhythmic effects of Na+-blocking agents which reduce both 
conduction velocity and wavelength212; and the unchanged wavelength seen in some 
experimental settings and in some AF patients213. The spiral-wave model was developed to 
settle this and is initiated when an activation wavefront encounters anatomical obstacle and 
circulates or rotates around it (also termed “Rotor theory”).11, 120, 205 This is best represented 
by the intricate relationship between the source and sink of electrical depolarization, with 
source being a recently activated region and sink, the region beyond that is still refractory.11, 
205 The wavefront curvature increases along the rotating spiral wave from regions with less 
source-sink mismatch to regions with the critical mismatch, often termed the rotor core. 
Interestingly, rotors have both been observed experimentally and in humans. In humans, rotor 
ablation has been associated with high success rates and, as seen in critical examples, leads to 
80% to 95% freedom from AF.214, 215 
 
1.3.5.5 Molecular Mechanism of AF 
While the formation of AF substrate and eventual perpetuation of AF circuits can be 
understood as involving gross structural, electrical and functionals changes, induction of 
cascades of abnormal signalling are also implicated. Data from animal and clinical studies 
have implicated signals from, but not limited to oxidative stress pathway; inflammatory 
pathway; autophagy; mitochondrial dysenergetics; Ca2+-modulating pathways; fibrotic 
signalling; and microRNA (miR) pathway. 
 




1.3.5.5.1 Oxidative Stress 
Oxidative stress, characterized by excess reactive oxygen species (ROS) and reactive 
nitrogen species (RNS), is shown to be higher in patients with AF216, 217, recurrent arrhythmia 
after catheter ablation218, and disease progression and post-operative form of AF219, 220. In 
mice, chronic cardiac overexpression of Rac1 GPase, an activator of nicotinamide adenine 
dinucleotide phosphate hydrogenase (NADPH) oxidase (NOX)-2, results in spontaneous 
development of AF, highlighting role of oxidative stress in atrial substrate formation.221, 222 
Myocardial ROS production tends to show differential temporal and spatial alterations. This 
was demonstrated by 1 weeks of AF in a porcine model; here, both Rac1 levels and NADPH 
oxidase activity were increased in left atrial tissue but no observable difference was seen in 
the right atrium compared to sinus rhythm.223 In the same study, short-term AF was 
associated with higher superoxide (˙O2-) production, with similar results seen in post-
operative AF.223 In contrast, long-term AF in goats224 and permanent AF in humans225 
demonstrated a shift in O2- production from NOX2-NADPH oxidase to uncoupled nitric 
oxide synthase (NOS) and mitochondrial complexes.  
 Mechanistically, the available body of data suggest oxidative stress contribute to AF 
substrate via oxidation and nitrosylation of targets. Indeed, oxidation of a regulatory 
methionine unit in the Ca2+/Calmodulin-dependent kinase II (CaMKII) by increased ROS 
levels has been reported.226 Oxidized CaMKII shows increased activity, with increased 
excitatory phosphorylation of RyR2 on serine residue 2814 leading to greater Ca2+ sparks, 
impaired Ca2+ handling and greater susceptibility to AF in atrial myocytes.227, 228 RyR2 is 
also a target of oxidation during states of oxidative stress and, in atrial myocytes, oxidized 
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RyR2 is significantly increased during chronic AF, with greater open probability.229 
Accordingly, genetic ablation of mitochondrial ROS production in a transgenic mouse model 
of leaky RyR2 was associated with reduced RyR2 oxidation and diastolic SR Ca2+ leak and 
AF induction.229 It is also interesting to note that ROS/RNS can act as signalling molecules 
and activates abnormal myocardial signalling. This is seen with: increase in expression of 
phospho-c-Jun N-terminal kinase 1, MAPK p38 and MMPs following H2O2 stimulation of 
atrial fibroblasts230; and reduction in NF-kB, cell apoptosis, fibrosis and hypertrophy after 
advanced glycation end-products’ blockade with myricitrin in mice with diabetic 
cardiomyopathy231. 
 
1.3.5.5.2 Abnormal Autophagic Events 
The autophagy pathway is a newly implicated molecular pathway in cardiac conditions. 
Physiologically, autophagy serves to protect cells and maintain cellular homeostatic control 
by clearing abnormal cellular structures (abnormal or misfolded proteins, dying 
organelles).232 Disease state ensues when this pathway is inhibited or hyperactivated. Several 
aspects of autophagy have been observed in models of ischaemia, ischaemia/reperfusion 
injury, mitral and tricuspid regurgitation, and hypertrophy, with both protective role and 
detrimental effects noted.233-236 Autophagy has been associated with reduced expression of 
Cx43 and ionic currents, indicating a likely remodelling of electrical coupling of 
myocytes.237, 238 In humans, electron micrograph of RAA samples of patients who went on to 
develop POAF following CABG demonstrated marked autophagosome vesicles but no 
statistically significant difference in fibrosis or inflammation.239 Greater processing of the 
microtubule-associated protein 1B-light chain 3(LC3B)-I to LCB3II, indicating formation of 
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double-membrane autophagosome cellular substructures, has been reported in human AF as 
well as pacing-induced arrhythmia in animal models.237, 240 Moreover, increased 
phosphorylation of AMP-induced protein kinase (AMPK) has been reported in AF, 
highlighting activation of the autophagic process consequent to tachycardia.241 
 
1.3.5.5.3 Inflammatory Signalling  
The infiltration of inflammatory cells and cytokines that mediate inflammatory response in 
myocardial tissue is associated with AF. Both local and systemic inflammation independently 
predict incident AF and recurrence after catheter ablation, cardioversion, and cardiac bypass. 
Inflammation is also implicated in both electrical and structural remodelling.242 Samir et al243, 
in a seminal paper, showed that increased fibrotic remodelling, reduced contractile function 
and abnormal Ca2+ transients in a transgenic mice model with atrial overexpression of tumour 
necrosis factor-alpha (TNF-a). In the same study, programmed stimulation resulted in 
induction of re-entrant atrial arrhythmias in isolated perfused hearts from TNF-a animals 
compared to controls.243 Myeloperoxidase (MPO) is increased in patients with AF244 and, in 
animal studies, ablation of MPO led to reduction of MMP-2 and -9 and fibrosis in mice 
treated with angiotensin II, effects that were rescued upon restoration of MPO245. Activation 
of the NLRP3 inflammasome has also been implicated in the formation of atrial substrate, 
involving myolysis, cardiomyocyte apoptosis, fibrosis, abnormal Ca2+-handling, shortening 
of refractoriness, and increased AF inducibility.246, 247 
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1.3.5.5.4 MicroRNA-mediated Atrial Remodelling 
MicroRNAs (miRNAs) and short non-coding RNA sequences are emerging as very useful 
biomarkers of AF. Circulating levels of miRs have been associated with greater risk of AF 
presence248, incidence248, progression, and recurrence post-catheter ablation249-251. In a cohort 
of 34 patients undergoing on-pump cardiac bypass grafting, higher pre-operative levels of 
miR-483-5p predicted greater incidence of new-onset post-operative AF252. There are even 
observations of altered expressions of miRs in the atrial tissues of AF patients versus AF-free 
individuals, thus underscoring a role for miR in AF substrate formation253, 254. This was 
recently demonstrated in an experimental model, wherein the clustering of miR-23b-3p and 
miR-27b-3p induced atrial fibrosis via activation of TGF-b receptor 3 (TGF-bR3)/SMAD3 
signalling pathway. Additionally, in heart failure after MI model, treatment with miR-21 
blocking agent (KD21) significantly reduced atrial fibrosis and AF induction.255 The 
repression of fibrosis was shown to be mediated by sprouty-1, an inhibitor of the pro-fibrotic 
ERK pathway, and miR-21 levels were negatively correlated with sprouty-1 levels in humans 
with valvular AF.255 Furthermore, miRs have been associated with induction of electrical 
remodelling256, 257 and conduction abnormalities258, 259 in preclinical models. Overexpressions 
of miR-130a and miR-206 have been shown to cause downregulation of connexin-43 with 
subsequent abnormal PR intervals, induction of cardiac arrhythmias, and shortening of 
lifespan.258  
 
1.3.6 AF Association with Adiposity 
The link between obesity and overweight and risk of AF was not evaluated until the turn of 
the 21st Century. There is strong rationale to suggest that obesity may precipitate AF 
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development. Obesity is associated echocardiographic markers of atrial dysfunction and 
shown to associate with atrial enlargement.260 Both AF and obesity are parallel burgeoning 
global conditions, trends that persist even in the wake of declining incidence of traditional 
risk factors. Moreover, obesity can co-segregate with and worsen cardiometabolic risk factors 
that are known to promote the development of arrhythmias, including HTN, T2D, and heart 
failure.1, 4, 7 
In a seminal paper by Wang et al261 in 2004, the authors demonstrated increasing age-
adjusted incidence rates for AF across BMI subgroupings (9.7 per 1000 person-years in BMI 
<25 kg.m-2, 10.7 in BMI 25 to 29.9 kg.m-2, and 14.3 in BMI ≥30 kg.m-2), and after 
adjustment made for CV risk factors and interim MI or CHF, 1-unit increase in BMI was 
associated with 4% greater risk of AF. Also, in the same study, obesity predicted a 52% 
increased risk of AF in males and 46% in females independently of traditional risk factors, 
including MI and CHF, highlighting obesity as important modifiable risk for AF.261 To 
further test the strength of this association, Wong et al262 conducted a meta-analysis by 
pooling multivariable adjusted odds ratios from 51 cohort and case-control studies. Quite 
intriguingly, the authors found 19% to 29% elevated risk of incident AF for every 5-unit 
increase in BMI.262 Additionally, BMI was also associated with recurrence of AF after 
catheter ablation and development of de novo AF following coronary artery surgery.262 
These findings beg the question that obesity might actually underlie 
pathophysiological changes promoting AF. Intriguingly, visceral adiposity has been shown to 
correlate with systemic pro-inflammatory state, worsening of atrial haemodynamics, markers 
of atrial structural remodelling, and neurohumoral system including autonomic tone 
dysregulation, all of which are strongly linked to promoting atrial arrhythmias.260 Similarly, 
there is experimental data suggesting that obesity leads to global biatrial endocardial 
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remodeling which is characterized by LA enlargement, fractionated electrograms, conduction 
abnormalities, diffuse atrial fibrosis.182  
 
1.3.7 Arrhythmogenicity of Epicardial Fat 
There is growing evidence to suggest that the increased risk of AF in obesity may be driven 
by expansion of epicardial adipose tissue (EAT), which is a sequela of increased adiposity 
seen during weight gain.263 Indeed, there has been an explosion of interests in this ectopic 
adipose depot, no less due to its strategic location. Important considerations for 
arrhythmogenic roles of epicardial fat are discussed below. 
 
1.3.7.1 Clinical Link between EAT and AF 
The clinical relation between epicardial fat and AF was first reported by three independent 
cohorts. In the Framingham Heart Study Offspring and Third Generation Cohorts, analysis of 
the pericardial fat by multi-slice computed tomography (MDCT) in 3217 individuals showed 
significant association with prevalent AF.264 This persisted even after correcting for AF risk 
factors, BMI and visceral fat. Interestingly, neither intrathoracic nor visceral abdominal fat 
associated with AF presence.264 In another study, Al Chekakie et al265 demonstrated lager 
volumes of total epicardial fat (quantified by CT) in patients with prevalent AF, which further 
associated with greater persistence of the arrhythmia. Additionally, Batal et al266 evaluated 
the hypothesis whether a more local ectopic fat may be impact AF risk. Using 169 
consecutive patients undergoing CT angiograms, they found that increased peri-atrial 
epicardial fat thickness at the posterior left atrium conferred more than 5-fold greater odds for 
AF.266 The associations have so far been replicated in other cohorts and by other imaging 
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modalities. For instance, Wong et al263 showed by cardiac magnetic resonance infrared scans 
that pericardial fat volumes, but not markers of general adiposity such as body mass index or 
body surface area, were independent predictors of prevalent AF. 
 
1.3.7.2 Characteristic Behaviour of EAT  
The EAT, like commonly found in other adipose tissue, contains not only adipocytes but non-
fat mesenchymal cells, including the resident macrophages, pre-adipocytes, lymphocytes, 
adipose tissue-derived stem cells. The expansion of EAT can be understood as both involving 
the proliferation and the differentiation of pre-adipocytes. Whether both are equally 
responsible for an expanding epicardial fat, or one is the prevailing mechanism of EAT 
accumulation is yet to be determined.  
The activity of EAT is also poorly investigated, including the profile of its secretome, 
their perceived contribution to LA remodeling and paracrine regulations. Recently, one study 
indicated that human EAT has specific regional and anatomic transcriptomic signature, 
depending on whether it is peri-atrial (PA-EAT), ventricular (PV-EAT), or coronary 
(PCA).267 In this study, transcriptomic analyses of EAT and thoracic subcutaneous fat (SAT) 
of 41 patients matched for AF, CAD, and CV risk factors showed up to 2,123 (at false 
discovery rate, FDR, 5) and 2,728 (FDR of 10) genes significantly up-regulated in total EAT 
as compared to SAT, with 400 of these genes commonly shared across the EAT stores.267 
Interestingly, the commonly shared genes were members of the gene families controlling 
extracellular matrix remodeling, inflammation, infection, and thrombosis.267 There was a 
disproportionate expression of these genes in the various depots, with PV EAT having 
overexpression of uncoupling protein 1 (UCP-1); PCA EAT having overexpression of 
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proliferation, O-N glycan biosynthesis, sphingolipid metabolism specific genes; and PA EAT 
specific for myocyte contractile and calcium signalling genes.267 More intriguingly, similar 
number of genes was down-regulated in EAT using SAT as a reference. While these results 
implicate differential gene expression of EAT depots, they raise important questions 
regarding what happens during AF substrate formation. For example, what would the 
behaviour of the secretome of EAT be during obesity or tachycardia/AF? UCP-1-expressing 
adipocytes are shown to be protective, with the characteristic non-shivering thermogenesis. 
AF patients are reported to have reduced expression of UCP-1 mRNA in EAT and UCP-1 is 
negatively correlated with LA dilatation, with the beige adipocyte phenotype (reduced during 
EAT expansion) shown to be an independent predictor of AF.268 Most importantly, if these 
pathways are remodelled in obesity or AF, are they due to EAT adipocytes or the stromal 
components of the adipose tissue? 
Some of these questions were recently investigated by Chilukoti et al269 in a human 
model of AF and an experimental model of rapid atrial pacing (RAP). After a 7-hour long 
pacing of pigs at 600-ms, RAP was shown to alter the expression of 66 genes controlling 
adipogenesis and adipocyte differentiation as shown by their elevated mRNA levels, which 
were confirmed upon 7 days of in vitro differentiation of 3T3-L1 fat cell lines after 7 days.269 
On the other hand, only a fraction of these genes, such as the metabolism-regulating genes 
RETN, IGF-1, HK-2, PYGM, LOX, and NR4A3, were differentially overexpressed in RA 
tissue samples of patients with AF as compared to controls, indicating more metabolic 
adaptation during AF.269 Further characterisation showed significant increase in expression of 
RETN in EAT of AF patients compared to controls, suggesting an induction of inflammatory 
program in fat pad.269 The results also showed that AF might activate a transcriptional 
maladaptation in EAT that favours tissue expandability and lipid accumulation as indicated 
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by increased expressions of NR4A3 in atrial tissue and ANGPTL4 in EAT of AF patients.269 
Noteworthy, these observations are limited by lack of data looking at obese vs non-obese 
models.  
 
1.3.7.3 Inflammation and Epicardial Fat 
Acet et al270 evaluated the neutrophil-lymphocyte ratio (NLR), a highly validated marker of 
systemic inflammatory response, in AF populations and showed a significant correlation with 
epicardial fat thickness (r = 0.66; p<0.001), which was independent of other co-variates 
(p<0.001). In another study, the inflammatory activity of epicardial fat using F-18-
fluorodeoxyglucose (FDG)-PET/CT in patients with AF and in controls was investigated. 
Using the maximal standardised uptake value (SUV) of FDG-PET/CT, the authors observed a 
greater inflammatory activity of EAT in AF patients than in controls (p < 0.001).271 
Additionally, EAT SUV was significantly greater than peripheral subcutaneous adipose tissue 
(SAT) and visceral thoracic fat for patients with AF and controls, with EAT SUV being the 
only independent predictor of AF.271 This lends credence to the postulation of a strong role of 
inflammatory component in epicardial fat-mediated pathogenesis of atrial arrhythmia, more 
so as FDG-PET/CT is reflective of macrophage burden.  
Noteworthy, epicardial fat, as an archetypical visceral adipose tissue, is characterised 
by an intense metabolic activity and functions as an endocrine organ, serving as a source of 
several cytokines and proinflammatory mediators. Accordingly, Mazurek et al272, in an 
earlier publication, demonstrated the presence of tumour necrosis factor-alpha (TNF-α), 
interleukin (IL)-1β and IL-6, and monocyte-chemotactic protein (MCP)-1, respectively, in the 
secretome of EAT from the patients with CAD. Direct release of MCP-1 attests to the 
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contribution of cellular infiltrates to the inflammatory phenotype of EAT. MCP-1 is a 
member of the C-C (gamma, γ) chemokine family of chemoattractants and it induces 
migration and recruitment of monocytes, the precursors of macrophages, in response to 
inflammation.273, 274 In addition to producing pro-inflammatory cytokines, EAT also secretes 
anti-inflammatory markers including adiponectin.275 In AF and obesity, it is plausible to 
speculate that the natural balance between pro- and anti-inflammatory cytokines of EAT 
becomes distorted and tilts in favour of a pro-inflammatory state. Indeed, reduced secretion 
of gelsolin (an anti-inflammatory adipokine) was has been reported in EAT of patients who 
went on to develop post-op AF after CABG.276 In addition to its anti-inflammatory role, 
gelsolin is a negative regulator of the L-type Ca2+ channel, such that its deficiency has been 
associated with increased propensity for AF in a mouse model.276  
Further, there is evidence to suggest involvement of EAT in activation of 
inflammatory cells. In patients with acute coronary syndrome, greater expressions of NOD-
like receptor protein 3 (NLRP3), caspase-1 and pro-IL-1β, thereby indicating induction of 
NLRP3 inflammasome pathway.277 Whether activation of this pathway is involved in 
induction of inflammation during EAT-mediated atrial remodelling remains to be elucidated. 
The lipotoxic nature of the resulting interstitial milieu has huge implications for induction of 
adipose tissue inflammation and a resultant higher propensity for the creation of AF 
substrate.  
 
1.3.7.4 Atrial Myocardial Fibrosis and Epicardial Fat 
The data on involvement of atrial fibrosis in EAT-induced structural remodelling are very 
limiting. Using an ex vivo organo-culture of rat atria with the secretome of EAT and 
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subcutaneous fat, Venteclef et al278 demonstrated marked induction of global and interstitial 
fibrosis in rat atria pre-treated with the secretome of EAT compared to controls but found no 
such observation in SAT-treated atria. This indicates that EAT is also capable of inducing 
fibrosis and a resultant structural remodelling of the atrial myocardium. 
The TGF-b pathway is considered the most important profibrotic pathway, insofar as 
it can occur downstream or independently of the renin-angiotensin-aldosterone system 
(RAAS) activation.125 TGF-b superfamily of proteins represents a distinct clad of proteins 
that act via receptors with serine/threonine kinase properties to elicit a range of functional 
changes, including growth and differentiation. A subfamily of these containing the TGF-bs 
(TGF-b1, 2 &3) and the activins are particularly involved in fibrosis.278 Interestingly, 
observation of abundant secretion of activin-A was made in the secretome of EAT in an ex 
vivo model, which was not the case for subcutaneous fat.278 In the same study, 
supplementation of the organo-culture medium with recombinant activin-A reproduced the 
pro-fibrotic effects of EAT, which was blunted when the atrial tissues where pre-treated with 
activin-A-neutralising antibody.278 This demonstrated that activin-A may mediate the pro-
fibrotic actions of EAT on the atrial myocardium. Additionally, the same authors found 
significant expressions of matrix metalloproteinases (MMPs 1, 2, 3, 8, 9, and 13) in EAT as 
compared to peripheral adipose tissue.278 Importantly, these molecules play key regulatory 
roles on extracellular matrix (ECM) remodelling, including matrix turnover, chamber 
dilatation, and basement membrane components. Increased activity of MMPs is tightly linked 
with heightened collagen fibres deposition, reactivity of fibroblast, and fibroblast-
myofibroblast transition.121  
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1.3.7.5 Fatty Infiltration into the Left Atrium 
Fat cell infiltration is a newly described histological substrate shown to be involved in 
formation of atrial substrate. In a seminal paper, Mahajan et al182 provided an experimental 
demonstration of abundant deposition of fat in the epicardium and intra-atrial fat cell 
infiltration in an ovine sheep model of obesity on histology. Fatty infiltration was more 
significantly seen in the obese sheep compared to the age-matched controls and was shown to 
be more profound in the posterior LA and less in LA appendage, correlating with regions of 
reduced endocardial voltage.182 
Clinical investigations of the phenomenon have been hampered by the limitation in 
available imaging modalities. Nonetheless, with the evolution of the Dark-blood DIR-
prepared Fat-Water-separated sequence MRI imaging method, Tereshchenko et al279 
provided preclinical evidence for fatty infiltration of the atrial septum in the PRIMERI study. 
By evaluating 90 patients with structural heart disease, the authors found that infiltrated intra-
atrial fat area was a significant and an independent predictor of a 10-year risk of AF risk 
based on the ARIC AF risk score (p=0.037).279 Surprisingly, neither BMI nor total EAT area 
significantly predicted higher AF, thus, underscoring intra-myocardial fat in the left atrium as 
an evolving risk factor of pre-clinical AF.279  
Rather than just being a mere histological observation or imaging assessment, 
infiltrated epicardial fat may underlie the formation of AF substrate. EAT adipocytes secrete 
a myriad of cytokines with the ability to alter the functional and structural properties of the 
atrial myocytes. Fatty infiltrates may exaggerate the paracrine or juxtacrine effects of EAT 
secretome atrial myocardium, allowing for a more direct modulating effect on the cardiac 
myocytes.120 Furthermore, fatty infiltration can also allow for closer and somewhat direct 
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cellular crosstalk between fat cells and intramyocardial fibroblasts. Consistent with this, 
Venteclef et al278, in a paper on atrial organo-culture, made an important observation of 
marked myocardial fibrosis in regions with EAT infiltration, with visible fibrotic fibres seen 
the interface between adipose and myocardial tissues. This was further confirmed by 
observations of association between AF and fibrosis of subepicardial fatty infiltrates in 
human and sheep models.280  
Infiltrating epicardial fat may represent a novel and unique structural remodelling of 
the atria, which as noted in prior section plays an important role in the formation of 
permissive substrate for AF. It is well understood that fat acts as insulating tissue to the body 
incapable of conducting heat or electrical impulse.281 Drawing from this premise, the 
presence of fat within the myocardial tissue can constitute local conduction blocks thereby 
leading to disorganization of the conduction waveforms and discontinuity in impulse 
conducting pathways/routes, behaving just like fibrotic fibres.282 Intriguingly, Murthy et al283 
observed a significant and independent correlation between infiltrating fat and P-wave 
fragmentation in patients with paroxysmal AF and those at risk of AF. Abnormal P-wave 
indices are known to predict occurrence of paroxysmal AF. For example, abnormal P-wave 
morphology was independently associated with increased risk of non-sudden cardiac death 
and AF development.284, 285 
 
1.3.7.6 Autonomic Tone Dysfunction and EAT expansion 
Catecholamine excess and neurohumoral cascade activation are amongst the mechanisms 
purported to be responsible for the pathogenesis of AF.64, 166, 286 These mechanisms are tightly 
linked to a dysfunctionality of baseline autonomic tone. Interestingly, epicardial fat is very 
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rich in ganglionated plexi, and thus has triggered an important postulate that it may 
negatively modulate the autonomic ganglia thereby enhancing a dysregulation of the 
autonomic tone which in turn may precipitate the episodes of AF.287 Consistent with this, 
Muhib et al288 reported some novel and intriguing findings from a hospital-based cohort with 
idiopathic hypertrophic cardiomyopathy and AF, showing a significant association between 
lower time-domain measures of heart rate variability (HRV) and the increase in EAT area. 
Additionally, these HRV measures also significantly decreased in patients with prevalent AF 
compared to AF-free controls, a relation that persisted after correcting for confounders.289 In 
another study, both heart rate turbulence (HRT) and HRV parameters were investigated in 
two populations of EAT thickness.290 In the same study, significant correlations between 
depression of these measures of cardiac autonomic functions and higher thickness of 
epicardial fat were noted.290 
HRV and HRT are important and reliable 24-Holter ECG indices that indicate heart 
autonomic balance.289, 291 HRV is an indirect measure of autonomic functions and reflects its 
influence on the sinoatrial node, whereas HRT is an indicator of baroreceptor sensitivity and 
is dampened in patients with reduced baroreceptor-cardiac reflex activity.289, 292 Both HRV 
and HRT have been shown to predict AF and post-operative AF.293-295 It may be possible that 
the secretome of EAT impact  autonomic neurones that make up the GP richly embedded in 
the fat depot. In fact, a new report has implicated cardiac fat pads in abnormal autonomic 
neural remodelling.296 Using canine model of AF, the authors demonstrated differential 
expression levels of long non-coding RNA (lncRNA) molecules involved in regulation of 
neural development, migration, neurodegenerative disorders, between patients with AF and 
SR controls.296 They further showed that these lncRNAs could actually produce pro-
arrhythmic effects, with genetic ablation of TCONS_00032546 shortening the atrial effective 
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refractory period thereby increasing AF vulnerability, whereas silencing of 
TCONS_00026102 prolonging ERP and  prevented AF.296 Thus, it may offer a potential 
mechanism to explain the increased propensity for AF due to epicardial fat expandability.   
 
1.3.7.7 Electrical Remodelling with EAT Expansion 
1.3.7.7.1 AF Triggers 
Events originating as ectopic or focal discharges (involving EADs and DADs) and re-entrant 
circuits are thought to serve as initiating mechanisms for AF. Interestingly, Lin et al297 
showed in an in vitro model of LA myocytes an increased DAD amplitude after co-
incubation with rabbit EAT adipocytes. In the same study, EAT significantly increased the 
incidence of triggered beats induced by isoproterenol, highlighting the importance of focal 
ectopy in EAT-induced arrhythmia.297  
As noted earlier, early afterdepolarizations (EADs) are caused by mechanisms that 
prolong action potential duration (APD), including inhibition or loss of the ultra-rapid IKur 
and uncontrolled activation of INa-Late, which allow time for ICa-L to recover from 
inactivation.298 Indeed, co-incubation of LA cardiomyocytes with EAT adipocytes for few 
hours is shown to increase INa-Late, with a concomitant increment in ICa-L, and 90% APD. 
Adipocytokines from EAT have also been shown to decrease IKur after 18 hours of incubation 
of myocytes with EAT secretome.298 
 
1.3.7.7.2 AF Electrical Substrates  
Mechanisms causing shortening of the effective refractory period (ERP) and conduction 
slowing form important substrates for AF. Consistently, a potential role of EAT in promoting 
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conduction disturbance of the atria has been investigated by several groups. In a study of 337 
patients, atrial electromechanical interval was significantly increased in individuals with 
expanded EAT, and in after multivariable adjustment, EAT was found as an independent 
predictor of atrial electromechanical delay.299 This denotes the involvement of reduction of 
voltage and lengthening of total activation time as potential mechanisms. This was recently 
corroborated by the work of Mahajan et al300, which demonstrated pronounced voltage 
reduction and conduction slowing in regions adjacent to epicardial fat depots in obese 
patients. In the same study, left atrial EAT volume was found to demonstrate the best 
correlations conduction velocity, performing even much better than BMI (r2 = 0.31 for LA 
EAT vs. r2 = 0.22 for BMI).300 
 
1.3.7.7.3 Mechanisms Maintaining AF 
While re-entry seems to be the currently favoured mechanism of AF, several clinical 
mapping correlates have been utilised and include high dominant frequency (DF) and 
complex fractionated atrial electrogram (CFAE) sites.156, 157, 160, 301 CFAEs are recognised as 
regions characterised by wave breaks and fusion which are associated with slow conduction 
and pivot activation.164, 175 This repetitive and dyssynchronous nature of wave propagations of 
CFAE regions make them an important substrate for the perpetuation of AF. DF, on the other 
hand, are described as AF drivers with very high activation rate and that are central to a 
focal-firing rotor or local re-entry circuit.160, 175 It is interesting that high DF sites have been 
shown to correspond to sites with larger EAT volume in both paroxysmal AF and persistent 
AF patients.302 But data from the same study showed no relation between EAT and CFAE.302 
However, in another study, EAT volume and CFAE sites were independently associated with 
 
   
 
49 
AF, and significantly correlated with each other.303 We have also demonstrated that EAT 
demonstrate correlation a better correlation with LA electrogram fractionation than BMI (r2 = 
0.55 for LA EAT vs. r2 = 0.36 for BMI).300 
 
1.3.7.8 Stroke and EAT Expansion 
Stroke and thromboembolic events are a major complication in AF, and are associated with 
poor outcomes, increased need for thromboprophylaxis and excess deaths in AF patients.21 
The risk of stroke in AF is inhomogeneous and is conferred by comorbidities including 
ageing, coronary artery disease (CAD), hypertension (HTN), congestive heart failure and 
prior stroke which tend to act in additive fashion. Whether adiposity may increase the risk of 
stroke in AF is still under-investigated. In a prospective cohort of 190 patients, EAT 
thickness significantly predicted the incidence of cardiovascular events and EAT >6 mm was 
associated with significant reduction in CV event-free survival.304 EAT was also shown to 
correlate with CHA2DS2-VASc score, though this was lost upon the addition of co-variates in 
the analysis.304 Consistent with this, Akdag et al305 found significantly increased EAT in 
nonvalvular AF patients at risk of stroke defined by a high CHA2DS2-VASc score. More 
recently, increased abundance of EAT volume was reported in AF patients who developed 
stroke and total EAT detected as an independent predictor of excess of stroke occurrence 
after AF diagnosis.305  
Endothelial damage or dysfunction is an important determinant of a hypercoagulable 
state and is often present in AF. Molecules like soluble cell adhesion molecule 1 (sICAM-1) 
and von Willebrand factor (vWF) are important markers of endothelial injury and are both 
elevated in AF, predicting future development of stroke.306 In a recent study, Girerd et al306, 
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investigated the association of global or local EAT with markers of endothelial dysfunction in 
49 AF patients. They found significant correlation between posterior EAT, located between 
the mid LA and the oesophagus (LA-ESO) or thoracic aorta (LA-ThA), and sICAM-1 and 
vWF in both local LA and peripheral vasculature independent of BMI and LA volume.306 
Whether this data provides a mechanistic insight into the potential role of EAT in 
thrombogenesis and risk assessment of patients for stroke in AF requires further studies. 
 
1.4 Sudden Cardiac Death – A Background 
Sudden cardiac death is a major public health issue, contributing to a significant proportion of 
cardiovascular deaths worldwide. SCD is best described by the rule of 50: 1, it contributes to 
over 50% of CV deaths; 2, in more than 50% of patients, SCD is usually the first presentation 
of a cardiac event; and 3, it leads to approximately 50% of years of potential life lost to heart 
disease as it occurs mostly during the most productive years of the victims.14, 307-309  
 The understanding of SCD is recently been appreciated despite a long history of the 
disease. In fact, the sudden nature of SCD was known and reported well before the time of 
modern medicine and molecular and genetic advancements. SCD has been described since 
the days of Hippocrates; in the Aphorism II, 41, around 400 BC, Hippocrates noted that 
individuals with syncope were more likely to die suddenly than those without. It would later 
be described by Da Vinci in the 1490s as occurring in victims of “shrunken and withered” 
coronary artery, and by Lancisi, in 1706 under the request of Pope Clement XI, as an 
epidemiological undertaking on sudden death, where he clearly linked SCD to cardiac 
hypertrophy and valvular diseases.310 
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1.4.1 Definition of SCD 
The definition of SCD is best conceptualized by understanding “cardiac arrest”, defined as: 
the cessation of mechanical function or activity of the heart, evidenced by termination of both 
cardiopulmonary and systemic circulations. Cardiac arrest could be of cardiac origin or non-
cardiac origin, described in Table 1. Thus, SCD is temporally defined as a natural death from 
“sudden” cardiac arrest (SCA) in patients without known cardiac abnormality, occurring 
within an hour of onset of symptom (witnessed) or 24 hours in an unwitnessed case.309, 311 
Importantly, this takes into account three key elements of SCD: natural, rapid, and 
unexpected nature of the death. 
 Despite this definition, conflicting views surrounding SCD still exist among 
investigators, especially regarding the “1-hour” component. These differences can be settled 
by considering SCD in four perspectives: 1, its prodromes; 2, its onset; 3, cardiac arrest; and 
4, biologic death.309, 310, 312 The prodromes are a body of cardiovascular signs and symptoms, 
including chest pain, palpitations, dyspnea and fatigability, preceding and predictive of 
imminent cardiac event, but not specifically SCA. Because of huge individual variability, 
some victims do not experience prodromes at all. To be characterized as prodromal of SCD, 
their onset must occur suddenly and must precede the onset of cardiac arrest – within the 1-
hour onset of terminal event that precipitate cardiac arrest. The biological death component 
refers to the consequence of a cardiac arrest, and it denotes the presence of irreversible 
damage caused by pathophysiological process that will ultimately lead to death. It is often 
where controversies arise as it is included in the 1-hour definition because, with prompt 
intervention and life support, death can be prolonged for few more hours to days despite there 
been an irreversible damage.310, 312  
 




1.4.2 Public Health Burden of SCD 
SCD is associated with a significant cost to the healthcare systems, communities and/or 
individuals alike. Between 2003 and 2012, Damluji et al313 showed a linear increase in 
hospitalizations and hospitalization-associated costs accruing to SCA, mostly due to 
automatic implantable cardioverter defibrillators (ICDs) use, hypothermia and oxygenation 
therapy (odds ratio 1.3 to 2.4). On a personal level, premature death from SCD accounts for 
50% of years of potential life lost (approximately 2 million years in men and 1.3 million 
years in women) from cardiac disease.14, 308, 309, 314  
Accurate estimation of the public health burden of SCD remains a significant 
challenge in cardiovascular epidemiology. By extrapolating from the Seattle Emergency 
Service system, Cobb et al315 estimated an annual incidence of 184,000 of treated out-of-
hospital cardiac arrest (OSCA) events per year in the United States from 1979 through 2000. 
Low estimates like this are usually when coronary artery disease is the primary aetiology of 
SCD. Interestingly, however, up to 460,000 events per year are reported when all factors 
contributing to SCD are taking into account.14, 309 The latest statistical textbook of the 
American Heart Association (2019) puts the annual rates of SCD at 366,494, representing 
more than 50% of all recorded deaths due to heart disease in the USA.14 Further, a recent 
prospective multicentre study demonstrated incidence of 84 OSCA cases per 100,000 in 27 
European countries, which, at a survival rate of 10%, equates to 131,544 SCD events per year 
for the 174-million population.316 The true SCD would even be higher when in-hospital SCA 
(ISCA), currently at 55.5% of 348 368 patients managed in teaching hospitals and 58.8% of 
among 376 035 managed in nonteaching hospitals in the USA alone, is taken into account.14  
 




1.4.3 Mechanism of SCD 
The general understanding is that the development of SCD requires two important 
components: 1, an established substrate (substrate-based cause); and 2, an arrhythmic trigger.  
The substrate-based causations are conditions that predispose to SCD; they consist in 
pathological myocardial, vascular, or molecular adaptations that culminate in arrhythmic 
expressions.317 A majority of these substrates are created in CAD settings; examples include 
the plaque transition, acute coronary syndromes, and ischaemia modules in patients.317, 318 It 
is crucial to note that, in non-ischaemic conditions, the substrates are starkly different. 
Mechanisms mediating the clinical expression of predisposing SCD substrates constitute the 
triggers; these are identified as pro-arrhythmic cascade events discussed below.318-322  
 
1.4.3.1 Lethal Ventricular Tachyarrhythmias 
The initial rhythm leading to sudden cardiac arrest and death typically starts as a ventricular 
tachyarrhythmic event, such as ventricular fibrillation (VF) and pulseless or sustained 
ventricular tachycardia (pVT). The incidence of tachyarrhythmic mechanism is documented 
in up to 80% of SCD cases.309 For example, data from the Resuscitation Outcomes 
Consortium investigators demonstrated rates of 38%, 60% and 79% of VF or pulseless pVT 
as witnessed by emergency-medical service personnel, a bystander and when a bystander 
applied an automated external defibrillator, respectively.323 The true rates might even be 
higher given the deterioration and progression to non-shockable events. 
The mechanism of pVT or VF bears semblance with atrial tachyarrhythmias, such as 
AF. In fact, SCD is associated with AF, and in a recent meta-analysis of 8401 AF patients 
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and 67,608 controls in sinus rhythm, 2.22-fold increased risk of SCD was seen in AF patients 
compared to SR even persisting after multivariable adjustment.324 Like in AF, ventricular 
tachyarrhythmias require electrical trigger events acting on vulnerable ventricular substrates. 
Importantly, induction of fibrotic scarring, inflammation, abnormal connexin proteins, 
abnormal Ca2+-handling and membrane currents, and molecular and cellular maladaptations 
have all been implicated in substrate the formation of re-entrant tachyarrhythmias.322, 325-329  
 
1.4.3.2 Non-tachyarrhythmic Mechanisms 
After the initial arrhythmic events during SCA, it is known that pVT/VF degenerates into 
non-tachyarrhythmic mechanisms, including asystole and pulseless electrical activity (PEA). 
PEAs are higher in younger patients and in IHCA victims.320 Additionally, asystole and PEA 
are more prevalent in non-ischaemic SCD cases than in ischaemic cases.330 There is also 
evidence that bradyarrhythmia can lead to SCD, especially severe episodes capable of 
causing loss of circulation (both cerebral and gross organ perfusions). Noteworthy, there is 
bidirectionality in deterioration of arrhythmic mechanisms, in that, just as tachyarrhythmias 
can degenerate into non-tachyarrhythmic events, these non-shockable arrhythmic can 
spontaneously change into shockable VF or pVT.310, 312 
 
1.4.4 High-risk vs Low-risk Risk Profiling – Scaling the 
Bottleneck in SCD Estimation 
Reduction of SCD burden is wholly dependent on the accurate identification of at-risk 
populations, but this is currently plagued by the available risk stratification tools. These tools 
adopt risk profiling of populations that are based on coronary heart disease, ischaemic heart 
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disease, congestive heart failure, inherited channelopathies, and cardiomyopathies, which 
traditionally have high incidence rates of SCD.312 Despite recent evidence purporting to the 
decline in prevalence of these high-risk cohorts and associated deaths, the occurrence of SCD 
has not demonstrated consequent decreasing trend, see Figure 4.14, 309, 312 Moreover, data has 
shown the general absolute events that occur per year are far greater than accounted for by 
the traditional cardiac risk factors and a history of heart disease, see Figure 2. 
Further, clinical risk profiling for implantable cardioverter defibrillators (ICD) 
prophylaxis using ejection fraction (EF) less than 30% has not yielded promising results. For 
example, retrospective assessment of LVEF by Stecker et al331 in victims of SCD 
demonstrated severe LV dysfunction (LVEF ≤35%) in only 30% patients, indicating that up 
to 70% of the victims would not have qualified to ICD prophylaxis. Thus, investigation of 
new risk markers for SCD in the general low-risk populations is warranted now more than 
ever. 
 
1.4.5 Contagion of SCD in Excess Adiposity  
A growing postulate posits that the increasing burden of SCD may be driven by the rise in 
novel cardiovascular risk factors, such as obesity, which is indeed a global epidemic, see 
Figure 4. And as earlier noted, the risk of high-risk SCD features are greatly increased in 
obese individuals compared to normal weight counterparts.4, 7, 332-336 Recent findings from 
community-based population studies have reported independent association between SCD 
and obesity.337, 338 More intriguingly, obesity-mediated cardiomyopathy has even been 
implicated as the most common non-ischaemic cause of SCD, suggesting involvement of 
adiposity in SCD development.339  
 




1.5 Stable Obesity or Weight Fluctuation – which is 
worse?  
Data showing the perils of increasing adiposity during weight gain, such as expansion of 
EAT, is just beginning to gain traction. The risks of arrhythmogenic conditions like AF261 
and SCD337 are increased in obese patients compared to normal weight subjects. This may be 
explained in part by the fact that obesity also promotes traditional clinical correlates, such as 
metabolic syndrome, sleep apnoea, heart failure, acute coronary syndromes, and valvular 
heart disease.5, 7, 335 However, the rising burdens of cardiac arrhythmias are more than can be 
explained by the mere presence of these comorbid states alone. With the induction of low-
grade systemic pro-inflammatory state, renin-angiotensin-aldosterone system activation and 
pro-fibrotic signalling in the obese, it is very likely that obesity directly impacts cardiac 
remodelling and arrhythmic substrates.340 Clinical associations are reported with markers of 
atrial dysfunction260, atrial enlargement260, chronic inflammation340, and neurohumoral 
dysfunction, all of which are strongly linked to atrial fibrillation (AF).Yet still, there is a lot 
we do not know about the excess fat/AF risk relation.  
In preclinical models, several defining links have been uncovered for the pro-
arrhythmogenic role of obesity. These include: increased fibrosis and gross endocardial 
remodelling found in a chronic ovine model182; marked expression of pro-fibrotic cytokine 
after induction of short-term obesity and overweight in sheep181; reduction of Cx40 protein 
and P-wave duration leading to sustained atrial arrhythmia in rats following high-fat feeding 
(8 weeks)341; abbreviation of PV refractoriness with subsequent increased vulnerability to AF 
in porcine atria after 18-week high-fat diet342.  
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Interestingly, these data show that therapeutically targeting adiposity could mitigate 
arrhythmogenic substrate and help improve AF management. Indeed, this has been tested in 
several clinical trials. For example, Abed et al334 showed that weight reduction with intensive 
cardiometabolic risk factor management reduces symptomatic burden and severity of AF and 
produces additional cardiac remodelling. Nevertheless, there are important questions 
surrounding the long-term sustainability of weight loss programs. Noteworthy, weight loss is 
associated with several compensatory mechanisms, including reduced resting energy 
expenditure343, increased appetite, and both short- and long-term changes in appetite 
regulators (e.g., leptin, ghrelin, and cholecystokinin)344, that ultimately lead to weight relapse 
in patients. Pathak et al345 prospectively tested this concept in patients who underwent 
catheter ablation for AF in the LEGACY (Long-term Affect of Goal-directed weight 
management of Atrial fibrillation: a 5-Year follow-up study) trial. The authors demonstrated 
that long-term weight loss significantly reduces the burden of AF and echocardiographic left 
atrial substrates. However, they found that the beneficial effects of weight loss were 
counteracted by >5% weight fluctuation (weight loss/gain cycles) in patients.345 More 
importantly, the effect of weight fluctuation was shown to be independent of baseline BMI, 
with over 2-fold greater risk AF recurrence predicted by >5% weight fluctuation (HR: 2.06, 
p=0.02).345 Thus, this data highlights the potential pro-arrhythmic consequences of 
fluctuating weight. The question remains whether the substrate for AF in stable obesity 
differs from weight fluctuation. If so, it is not known which is worse as knowledge of this 












Terms Description Reversibility 
Sudden cardiac 
death 
Sudden, irreversible cessation of 
all biological, biochemical and 
biomechanical functions as a 
consequence of cardiac arrest 
Not reversible 
Cardiac arrest 
Cessation of cardiac mechanical 
function that may lead to death in 
the absence of reversal by a 
prompt intervention. May be: 
- Medical (e.g., cardiac, 
anaphylaxis, asthma or DI 
bleed) 
- Traumatic 
- Drug overdose 
- Drowning 
Rarely reverse spontaneously. 
Reversibility determined by: 
- Mechanism of arrest 
- Clinical setting, and 
- Prompt return of circulation 
Cardiovascular 
collapse 
Characterised by sudden loss of 
effective blood flow because of 
cardiac and/or peripheral vascular 
factors 
May reverse spontaneously: 
- Neurocardiogenic syncope 
- Vasovagal syncope or 
May require interventions: 
- Cardiac arrest 
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1.7 FIGURE LEGENDS 
Figure 1. Mechanism of Excitation-contraction Coupling of Cardiomyocytes  
Figure 2. Mechanisms of Focal Ectopic Activities 
(a.) Normal action potential phases with a resting potential around -80 mV, Na+-induced 
upstroke, plateau phase mediated by Ca2+ entry through both LTCC and RyR2, early 
repolarisation and late repolarisations. (b.) Formation of early afterdepolarisations occurring 
during the plateau phase of AP, and sustained ectopics. (c.) Formation of DADs during late 
phase (4) of repolarisation. Insufficient diastolic Ca2+ leak may cause membrane oscillation 
but not enough to cause AP; but when this is strong enough, full AP may be generated 
leading to DAD and ectopics when sustained.  
Figure 3. Mechanisms of Re-entry 
Figure 4. The Incidence of SCD and Absolute Annual Events in Population Subsets  
With increasing incidence, based on subgroup profiling, a decrease in proportion of the total 
sudden death burden is seen. This effect relates to the population impact of known evidence-
based outcomes of various prevention therapies, and it highlights the challenge of the low-
risk, high-numbers subsets. (Modified from Myerburg RJ, Junttila MJ. Sudden cardiac death 
caused by coronary heart disease.) 
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2. Chapter Two 









Evidence from a body of clinical and experimental studies have established fibrosis as the 
hallmark of structural remodelling that forms the substrate for atrial fibrillation.125 Fibrosis is 
associated with greater risk of cardiac arrhythmias and shown to predict poorer prognosis 
post-catheter ablation. Despite this, identifying modifiable risk correlates of fibrotic 
remodelling that would help detect patients at risk of future AF remains a challenge. 
 More recently, studies have suggested that galectin-3 (Gal-3) may be important for 
risk stratification and prognostication of AF.346, 347 Gal-3, a b-galactoside-binding lectin, is 
shown to be involved in important regulatory functions, such as cell adhesion, inflammation, 
and fibrosis.348 Consequently, Gal-3 is reported to have important prognostic value in 
traditional risk factors for AF. Indeed, Gal-3 is associated with fibrotic remodelling in heart 
failure349, and high serum Gal-3 is correlated with increased risk of incident of heart 
failure348, 350 and mortality in several epidemiological studies348. It is notable that diminished 
atrial electrical and fibrotic remodelling were reported following therapeutic targeting of 
cardiac Gal-3 in an experimental model.351 In the same study, Gal-3 inhibition was associated 
with increased AF termination and reduced AF burden, indicating that Gal-3 may be a 
druggable upstream target for the prevention of AF.351 Nevertheless, the nature and strength 
of the relation of this fibroinflammatory biomarker with AF prevalence and incidence have 
not been properly defined. Moreover, it not well described whether Gal-3 could influence the 
prognosis of catheter ablation. 
In the present study, we hypothesised that plasma Gal-3 would be increased in 
patients with AF and that it be a predictor of recurrent arrhythmias after catheter ablation for 
AF. Thus, we aimed to: (1) Investigate the relation between Gal-3 and the presence of AF; 
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(2) Evaluate its association with the risk of incident AF in prospective or retrospective cohort 
studies; and (3) Characterise association between baseline or pre-ablation Gal-3 levels and 
the recurrence of AF after catheter ablation.  
 
2.2 METHODS 
2.2.1 Search Strategy 
This meta-analysis is being registered on PROSPERO (ID: 129278) and conducted 
according to the Meta-analysis of Observational Studies in Epidemiology (MOOSE) 
statement. References were identified through online database searches done on PUBMED, 
EMBASE, Ovid MEDLINE and the Core Collection of Web of Science. Searches were 
conducted from inception of each database through 16 March 2019; the following keywords 
were used: (Galectin-3 OR Gal-3) AND (Atrial Fibrillation OR AF). The retrieved papers 
were exported to and sorted by EndNote X9.1 software.  
 
2.2.2 Inclusion and Exclusion Criteria 
Review authors Thomas A. Agbaedeng and Mehrdad Emami carried out the screening of 
references for eligibility and inclusion, with any discrepancy resolved by consensus. Papers 
were retrieved based upon the titles followed by the scrutiny of their abstracts and full-texts 
to ensure nothing was missed. Papers were first excluded based on the following criteria: (1) 
non-English publications; (2) Whether they were conference reports and abstracts that were 
not yet published; (3) editorials and letters to the editor; (4) case reports and case series; and 
(5) duplicate publications. The reference lists of review articles were searched for relevant 
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original papers and excluded thereafter. In the next stage, the full-texts of the references were 
properly perused, with non-relevant studies excluded thereafter. Finally, we included studies 
if they reported on: (1) Serum Gal-3 levels in patients with and/or without prevalent or 
incident AF; (2) Odds ratio (OR), relative risk (RR), or hazard ratio (HR) of association of 
Gal-3 with AF; (3) AF prevalence or incidence in different quartiles of Gal-3; (4) Serum Gal-
3 levels in patients with or without recurrence following catheter ablation of AF; and (5) OR, 
RR or HR of association between Gal-3 with post-ablation AF. 
 
2.2.3 Study Selection and Data Extraction 
The study selection and data extraction were done by review authors using an a priori 
determined set of guidelines. The following outcomes and data were collected: (1) Study 
authors; (2) Publication year; (3) Country of publication; (4) Study design; (5) Mean age of 
participants; (6) Participants; (7) Study endpoints; (8) Follow-up duration; (9) AF incidence, 
prevalence, recurrence after catheter ablation; (10) Serum Gal-3 level; and (11) Risk 
estimates (OR/RR/HR). 
 
2.2.4 Risk of Bias and Quality Assessment 
The methodological qualities of the included studies were assessed on the bases of the study 
design using the Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised 
studies in meta-analyses. The scales for case-control studies and cohort studies were used to 
assess the quality of case-control and cohort studies, respectively. The following perspectives 
were used to evaluate quality of cohort studies: 
1. Selection of study groups, 
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2. comparability of these study groups, and  
3. The ascertainment of the outcome of interest.  
And the following for case-control studies:  
1. The selection study groups,  
2. The comparability of the participant groups, and  
3. The ascertainment of the exposure of interest.  
The judgement of the studies was done using a “Star System” and computed as quality scores 
ranging from 1 to 9. A quality score of 1 indicated an extremely poor methodological design 
and a score of 9 was indicative of a very good quality.  
Randomised controlled trials were assessed for risk of bias (RoB) using the Cochrane 
Risk of Bias Assessment Tool for Randomised Studies of Intervention (the Cochrane 
Collaboration). We assessed the RoB in RCTs based on seven domains through which bias is 
likely to be introduced into these studies, namely: 
1. Bias due to random sequence generation (Selection Bias) 
2. Bias due to allocation concealment (Selection Bias) 
3. Bias in blinding of participants and personnel (Performance Bias) 
4. Bias in blinding of outcome assessment (Detection Bias) 
5. Bias due to incomplete outcome reporting (Attrition Bias) 
6. Bias due to selective reporting of outcomes (Reporting Bias) 
7. Bias due to other sources (Other Bias) 
 
 
   
 
69 
2.2.5 Data Synthesis and Analysis 
A random effects meta-analysis was conducted on the pooled results from the various 
citations using RevMan (The Cochrane Collaboration, Copenhagen). Two meta-analytic 
effects size types were used for the data analyses, namely: standardised mean difference 
(SMD) and risk ratios (RR). SMD typically measures the size of an outcome relative to the 
standard deviation (SD) of the outcome, thus, reflecting the real differences in the variability 
of the measured outcomes. RR’s were pooled from studies that conducted multivariable 
analysis, and this was done to show independent association with AF as well as a prediction 
of AF. We used the most adjusted model, which corrected for the following clinical 
correlates: age, sex, heart failure, type 2 diabetes, hypertension, obstructive sleep apnoea, 
coronary artery disease, myocardial infarction, obesity, valvular heart disease, peripheral 
vascular disease, and stroke. 
Serum galectin-3 was measured by enzyme-linked immunosorbent assay and pooled 
as mean plus/or minus standard deviation (mean±SD). The degree of heterogeneity of Gal-3 
estimates across the studies was assessed by examination of forest plots, chi-squared (Chi2) 
test and I-squared (I2) statistic. The latter two provide numerical values for an assessment of 
heterogeneity, with a high Chi2 relative to the degree freedom suggestive of variations in 
effect estimates and I2 greater than 50% indicative of a considerable amount of heterogeneity 
(p<0.1 defined as the cut-off). Statistical significance was set at p≤0.05. 
 




2.3.1 Search Result and Synthesis of the Literature  
The online database searches and supplementary searches conducted resulted in a total of 460 
references. One hundred and twenty-three duplicate publications were removed and a further 
320 references upon applying the exclusion criteria. Fifteen studies (13 observational and 2 
randomised controlled trials [RCT]) met our inclusion criteria and were included in this 
review. A pictorial overview of the search strategy and selection methodology is shown as a 
flowchart in Figure 1. 
 
2.3.2 Study Characteristics  
A full description of the characteristics of the included studies are provided in Tables 1 to 3, 
including study designs, quality scores, demographics, methodology, study endpoints, 
follow-up, and participants.  
The 15 included studies had a total of 13,736 participants (6,454 [47.0%] males and 
7,282 [53.0%] females) from 9 countries (1 study from both Switzerland & Germany, 1 from 
Italy, 1 from Germany, 1 from China, 1 from France, 1 from the UK, 2 from Serbia, 3 from 
Turkey, and 3 from the USA). Of the 13 observational studies, 9 reported on pre-ablation 
(incident and prevalent) AF346, 347, 352-358, 2 on post-ablation AF359, 360, and 2 on both pre- and 
post-ablation AF361, 362, respectively. There were 9 case-controls, 7 cohorts, and 1 
prospective, community-based study.  
In the RCTs, Wijk et al363 reported on 2 trials (Trial of Intensified versus Standard 
Medical Therapy in Elderly Patients with Congestive Heart Failure [TIME-CHF] and Gruppo 
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Italiano per lo Studio della Sopravvivenza nell’Insufficienza Cardiaca [GISSI-HF]) and thus 
contributed to studies. Of the three RCTs, PROTECT study was a single-centre, prospective, 
randomized trial364; TIME-CHF was multicentre, multinational trial involving 15 centres in 
Switzerland and Germany363; and GISSI-HF were multicentre, randomized trial involving 
357 centres in Italy363. The follow-up period ranged from 0.8 years in PROTECT study to 
nearly 4 years in GISSI-HF study (mean±SD: 2.0±1.7 years). In total, the RCT contributed 
1,001 patients (82.9% males and 17.1% females) and average age of 72±8.5 years. 
 
2.3.3 Risk of Bias and Study Quality 
The methodological study quality was assessed using the NOS quality scale, running on a 1-9 
scale. In the case-control studies evaluating AF presence and severity, the quality was judged 
to be average, ranging from 5 to 7, see Table 1. The two prospective cohorts that investigated 
AF incidence had high quality score (8 in both). For the 3 RCTs, RoB assessment yielded 
low to moderate risk of bias, see Table 2 & Figure 2. The quality of the studies on post-
ablation AF was judged to be moderate (mean [±SD]: 5.5±1.3), with least being 4 and highest 
scoring 6, see Table 3.  
 
2.3.4 META-ANALYSIS 
2.3.4.1 Gal-3 and AF Presence 
We identified seven case-control studies352-355, 357, 358, 361 reporting on serum Gal-3 and the 
presence of AF with a total of 718 participants. Mean serum Gal-3 levels (±SD) was 
extracted from each study and pooled in a random-effects meta-analysis. There was a 
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significant difference between the levels of Gal-3 in patients with pre-existing AF and sinus 
rhythm (SR) controls, Figure 3. We found 0.58 ng/mL higher plasma Gal-3 in AF patients as 
compared to SR controls (SMD: 0.58, 95% CI: 0.38 to 0.78, p<0.0001). We could not further 
compare the association of Gal-3 with AF presence due to lack of adjusted risk estimation in 
the studies. The largest contribution to the overall estimate was by Gurses et al353 at 20.4%, 
followed by Begg et al355 (16.9%), Wu et al362 (14.8%), equally by Sonmez et al352 and 
Selcoki et al354 (13.9%), and Pavlovic et al357 and Kornej et al361 coming bottom (10.2% and 
9.9%). 
 
2.3.4.2 Gal-3 and AF Incidence 
We identified 2 references363, 364 reporting on prospective, randomized trials compared the 
incidence of AF in a dichotomous Gal-3 population (high vs. low).  One of the references 
reported two RCTs, namely TIME-CHF and GISSI-HF, so there were 3 trials altogether. We 
found significant association between high Gal-3 level and AF incidence, Figure 4. High 
plasma Gal-3 associated with 57% increased odds of AF compared to low Gal-3 level (OR: 
1.57, 95% CI: 1.15 to 2.15, p=0.005). GISSI-HF trial explained almost half the pooled risk 
estimate, with PROTECT and TIME-CHF trials contributing a quarter each, Figure 4.  
Next, wanted to explore the relationship between continuous increment in Gal-3 and 
AF incidence. We found 2 large prospective, cohort studies347, 356 that included 11,742 
patients (1,435 incident AF cases) and pooled effect size estimates from the most adjusted 
models. Covariates adjusted for included: age (years), sex (male, female), height (metres), 
weight (kg.m-2), systolic and diastolic blood pressures (mm Hg), antihypertensive medication 
use (yes, no), diabetes mellitus (yes, no), smoking status (current, former, never), history of 
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myocardial infarction (yes, no), history of HF (yes, no), total cholesterol (mg/dL), eGFR 
(mL/min/1.73 m2), rs4644 genotype (CC, AC, AA), ln NT-proBNP (ln pg/mL), ln CRP (ln 
mg/L), and ln TnT (ln ng/L).347, 356 Gal-3 associated with increased incidence of AF, with 1-
unit increment in Gal-3 associated with 26% increased hazards of incident AF ([OR: 1.26, 
95% CI: 1.08 to 1.48, p=0.004]; Figure 5). 
 
2.3.4.3 Gal-3 and AF Severity 
Three studies346, 353, 358 provided data on Gal-3 assessment in patients with paroxysmal and 
non-paroxysmal AF (persistent and permanent AF). A total of 314 patients contributed to this 
analysis. When they were pooled, we found a significantly higher level of Gal-3 in patients 
with non-paroxysmal form of AF as compared to paroxysmal AF, see Figure 6. NPAF was 
associated with 0.51 greater SMD of Gal-3 as compared to PAF (95% CI: 0.28 to 0.73, 
p<0.0001). More than half of this is explained effect estimate from Clementy et al346 (58.9% 
weight). 
 
2.3.4.4 Gal-3 and AF Recurrence 
Four studies359-362 were identified that investigated relation of Gal-3 with catheter ablation 
outcomes. In the pooled analysis, we found that patients with AF recurrence had greater 
baseline plasma Gal-3 levels as compared to those without recurrence. Patients with 
arrhythmia recurrence had 0.96 higher SMD Gal-3 ([95% CI: 0.09 to 1.83, p=0.03]; Figure 
7). Interestingly, we pooled the adjusted risk estimates, we found non-significant association 
between 1-SD increase in Gal-3 and risk of recurrence. According to Figure 8, although 
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there were 22% adjusted odds of AF recurrence per 1-SD Gal-3, this did not achieve 
statistical significance (OR: 1.22, 95% CI: 0.86 to 1.72, p=0.26). 
 
2.3.4.5 Heterogeneity and Sensitivity Analysis 
We evaluated statistical heterogeneity in the studies using Chi2 (degree of freedom) and I2-
statistic. The pooled analysis for Gal-3 and AF presence showed only mild inconsistency in 
effect size estimates (Chi2: 9.18, df: 6, p=0.16; I2: 35%), Figure 3. In NPAF vs. PAF 
analysis, there was no evidence statistical heterogeneity (Chi2: 0.69, df: 2, p=0.71; I2: 0%), 
Figure 6. Similarly, no evidence of heterogeneity was found in the analysis of AF incidence 
([Chi2: 0.12, df: 6, p=0.94; I2: 0%]; [Chi2: 0.27, df: 1, p=0.60; I2: 0%]; Figures 4 & 5). 
However, we found moderate to substantial heterogeneity in the rest of AF recurrence 
comparisons, see Figures 7 & 8.  
 
2.4 DISCUSSIONS 
2.4.1 Major Findings 
Gal-3 is implicated in cardiometabolic risk factors like obesity and heart failure. Its role in 
the pathogenesis of AF has been suggested but not fully described. In this meta-analysis, we 
explore the relationship between plasma Gal-3 and AF, demonstrating that: 
1. Plasma Gal-3 is significantly increased in prevalent AF compared to having no 
pre-existing AF 
2. High Gal-3 associates with 57% greater risk of incident AF 
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3. For every 1-SD increase in Gal-3, patients are at 26% elevated risk of developing 
AF, even after correcting for baseline covariates 
4. Patients with non-paroxysmal AF significantly increased levels of Gal-3 
compared to paroxysmal AF 
 
2.4.2 Mechanisms Promoting AF 
AF is a heterogenous condition with several factors identified to promote its development. 
These factors are further classified as mechanisms responsible for AF initiation and 
mechanisms perpetuating the arrhythmia once initiated. AF triggers were first identified by 
Haïssaguerre et al119 as ectopic activities originating from the pulmonary veins. In this 
seminal investigation, localization of ectopic foci in the PVs, by multielectrode catheter 
mapping, was observed in 94% of patients with paroxysmal AF (PAF), which were 
successfully ablated with radio-frequency energy. The author further demonstrated high 
efficacy of therapeutic targeting of these foci, with 62% patients shown to be free of AF 
recurrence after 8(±6) months of follow-up post-ablation.119 These findings have been 
replicated by multiple investigators365-367, with up to 86.1% freedom from AF recurrence 
reported in follow-up studies365. Additionally, AF triggers have been identified in other sites, 
such as: posterior wall of the left atrium; the superior vena cava; inferior vena cava; crista 
terminalis; ligament of Marshall; coronary sinus ostium; and interatrial septum.368, 369  
Localized re-entrant and multiple wavelets11, 94, 120, 205 are hypothesised to drive AF 
maintenance. These have been mapped to structural and morphological changes94, electrical 
alterations151, re-entry involving functional370, 371 and anatomic166 lines of block in the atrial 
tissue. Interesting, fibrosis is understood as the histological hallmark of structural substrate 
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for initiation and perpetuation of AF.125 Data from the DECAAF study indicated that left 
atrial fibrotic substrate by delayed-gadolinium enhancement MRI independently predicts AF 
recurrence following ablation.372 Others have further confirmed this finding, including 
association of fibrosis with cardiac and all-cause mortality and sudden cardiac death.373-375 
Taken together, these data show that full understanding of the pathophysiology of AF would 
require investigations of multiple pathways, including the role of biomarkers in substrate 
formation.   
 
2.4.3 Galectin-3 and AF 
Recent findings have implicated galectin-3 in the clinical link between fibrosis and 
development of atrial substrate for AF. In two large prospective cohorts, 1-unit increment in 
circulating Gal-3 was associated with 2.29- and 1.19-fold increased hazards of incident 
AF.347, 356 In the Framingham Offspring Cohort, it was shown that this association becomes 
nonsignificant after correcting for traditional risk factors for AF, thus highlighting role of 
other modifiable risk factors in this picture.347 Despite this, when we pooled the two cohorts 
together in a meta-analysis, we found elevated adjusted risk of AF per unit increment in the 
biomarker. We also found higher rates of AF incidences in high Gal-3 populations compared 
to low Gal-3 and associated Gal-3 with greater persistence of AF. We believe this meta-
analysis provides robust evidence for association between Gal-3 and AF. We employed 
multiple study types, including case-controls, prospective cohorts, and randomized trials to 
evaluate this association.   
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2.4.4 Galectin-3 and AF: Role of Increased Adiposity 
The association of Gal-3 and AF may be attributed to cardiometabolic perturbations. 
Circulating levels of Gal-3 are higher in patients with obesity376, abdominal adiposity377, 
dyslipidaemia377, and hypertension377. Similar findings are reported in pre-clinical models. In 
obese rats, treatment with Gal-3 inhibitor modified citrus pectin (100 mg.kg-1 per day) 
ameliorated adipocyte differentiation, adipose tissue inflammation, pericellular collagen 
deposition, prompting the authors to conclude that Gal-3 could play an important role in 
metabolic alterations resulting from obesity.378 Increased Gal-3 levels are also associated 
with adipocyte dysfunction, contributing to insulin resistance , and cardiac lipotoxicity in 
obesity. 
Galectin-3 is a b-galactoside-binding lectin mainly secreted by macrophages and to a 
lesser extent by adipocytes and fibroblasts.379 We speculate that, during obesity, Gal-3 may 
mediate epicardial fat dysfunction and downstream atrial structural and electrical 
remodelling. Consistently, Gal-3 levels are reported to associate with diastolic dysfunction 
the morbidly obese376; in obese male Wistar rats (induced by HFD), Gal-3 is associated with 
fibrosis and inflammation378. This is further mapped to abnormal leptin, an adipokine 
secreted by epicardial fat, signalling; Gal-3 reportedly promotes leptin-induced deposition of 
collagen I and oxidative stress.379 The most compelling evidence comes from a seminal 
investigation Takemoto et al351.  The authors observed increased expression of Gal-3 in 
cardiac microcirculation of persistent AF than paroxysmal AF.351 LA Gal-3 level was found 
to be an independent predictor of AF recurrence after catheter ablation. The authors also 
report reduction of proliferation of atrial fibroblasts in vitro, and amelioration of atrial 
enlargement, hypertrophy, fibrosis, and dominant frequencies in sheep, following Gal-3 
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inhibition.351 These translated to reduction vulnerability to spontaneous AF and AF burden in 
the sheep model380, thus underscoring a role in of Gal-3 in local atrial remodelling.  
 
2.4.5 Study Limitations 
There were several limitations that we noted about the data used in the current meta-analysis. 
The amount of heterogeneity in post-ablation AF comparison is worth noting. Although this 
was significant in some comparisons, we believe that the level of heterogeneity was not 
critical and may not have affected our risk estimates. The use of serum Gal-3 instead of local 
atrial Gal-3 may limit the clinical application of our results. It is crucial to note that serum 
Gal-3 changes may underlie systemic fibrotic diseases not just AF. 
 
2.5 CONCLUSIONS 
The present meta-analysis demonstrates an independent association between galectin-3 and 
AF. Our findings show that serum Gal-3 is increased in prevalent AF compared to no pre-
existing AF. High Gal-3 levels associate with 57% greater risks of incident AF compared to 
low biomarker levels. More crucially, 1-SD increment in Gal-3 levels is predicts 44% greater 
risks of incident AF, persisting even persisting after correcting for baseline AF risk factors 
and comorbidities. Furthermore, Gal-3 is associated with AF severity, with serum Gal-3 more 
greatly increased in non-paroxysmal AF than in paroxysmal AF. In contrast to these findings, 
baseline Gal-3 levels do associate AF recurrence post-CA ablation, such that the association 
with AF is lost after pooling multivariate adjusted risk estimates.
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2.6 TABLES 
Table 1. Clinical Characteristics of Studies Reporting Galectin-3 and Atrial Fibrillation 


















187 (68) ng/ml 187 (100) 




N/A 151(47) ng/ml 76 (50) 




N/A 96 (96) ng/ml 50 (52) 
Kornej et al 2015 Germany Case-control N/A 5 N/A 119 (63) ng/ml 105 (88) 
Sonmez et al 2015 Turkey Case-control N/A 4 71±8 85 (38) pg/ml 52 (61.2) 




54 (59.3) ng/ml 32 (59.3) 
Selcoki et al 2016 Turkey Case-control N/A 6 N/A 84 (44) ng/ml 46 (54.8) 




88 (36.4) ng/ml 51 (57.9) 
Begg et al 2017 UK Case-control N/A 6 N/A 129 (69) ng/ml 92 (71.3) 
Ho et al 2014 USA Prospective cohort 11.2 8 59.0 3306 (47) ng/ml 250 (7.5) 




62.6±5.6 8436 (41.3) ng/ml 1185 
(14.05) 
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Table 2. Characteristics of Randomised Clinical Trials 



























1.3±0.5 Moderate 78±7 219 (64) ng/mL 61 (28) 
GISSI-HF 
Study 
2016 Italy Multicentre, RCT 3.9±1.3 Low 66±11 631 (89) ng/mL 118 (18) 
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Table 3. Characteristics of Post-ablation AF Studies 














2015 Germany Cohort 0.5 5 62±9 105 (63) ng/ml 36 (39.1) 
Clementy 2016 France Cohort 1.0 6 61±10 160 (71) ng/ml 55 (34.4) 
Wu et al 2015 China 
Prospective, 
Community-based 
1.42±0.34 7 48.9±7.8 96 (96) ng/ml 32 (64) 
Begg et 
al  
2018 UK Prospective cohort 1.0 4 N/A 92 (69.6) ng/ml 42 (45.6) 
Total    0.98±0.4 5.5±1.3 57.3±7.3 453 (74.2)  165 (36.4) 
  
   82 
2.7 FIGURE LEGENDS 
Figure 1. CONSORT Diagram of the Search Strategy 
Figure 2. Risk of Bias Chart: A Summary of Judgements of ‘Risk of Bias’ in the 
Included Randomised Clinical Trials  
Figure 3. Galectin-3 and Prevalent AF 
Figure 4. Evaluation of Association of Galectin-3 and AF Incidence in Randomized 
Clinical Trials 
Figure 5. Evaluation of Galectin-3 and Risk of Incident AF in Cohort Studies 
Figure 6. Galectin-3 and AF Severity 
Figure 7. Galectin-3 and Post-ablation AF 
Figure 8. Galectin-3 and Risk of Post-ablation AF 
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{(Galectin 3 [TW] OR Galectin-
3 [TW] OR Galectin 3 [MH] OR 
Gal-3 [TW] OR Mac-2 antigen 
OR Galactose-specific lectin 3) 
AND (Cardiac arrhythmia [MH] 
or Cardiac arrhythmia [TW] OR 
Atrial fibrillation [TW] or AF 
[TW])}
460 References from combined 
database and supplementary 
searches
337 References screened based on 
titles, abstracts, and full texts
15 References included in meta-
analysis
123 references excluded as duplicates
322 References excluded:
• Case series and reports 
• Conference abstracts and editorials
• Animal, in vitro and  ex vivo studies
• Reviews and meta-analysis
• Articles not addressing study questions
• Assessment of left atrial galectin-3
Gal-3 & AF incidence/prevalence 
(n=11)
Gal-3 & Post-ablation AF (n=2)
Gal-3 & AF & post-ablation AF (n=2)
Embase
{('galectin 3'/exp OR 'galectin 3'/SYN OR 'mac-2 
antigen'/SYN OR 'mac-2 antigen'/EXP OR 'gal 
3'/SYN OR 'gal 3'/EXP OR 'carbohydrate-binding 
protein 35'/SYN OR 'carbohydrate-binding protein 
35'/EXP OR 'galactoside-binding protein'/exp OR 
'galactoside-binding protein'/SYN) AND ('atrial 
fibrillation'/exp OR 'atrial fibrillation'/SYN OR 'heart 
arrhythmia'/exp OR 'heart arrhythmia'/SYN)} 
Web of Science 
Core Collection
{(Galectin-3 OR 
Galectin 3 OR Gal-
3) AND (Atrial 





Galectin 3/ OR Gal-






Search strategy: PubMed, Embase, Web of Science Core Collection, MEDLINE, and manual bibliographic searching
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Figure 4. Evaluation of Association of Galectin-3 and AF Incidence in Randomized Clinical Trials 
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3. Chapter Three 
Epicardial Adipose Tissue and Atrial Fibrillation 
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3.1 INTRODUCTION  
A growing body of evidence has demonstrated atrial fibrillation (AF) as a cardiovascular 
epidemic, which is associated with reduced quality of life and increased risk of stroke and 
heart failure.12, 13, 29 Moreover, new-onset AF occurring after open heart surgery (post-
operative AF, POAF) is recognised as a significant complication during the post-operative 
period, affecting 20% to 60% of post-surgery patients.381-385 It is shown to be associated with 
long-term complications, such as worsening of cardiac haemodynamics, increased incidence 
of ventricular arrhythmias, heart failure, cognitive impairment, and increased mortality.22, 386, 
387  
The burgeoning burden of AF has been attributed to the emergence of novel risk 
factors, such as obesity. Indeed, obesity accounts for 20% of all AF and 60% of the rising 
incidence rate of the arrhythmia.22 More recently, epicardial adipose tissue (EAT) has 
emerged as an important element in the pro-arrhythmic substrate formation, with reports 
showing that it might explain the clinical link between obesity and AF.263, 265, 266, 300 EAT is a 
metabolically active fat depot found on the visceral layer of the pericardium and in close 
proximity to the myocardium, sharing the same microcirculation with the cardiac 
musculature.182, 263 This unique anatomic position has raised the postulate of a paracrine 
effect on cardiac musculature. Accordingly, EAT expansion has been reported in 
experimental models181, 182 and shown to underlie increased secretion of pro-fibrotic and 
inflammatory cytokines.278 Indeed, EAT has been associated with induction of atrial 
interstitial fibrosis (the histological surrogate for atrial structural remodelling) and fat cell 
infiltration in animal models, and increased inflammatory activity in patients with AF.182, 280, 
388  
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In this study, we hypothesised that expansion of the ectopic fat pad might predispose 
individuals to excess risk of developing AF, increased risk of relapse following catheter 
ablation and increased incidence of AF post-surgery. Therefore, the aims of this systematic 
review of the literature and meta-analysis were to evaluate the association between EAT and 
(1) AF prevalence and incidence; (2) severity of AF (non-paroxysmal vs. paroxysmal forms); 
(3) recurrence of AF post-ablation; and (4) incidence of AF post-cardiac surgery.  
  
3.2 METHODS  
3.2.1 Literature Search Strategy 
This meta-analysis was registered on PROSPERO (ID: CRD42018105707) and conducted 
according to the guidelines given by the Preferred Reporting Items for Systematic Review 
and Meta-Analysis (PRISMA) and Meta-analysis of Observational Studies in Epidemiology 
(MOOSE). We identified the studies used for this systematic review and meta-analysis 
through online database search done on PUBMED, EMBASE, Ovid MEDLINE and the Core 
Collection of Web of Science. Full keywords used are as follows: 
PubMed: (Fat [TW] OR Adipose Tissue [TW] OR Adipose Tissue [MH] OR Adipocyte* 
[TW] OR Adipocyte* [MH]) AND (Epicardi* [TW] OR Epicardi* [MH] OR Pericardi* 
[TW] OR Pericardi* [MH] AND (Cardiac Arrhythmia [MH] OR Cardiac Arrhythmia [TW] 
OR Atrial Fibrillation [TW] or AF [TW]) 
EMBASE: ('Fat'/EXP OR ‘Fat’/SYN OR 'Adipocyte'/EXP OR ‘Adipocyte’/SYN OR 
'Adipose Tissue'/EXP OR 'Adipose Tissue'/SYN) AND (‘Epicardi*’/EXP OR 
‘Epicardi*’/SYN OR ‘Pericardi*’/EXP OR ‘Pericardi*’/SYN) AND ('Atrial Fibrillation'/EXP 
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OR 'Atrial Fibrillation'/SYN OR 'Heart Atrium Arrhythmia'/EXP OR 'Heart Atrium 
Arrhythmia'/SYN OR AF) 
The Core Collection of Web of Science: (“Adipose Tissue” OR Fat OR Adipocyte* OR 
Lipocyte*) AND (Pericardi* OR Epicardi*) AND (“Atrial Fibrillation” OR “Supraventricular 
Arrhythmi*” OR AF OR “Atrial Arrhythm*”) 
Ovid MEDLINE: (Adipocyte.mp. or Adipocytes/ or Fat.mp. OR Adipose Tissue.mp.) AND 
(Epicardi*.mp. OR Pericardium/ OR Pericardi*.mp.) AND (Atrial Fibrillation/ OR AF.mp. 
OR Arrhythmias, Cardiac/) 
We conducted online database searches from inception through to 5 July 2018, with retrieved 
papers exported to and sorted by EndNote X8.2 software. 
 
3.2.2 Inclusion and Exclusion Criteria 
Screaming for eligibility and inclusion was conducted by two investigators, with any 
disagreement settled by consensus. We screened the retrieved papers based upon the titles 
followed by the scrutiny of their abstracts and full-texts to ensure nothing was missed. Papers 
were first excluded based on the following criteria: (1) publication in non-English languages; 
(2) whether they were conference reports and abstracts that were not yet published; (3) 
editorials and letters to the editor; (4) case reports. The reference lists of review articles were 
searched for relevant original papers and excluded thereafter. In the next stage, the full-texts 
of the references were screened, with non-relevant studies excluded thereafter. Finally, we 
included studies if they reported on: (1) the association between EAT/pericardial fat and the 
prevalence or incidence of AF; (2) EAT and outcome after catheter ablation of AF; (3) 
association of EAT with non-paroxysmal (Non-PAF) AF vs. PAF; (4) the association 
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between the EAT and post-operative AF; and (5) maintenance or dissection of the anterior 
epicardial fat pad and post-op AF. 
 
3.2.3 Study Selection and Data Extraction 
The study selection and data extraction were done by two investigators (Thomas Agbaedeng 
and Andien Munawar), using an a priori determined set of guidelines with any disagreement 
resolved by consensus or with a third author, where necessary. The following outcomes and 
data were collected: (1) AF incidence, prevalence, recurrence after catheter ablation; (2) 
EAT/pericardial fat thickness and volume; (3) Risk estimates; (4) Study endpoints; (5) Study 
design; (6) Participants; (7) EAT measurement modality; (8) study country; and (9) imaging 
modality.  
 
3.2.4 Risk of Bias and Quality Assessment 
The methodological qualities of the included studies were assessed on the bases of the study 
design using the Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised 
studies in meta-analyses. The scales for case-control studies and cohort studies were used to 
assess the quality of case-control and cohort studies, respectively. The following perspectives 
were used to evaluate quality of cohort studies: 
1. Selection of study groups, 
2. comparability of these study groups, and  
3. The ascertainment of the outcome of interest.  
And the following for case-control studies:  
1. The selection study groups,  
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2. The comparability of the participant groups, and  
3. The ascertainment of the exposure of interest.  
The judgement of the studies was done using a “Star System” and computed as quality scores 
ranging from 1 to 9. A quality score of 1 indicated an extremely poor methodological design 
and a score of 9 was indicative of a very good quality.  
Due to the apparent limitation of quality checklists and scales for intervention studies, 
we further assessed ablation studies using “a Cochrane Risk of Bias Assessment Tool: for 
Non-Randomised Studies of Intervention (ACROBAT-NRSI).” We assessed the risk of bias 
(RoB) in observational studies based on seven domains through which bias is likely to be 
introduced into these studies, namely: 
1. Bias due to confounding, 
2. Bias in selection of participants into the study, 
3. Bias in measurement of interventions, 
4. Bias due to departures from intended interventions, 
5. Bias due to missing data,  
6. Bias in measurement of outcomes, and 
7. Bias in selection of the reported result. 
See Table 1 for the criteria used. 
 
3.2.5 Data Synthesis and Analysis 
A random effects meta-analysis was conducted on the pooled results from the various 
citations using RevMan (The Cochrane Collaboration, Copenhagen). Two meta-analytic 
effects size types were used for the data analyses, namely: standardised mean difference 
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(SMD) and odds ratios (OR). We used SMD to present the change or difference in EAT on a 
uniform scale, insofar as the studies reported heterogenous definitions of EAT (total 
epicardial, peri-atrial, and/or pericardial) measurement. SMD typically measures the size of 
an outcome relative to the standard deviation (SD) of the outcome, thus, reflecting the real 
differences in the variability of the measured outcomes. OR’s were pooled from studies that 
conducted multivariable analysis, and this was done to show independent association with AF 
as well as a prediction of AF.  
EAT was pooled as a volumetric measure or thickness measure and presented as mean 
and standard deviation (mean±SD). Where EAT was reported as median and interquartile 
ranges (IQR), we converted these to mean±SD using models derived by Wan et al389 The 
degree of heterogeneity in outcomes across the studies was assessed by examination of forest 
plots, chi-squared (Chi2) test and I-squared (I2) statistic. The latter two provide numerical 
values for an assessment of heterogeneity, with a high Chi2 relative to the degree freedom 
suggestive of variations in effect estimates and I2 greater than 50% indicative of a 
considerable amount of heterogeneity (p<0.05 defined as the cut-off). Statistical significance 
was set at p<0.05 
  
3.3 RESULTS 
3.3.1 Search Result and Synthesis of the Literature 
The online database searches and supplementary searches conducted resulted in a total of 
1316 references. We excluded 1257 articles that did not meet our inclusion criteria. Thirty-
three observational studies with a total of 24,091 participants (59.1% males and 40.9% 
females) were included in this review. Analysis was done for: (1) epicardial fat and prevalent 
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AF; (2) epicardial fat and incident AF from cohort studies; (3) epicardial fat and recurrent AF 
after catheter ablation; and (4) epicardial fat and POAF after cardiac surgery. A full 
description of the characteristics of the included studies, including study designs, quality 
scores, demographics, methodology, study endpoints, follow-up, and participants, is provided 
in Tables 2 through 5. An overview of the search strategy and selection methodology is 
shown as a flowchart in Figure 1. 
 
3.3.2 Epicardial Fat and Prevalent AF 
Eighteen studies264, 265, 270, 303, 305, 390-397 investigated the prevalence of AF, corresponding to 
7,738 participants (46.8% females). Computed tomography (CT) was the predominant 
technique (75%) for EAT measurement, followed by transthoracic echocardiography (TTE) 
(20%), and cardiac magnetic resonance (CMR) (5%), see Table 2. Overall, we found 
significantly increased EAT volume in patients with AF as compared to sinus rhythm, with a 
SMD of 0.72 (95% Confidence Interval, CI: 0.49 to 0.95; p<0.001) (Figure 2). However, 
there was significant heterogeneity in this comparison (I2 >84%; p<0.001). Subgroup analysis 
showed that the heterogeneity was contributed by Greif et al393, which measured pericoronary 
EAT from coronary calcium score CT images. We next excluded Greif et al393 and still found 
significant difference in EAT between AF and SR controls ([SMD: 0.79; 95% CI: 0.64 to 
0.93; p<0.001] and [I2; p=0.12]).  When we pooled the multivariable-adjusted OR’s from 
seven studies reporting this, 1-standard deviation (SD) increase in EAT volume was 
significantly and independently associated with the presence of AF (OR: 1.03; 95% CI: 1.00 
to 1.05; p=0.03), Figure 3. This comparison had substantial heterogeneity ([I2: 79%; 
p<0.001], Figure 3), which was lost after limiting the analysis to Kanazawa et al303, 
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Mahabadi et al394 and Sevinc et al395 (I2: 49%; p=0.14). In a sub-analysis involving only left 
atrial EAT, significant association with AF presence was also noted ([SMD: 0.78; 95% CI: 
0.43 to 1.12; p<0.001], Figure 4). The heterogeneity in this analysis was moderate and not 
significant (p=0.08; Figure 4). Similarly, EAT was significantly thicker in prevalent AF 
patients as compared with controls (SMD: 1.30; 95% CI: 0.36 to 2.24; p=0.007), Figure 5. 
But there was considerable heterogeneity ([I2=97%, p<0.001], Figure 5), which was 
contributed by Yorgun et al,396 ([SMD: 1.70, 95% CI: 1.13 to 2.28, p<0.001] and [I2: 80%, 
p=0.02] after removing source of heterogeneity).   
 
3.3.3 Epicardial Fat and Incident AF 
Three cohort studies394, 398, 399 reporting incident AF, corresponding to 14,031 individuals 
(54.2% females) with EAT measurement performed using CT, Table 3. Patients were 
followed up for a mean of 7.3 years (SD: 2.4) and 8.8% of them (968) had incidence of new-
onset AF. In the pooled analysis, there was no significant association between EAT volume 
and the risk of incident AF, (OR: 1.07; 95% CI: 0.99 to 1.15; p=0.10), see Figure 6. The 
three studies were well matched, with no statistical evidence of heterogeneity (I2=0%; 
p=0.95).  
 
3.3.4 Epicardial Fat and Severity of AF 
The relationship between epicardial fat and the severity of AF was reported in 14 studies265, 
270, 302, 303, 306, 390-393, 400-404 (2,533 patients; 30% females). From the pooled analysis, both total 
and left atrial EAT volumes were significantly increased in the patients with non-paroxysmal 
AF compared to those with paroxysmal AF (total EAT [SMD: 0.46, 95% CI: 0.24 to 0.67, 
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p<0.001]; LA-EAT [SMD: 0.62, 95% CI: 0.26 to 0.98, p<0.001], see Figures 7 & 8). Pooled 
analysis of EAT thickness showed similar results, with non-PAF patients having 1.34 SMD 
greater EAT than PAF patients (SMD: 1.34; 95% CI: 0.65 to 2.02; p<0.001), Figure 9. 
Pooled analyses involving total EAT volume and LA-EAT volume had moderate amounts of 
heterogeneity (total EAT [total EAT [I2: 69%, p<0.001] and [I2: 54%; p=0.05)], Figures 7 & 
8). In total EAT, heterogeneity was caused by inclusions of Kim et al402, Masuda et al403 and 
Nakamori et al404 ([SMD: 0.60, 95% CI: 0.44 to 0.77, p<0.001] and [I2: 20%; p=0.27] after 
exclusions); and by Nakamori et al404 in LA-EAT ([SMD: 0.72, 95% CI: 0.38 to 1.07, 
p<0.001] and [I2: 43%, p=0.14]). Furthermore, considerable heterogeneity was noted for EAT 
thickness ([I2: 88%, p<0.001], Figures 9) and was contributed by Iacobellis et al401 ([SMD: 
1.68, 95% CI: 1.40 to 1.96, p<0.001] and [I2: 17%, p=0.27] after exclusion). 
 
3.3.5 Epicardial Fat and Recurrent AF  
Ten cohort studies263, 390, 392, 397, 400, 402, 403, 405-407 reported on AF recurrence after catheter 
ablation with a total of 1,938 patients (31.6% females) (Table 4). After a mean follow-up 
period of 18.6±4.6 months, 523 (27.0%) AF patients undergoing catheter ablation 
experienced AF recurrence, defined as AF or atrial tachycardia >30 seconds after 3-month 
blanking periods. The dominant technique for estimating EAT was CT (70.0%), with only 
three studies using CMR and TTE. Total EAT volume was significantly increased in the 
recurrent AF group ([SMD: 0.49; 95% CI: 0.01 to 0.98; p=0.05], Figure 10), with 
independent association demonstrated upon multi-variable adjustment, Figure 11. In three 
studies where EAT thickness was assessed, there was also significant correlation between 
EAT and recurrent AF, ([SMD: 0.98; 95% CI: 0.64 to 1.93; p<0.001], Figure 12). However, 
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there was evidence of significant heterogeneity amongst some of the studies ([I2: 75%, 
p<0.007 & 0.02], Figures 10 & 12).  The source of heterogeneity was traced to EAT depots 
assessed in Nagashima et al390 and Nakatani et al406 (I2: 53%, p=0.14), and CT assessment of 
EAT thickness in Kocyigit et al405 (I2: 51%, p=0.15). 
 
3.3.6 Epicardial Fat and Incident AF Post-cardiac Surgery 
Two studies408, 409 investigated the effects of total epicardial fat on the incidence of post-
operative AF and involved a total of 185 participants (24.9% females). All were prospective 
cohort studies; Opolski et al409 had a retrospective design, whereas Drossos et al408  had a 
prospective design, respectively, Table 5.The results of the meta-analysis showed that 
epicardial fat was significantly increased in patients with incident post-operative AF 
compared to individuals in sinus rhythm (SMD: 0.87; 95% CI: 0.34 to 1.39; p=0.001), see 
Figure 7. The amount of heterogeneity in the analysis was moderate and did not reach 
statistical significance (I2 = 59%; Chi2 = 4.93; p=0.08).  
 
3.3.7 Assessment of Risk of Bias 
The methodological study quality was assessed using the NOS quality scale, running on a 1-9 
scale. Generally, the quality was good across these studies, and ranged from moderate to high 
quality ([mean±SD: 6.4±0.9, 8.0±1.0, and 6.3±1.2 for prevalent, incident and recurrent AF, 
respectively] Tables 2 through 5). Further, risk of bias assessments were performed for all 
included studies and summarised in Figure 8. 
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3.4 DISCUSSION  
3.4.1 Major Findings 
Epicardial fat has been implicated in the risk of cardiovascular disease and is currently being 
investigated as the mechanistic link between increasing adiposity and the development of AF. 
In this meta-analysis, we sought to thoroughly define the association that has been described 
between epicardial fat and AF. It demonstrates that: 
1. Epicardial fat is significantly larger in patients with prevalent, but not associated 
with new-onset AF.  
2. Increased epicardial fat, both as volumetric and thickness measures, is 
significantly associated with greater severity of AF.  
3. The prognosis of AF after a radiofrequency catheter ablation is worsened with 
increasing amount of EAT. Increased EAT is significantly associated with the 
recurrence of AF after ablation.  
4. Finally, epicardial fat is significantly elevated in patients with POAF. 
 
3.4.2 Epicardial Fat and AF 
EAT has emerged as an important visceral adipose tissue that may refine our understanding 
of the role of adiposity in AF risk, and has been implicated as the putative mechanistic link 
between obesity and AF. Batal et al266, Al Chekakie et al265, and Thanassoulis et al264 
independently reported an association between epicardial fat and AF prevalence less than a 
decade ago, and since then, EAT has been consistently shown to be larger in AF patients than 
in those in SR. Wong et al263 associated total pericardial fat with 3.56 to 11.25 odds of AF 
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prevalence and chronicity, which was independent and much stronger than any traditional 
obesity marker, including BMI. In the same study, periventricular fat was associated with 
almost 4-fold increased risk of recurrent AF.263 Interestingly, we have demonstrated that 
epicardial fat is significantly larger in patients with prevalent and new-onset AF, with 1-unit 
increment in EAT volume associated with more than excess odds of AF occurrence 
independently of traditional risk factors. Our pooled analyses also showed associations of 
EAT with progression of AF after catheter ablation. 
 
3.4.3 AF Substrate Due to Epicardial Fat 
EAT is a unique and metabolically active fat depot subtending the visceral layer of 
pericardium and in close proximity to the myocardium, a feature that has ignited much 
interest in its potential paracrine effects on cardiac musculature.182, 278, 280 Accordingly, in 
clinical studies, EAT has been significantly associated with marked conduction 
abnormalities300, electrical imbalance283, cardiac autonomics dysfunction290, and increased 
inflammatory activity271.  
The pro-arrhythmic mechanism of expanding EAT is probably complex. We 
previously demonstrated expansion of epicardial fat with progressive weight gain and 
obesity, with a consequent induction of fat cell infiltration of the posterior left atrial 
myocardium.182 The secretome of EAT has been reported to induce global fibrosis of rat 
atria278, the histological hallmark of structural remodelling, with fibrotic remodelling of EAT 
significant correlated with atrial interstitial fibrosis in left atrial appendage samples from 
humans388. We hypothesised that fibro-fatty infiltrations are sufficient to create AF substrate, 
which might be driven by loss of cell-cell coupling, increased local conduction blocks and 
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conduction heterogeneities.131 Additionally, co-incubation with EAT adipocytes is shown to 
cause abnormal remodelling of membrane currents, afterdepolarisations and increased 
ectopic activities in experimental models, further highlighting the important role of 
infiltrating EAT adipocytes in formation of AF substrate.297  
 
3.4.4 Post-operative AF Substrate Due to Epicardial Fat 
POAF, like other clinical forms of AF, has a complex pathophysiological mechanism and 
several loops have been implicated, such as local and systemic inflammation, oxidative 
stress, neurohumoral cascade activations, and ion channel remodelling. Intriguingly, there is 
an increasing body of evidence to suggest that EAT may contribute to the atrial 
arrhythmogenic substrate, which can predispose to and maintain POAF. In 76 patients 
undergoing CABG, Viviano et al276 demonstrated that gelsolin, an anti-inflammatory protein, 
in the secretome of epicardial fat was predictive of maintenance of sinus rhythm post-
surgery. Noteworthy, by reducing expression of anti-inflammatory factors like gelsolin and 
directly inducing pro-inflammatory cytokine production, as seen in the peri-operative 
settings271, 272, 388, 410, EAT could heighten the vulnerability of atrial tissue to inflammatory 
cascades that ultimately leads to formation of POAF substrate. More importantly, the 
presence of an established AF substrate, such as fibro-fatty infiltrates, directly relates to EAT 
and might impact the POAF risk. Indeed, the degree of fibrosis and P-wave duration during 
the start of open-heart surgery was shown to be predictive of POAF.411  
 
 




There are a few limitations that are worth noting regarding the data in the current meta-
analysis. We found a significant amount of heterogeneity in a number of our pooled analyses. 
Additionally, the use of overwhelmingly non-randomised observational studies as opposed to 
randomised controlled trials is an important drawback and may have biased our analysis. 
Notwithstanding this limitation, the methodological quality of these studies was good, 
ranging from moderate to high quality scores, as well as their risk of bias level.  
Finally, the definition of epicardial fat varied in the included studies, with some 
reporting it as ‘epicardial adipose tissue’ and others as ‘pericardial fat’; while others use both 
definitions interchangeably. This is partly to do with the inconsistency in the literature 
regarding what constitute epicardial adipose tissue and pericardial adipose tissue.412 EAT 
pertains to the fat lying contiguously with the myocardium and found between the latter and 
the visceral layer of the pericardium.413 Pericardial fat is a loose term because it incorporates 
all the fat found around the heart, including the EAT and another adipose tissue ‘paracardial 
fat’, which is located externally to the parietal pericardial layer or membrane.413 One 
important drawback to this vague distinction of these fat zones is that it may lead to 
overestimation or underestimation of the reported values of EAT. 
 
3.4.6 Clinical Implications 
These findings reinforce the clinical associations reported between expansion of epicardial fat 
and AF. Although the best imaging technique to quantify and characterize EAT amount and 
distribution remains unclear, EAT may represent an interesting risk marker to identify 
patients with increased AF risk which could allow a more personalized risk stratification. 
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EAT may hold promise as a novel target for atrial fibrillation, a concept recently tested in 
patients who underwent pulmonary vein isolation wherein treatment with atorvastatin led to 
reduction in EAT volume.414 In addition to pharmacological interventions, combined 
modification of risk factors, which are individually associated with EAT, and weight loss 
may be another strategy to target EAT.345, 415 Further studies are warranted to improve our 
understanding of EAT-mediated atrial remodelling and to determine whether its reduction 
constitutes a treatment target for primary and secondary prevention of AF. 
 
3.5 CONCLUSIONS 
This meta-analysis provides evidence for an independent association between EAT and AF. 
We show that EAT is significantly increased in patients with prevalent AF, and that this 
association is independent of traditional risk factors. EAT was not associated with incident 
new-onset AF, but significantly associated with greater severity of AF, and recurrence of AF 
after catheter ablation. Moreover, increased amount of EAT was also significantly correlated 








Table 1. Criteria for assigning risk of bias to studies based on the Cochrane guideline 
RESPONSE OPTION CRITERIA 
Low risk of bias  The study MUST be judged to be at low risk of bias for all domains. 
Moderate risk of bias  
The study MUST be judged to be at low or moderate risk of bias for all 
domains (i.e., there is moderate risk of bias in at least one domain). 
Serious risk of bias  
The study MUST be judged to be at serious risk of bias in at least one 
domain, but not at critical risk of bias in any domain. 
Critical risk of bias  
The study MUST be judged to be at critical risk of bias in at least one 
domain. 
No information on which to base a 
judgement about risk of bias. 
There is no clear indication that the study is at serious or critical risk of 
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Table 2. Summary characteristics of studies investigating epicardial fat and prevalent AF 




(technique) AF diagnosis Type of AF (% PAF) 









Greif et al. 
2013 
Germany Retrospective 6 1,288 (58.9) Volume (CT) 
Interview/ECG/med
ical history 
PAF & PerAF (63) 
Al Chekakie 
et al. 2010 
United States Case-Control 6 273 (50.2) Volume (CT) NS PAF & PerAF (64) 
Shin et al. 
2011 
South Korea Retrospective 5 80 (72.5) Volume (CT) NS PAF & PerAF (50) 
Kanazawa et 
al. 2014 
Japan Case-Control 5 240 (79.6) Volume (CT) NS PAF & PerAF (66.7) 
Batal et al. 
2010 
United States Case-Control 7 169 (65.1) Thickness (CT) NS PAF PerAF (62.5) 
Nagashima et 
al. 2011 
Japan Case-Control 5 77 (76.6) Volume (CT) 
12-L ECG & 24-h 
holter 
PAF & PerAF (60) 
Nagashima et 
al. 2012 




PAF & PerAF (47) 
Acet et al. 
2014 
Turkey Case-control 6 197 (46.7) Thickness (TTE) − Non-valvular (53) 
Yorgun et al. 
2015 Turkey Retrospective 7 618 (53.2) Thickness (CT) 
Resting ECG; 24-h 
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Table 2. CONT… 




(technique) AF diagnosis Type of AF (% PAF) 
Tsao et al. 
2011 









ECG or 24-h 
Holter 
PeAF | PAF (23.8) 





6 53 (68) 
LA-EAT | total 
EAT volume (CT) 
NS PAF | PerAF (42) 





7 132 (37.1) 
Atrial pericardial 
fat (CT) 
NS PerAF (0) 





6 49 (83.7) EAT volume (CT) NS PAF | PeAF (51) 

















8 3905 (47) EAT volume (CT) 12-L ECG NS 
Nakamori et 
al. 2018 




PAF | PerAF | LS-
PerAF (74) 
Subtotal    6.4±0.9 7,738 (53.4)    
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Table 3. Summary of cohort studies investigating epicardial fat and AF 


















8 5 3,905 (47) 12-L ECG 50 (1.4) EAT volume (CT) 




Cohort 7 9.7 2,135 (46.7) 12-L ECG & holter 162 (7.6) 






Cohort 9 7.25 7991 (45) 
ICD-9 code for AF 
or flutter 
756 (9.5) 
Pericardial fat volume 
(CT) 
Total   8±1 7.3±2.4 
14,031 
(45.8) 
 968 (8.8)  
AF, atrial fibrillation; CA, catheter ablation; EAT, epicardial adipose tissue; ECG, electrocardiograph; CT; computed tomography; and ICD, 
international classification of disease code. 
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Table 4. Summary characteristics of studies evaluating epicardial fat and AF ablation outcome 
















176 (26.5) Pericardial fat volume 
(CT) 
Wong et al. 
2011 Australia 
Cross-







pericardial fat volume 
(CMR) 
Nagashima 
et al. 2011 








Left-atrial & total 
EAT volume (CT) 
Tsao et al. 
2011 








Atrial EAT volume 
(CT) 
Chao et al. 
2013 Taiwan Case-control 16±9 283 (69.6) 6 NS 
24-h 
Holter 95 (33.6) EAT thickness (TTE) 
Canapolat 




 234 (51.3) 6 NS 
24-h 

















EAT thickness (CT) 
Stojanovska 




cohort 33.0±9.0 169 (76) 6 NS 
Event 
monitor 45 (26.6) EAT volume (CT) 
 





Japan Cohort >12 55 (75) 5 







10 (18.2) EAT volume (CT) 
Masuda et 
al. 2015 Japan Cohort 16±4.4 53 (68) 6   41 (77.4) 
LA-/total EAT 
volume (CT) 
Subtotal    >18.6±4.6 1,938 (68.6) 6.0±0.7   482 (26.8)  
AF, atrial fibrillation; CA, catheter ablation; CMR, cardiac magnetic resonance imaging; CT, computed tomography; EAT, epicardial adipose 





























































Subtotal    185 (75.1) 7±0   48 (25.4)  
AF, atrial fibrillation; CABG, coronary artery bypass grafting; CCTA, coronary computed tomography angiography; CT, computed tomography; 
EAT, epicardial adipose tissue; ECG, electrocardiograph; LA-EAT, left atrial epicardial adipose tissue; NS, not specified; PAF, paroxysmal AF; 
POAF, post-operative AF; and TTE, transthoracic echocardiography. 
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3.7 FIGURE LEGEND 
 
Figure 1. CONSORT Diagram of the Search Methodology 
Figure 2. Comparison of Epicardial Fat in Prevalent AF Versus Sinus Rhythm 
This analysis looks at the relation between epicardial fat volume and prevalent AF, 
comparing patients with pre-existing AF vs. those in sinus rhythm. Effects size presented as 
standardized mean difference (SMD) of EAT.  
Figure 3. Association of Epicardial Fat with AF Presence 
This comparison looks at the association of EAT with risk of AF presence. Effects were 
pooled as adjusted odds ratio (OR, per 1-SD increase in EAT) of AF (covariates: age, sex, 
obstructive sleep apnoea, type 2 diabetes mellitus, BMI, hypertension, heart failure, 
ischaemic heart disease, valvular heart disease, left atrial volume). The small squares 
represent effect sizes; the horizontal bars as 95% confidence intervals; and big diamond box 
as overall effect size estimate, respectively.  
Figure 4. Comparison of Left Atrial Volume and AF 
Figure 5. EAT Thickness and Prevalent AF 
Figure 6. Total EAT Volume and Risk of Incident AF 
Figure 7. Evaluation of Epicardial Fat and AF Progression 
This analysis investigates epicardial fat in patients with non-paroxysmal AF versus 
paroxysmal AF. Effect size presented as SMD. a.) 
Figure 8. Comparison of Left Atrial Epicardial Fat Volume in Non-paroxysmal Versus 
Paroxysmal AF 
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Figure 9. Comparison of Total Epicardial Fat Thickness in Non-paroxysmal AF Versus 
Paroxysmal AF 
Figure 10. Evaluation of Epicardial Fat Volume in Recurrent AF 
This analysis looks at the relation between volume of epicardial fat and AF recurrence after 
catheter ablation compared no clinical recurrence. Effects size presented as SMD of EAT 
measured in patients that developed recurrent AF or maintained sinus rhythm.  
Figure 11. Epicardial Fat Volume and Risk of Recurrent AF 
Figure 12. Epicardial Fat Thickness and AF Recurrence  
Figure 13. Comparison of Epicardial Fat and Post-operative AF  
This analysis looks at the relation between epicardial fat volume and POAF compared to that 
in sinus rhythm. Effects size presented as standardized mean difference (SMD) of EAT.  
Figure 14. Risk of Bias Chart: A summary of Judgements Regarding ‘Risk of Bias’ 
Presented as Percentages Across all Included Studies 
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Figure 1. CONSORT Diagram of the Search Methodology 
  






31 articles Included in meta-analysis
- 2 Incident AF
- 1 Incident and prevalent AF
- 2 AF post-cardiac surgery
- 6 AF post-ablation
- 6 Recurrent AF/Prevalent AF
33 Non-English references
1,252 Excluded:
1. Case series and reports 
2. Conference abstracts and 
editorials
3. Animal, in vitro & ex vivo studies
4. Reviews and meta-analysis
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Figure 2. Comparison of Epicardial Fat in Prevalent AF Versus Sinus Rhythm 
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Figure 3. Association of Epicardial Fat with AF Presence 
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Figure 4. Comparison of Left Atrial Volume and AF 
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Figure 7. Evaluation of Epicardial Fat and AF Progression 
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Figure 8. Comparison of Left Atrial Epicardial Fat Volume in Non-paroxysmal Versus Paroxysmal AF 
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Figure 10: Evaluation of Epicardial Fat Volume in Recurrent AF 
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Figure 14. Risk of Bias Chart: A summary of Judgements Regarding ‘Risk of Bias’ Presented as Percentages Across all Included Studies 
  
0% 20% 40% 60% 80% 100%
Bias to confounders (selection bias)
Bias to selection of participants (selection bias)
Bias due to measurement of intervention 
(measurement bias)
Bias due to departure from intended 
interventions (performance bias)
Bias due to missing data (Attrition bias)
Bias due to outcome assessment (Detection 
bias)
Bias due to selective reporting (reporting bias)
Low risk of bias Moderate risk of bias Serious risk of bias
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4. Chapter Four  
Electrical and Electroanatomic Characterisation of 
the Atria in Obesity and Weight Fluctuation 
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4.1 INTRODUCTION  
Obesity has emerged as an important modifiable risk for atrial fibrillation (AF). Body mass 
index, a measure of overall adiposity, is demonstrated to predict excess risk of incident new-
onset AF261 and progression416, recurrent post-ablation AF417, and new-onset AF after cardiac 
surgery418. More recently, data has implicated epicardial adipose tissue (EAT) expansion, 
which occurs during weight gain, in the clinical link between obesity and AF.263 However, 
the mechanisms associating EAT with AF risk have not been fully elucidated. While we have 
previously reported increased EAT in the obesity in both short term and long-term, we do not 
fully understand how ectopic fat relates with atrial electrical substrates 
Furthermore, weight fluctuation, a common finding in the clinic, is has been 
implicated in adverse health conditions343, 344. For example, in the LEGACY study, long-term 
prospective study, we demonstrated benefit of weight loss in reducing the burden of recurrent 
AF in long-term follow up. However, up to 5% weight fluctuation significant reduction in the 
freedom from AF compared to linear weight loss.345 The puzzling question remains as to 
what constitute the atrial substrate due to fluctuating weight. We hypothesis that weight 
fluctuation during weight loss will result in persistent atrial remodelling.   
The aims of the current study were to: (1) characterise atrial electrical substrates in 
stable obesity; (2) characterise atrial electrical substrates due to weight fluctuation; (3) 
evaluate epicardial fat in weight fluctuations and compare these to obesity; and (4) evaluate 
the relation between epicardial fat remodelling and electrical substrates. 
 
 




4.2.1 Animals  
Twenty-four Merino Cross Wethers sheep (Ovis aries) were studied in accordance with 
guidelines outlined in the “Australian Code for the Responsible Conduct of Research, 2007 
(the 2007 Code)” adopted jointly by the National Health and Medical Research Council, the 
Australian Research Council and Universities Australia. The protocol and animals used 
herein were approved by both the animal research ethics committees of the University of 
Adelaide and the South Australian Health and Medical Research Institute, Adelaide, 
Australia, which adhere to the Guidelines for the Care and Use of Animals for Research 
Purposes. 
 
4.2.2 Obese Ovine Model  
Obesity was induced in 8 sheep using a previously well characterised protocol. In brief, sheep 
were commenced on a high-calorie diet for a period of 40 weeks and maintained in this state 
for another 40 weeks. Obesity induction was started at baseline, whereby healthy sheep with 
normal weight were put on a diet consisting of energy-dense soy-bean oil (2.2%) and 
molasses-fortified grain and maintenance hay with weekly weight measurement. Excess 
voluntary intake was predominantly of grass alfalfa silage and hay. Pellets were gradually 
introduced at 8% excess basal energy requirements and rationed to 70% of total dry-matter 
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4.2.3 Weight Fluctuation Model  
Another group of 8 sheep was maintained as the weight fluctuation animal and were 
commenced on a four 20-week cycles of weight gain/weight loss. All animals were 
commenced on a high-calorie diet similar to obese sheep for a period of 20 weeks. 
Thereafter, sheep were maintained on high quality hay for another 20 weeks to induce weight 
loss, with energy-dense pellets rationed at just 0.75% of body weight. At the end of the 20 
weeks, the cycle was repeated again. Blood samples were periodically collected to ensure 
electrolyte and acid-base homeostasis.  
 
4.2.4 Lean Control Model  
Eight age-matched sheep were maintained as controls at their baseline weight. To do this, 
high-quality hay was provided ad libitum, while energy-dense pellets were rationed at 0.75% 
of body weight. The nutritional content of food and housing conditions were identical for all 
three groups, with only the amount of food intake varying. 
 
4.2.5 Animal Preparation 
Animals were pre-acclimatized for at least 1 week before any surgery. Shorn weight was 
recorded immediately before surgery. 
 
 




4.2.6.1.1 Haemodynamic Assessment  
Invasive blood pressure (BP) monitoring was performed during the electrophysiology study. 
Left atrial (LA) and right atrial (RA) pressures were recorded. 
 
4.2.6.1.2 Cardiac MRI  
Before open chest surgery, animals underwent cardiac MRI using 1.5 Tesla (Siemens Sonata, 
MR Imaging Systems, Siemens Medical Solutions, Erlangen, Germany) with 10-mm slices 
through the ventricles without interslice gaps. To do this, animals were securely placed in the 
dorsal recumbent position for scanning. Mechanical ventilation was maintained, facilitating 
electrocardiogram-gated image acquisition with periodic breath holding. Analyses were 
performed offline by blinded operators by using the proprietary software QMass MR (Medis 
medical imaging systems, Leiden, The Netherlands). The following parameters were 
measured as previously described: Left ventricular chamber mass; LV ejection fraction 
(LVEF); Left atrial end-systolic volume (LA-ESv); LA end-diastolic volume (LA-EDv); 
right atrial end-systolic volume (RA-ESv); and epicardial fat volumes. 
Quantification of EAT:  Epicardial fat volumes were quantified using previously validated 
protocol.413 Briefly, a 3D model was constructed from consecutive end-diastolic short-axis 
images using semi-automated software. Regions of adipose tissue were marked in each slice 
followed by linear interpolation of pixel intensities in spaces between consecutive image 
slices. Periatrial and periventricular fat were defined as any pericardial fat subtending the the 
right and left atria and ventricles and below the visceral pericardium, respectively. Total 
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volume of adipose tissue was calculated as a total volume of the 3D model and the mass 
estimated from volume measurements.  
 
4.2.6.1.3 Electrophysiological Study  
The electrophysiological study was carried out based on previously published 
methodology182 and in the post-absorptive state under general anaesthesia. Briefly, venous 
access was obtained through the right femoral and left internal jugular veins. A 10-pole 
catheter with 2-5-2 mm inter-electrode spacing (Daig Electrophysiology, Minnetonka, MN) 
was advanced through the left internal jugular vein and positioned in the coronary sinus (CS). 
A conventional trans-septal puncture was performed using a BRK1 needle and SL0 sheath to 
access the left atrium.  
 Surface electrocardiogram (ECG) and bipolar endocardial electrograms were 
continuously monitored and stored on a computer based digital amplifier/recorder system for 
off-line analysis (LabSystem Pro, Bard Electrophysiology, Lowell, MA, USA). Intracardiac 
electrograms were filtered from 30 to 500 Hz, and measured with computer assisted calipers 
at a sweep speed of 200 mm/s. The following were conducted: 
 
4.2.6.1.3.1 Effective Refractory Period Assessment  
The effective refractory period (ERP) was performed using a rove catheter after the 
electroanatomical mapping study. All ERPs were evaluated at twice the diastolic threshold at 
cycle length (CL) of 400 ms using an 8-beat drive train followed by an extra-stimuli (S2), 
which started with an S2 coupling interval of 120 ms increasing in 5 ms increments. The ERP 
was defined as the longest coupling interval failing to propagate to the atrium. ERP was 
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measured from the following 8 sites: 1) RA appendage; 2) RA lateral wall, upper; 3) RA 
lateral wall, lower; 4) proximal CS; 5) distal CS; 6) LA appendage (LAA); 7) LA posterior 
wall; and 8) LA inferior wall.  
 
4.2.6.1.4 Electroanatomical Mapping  
Electroanatomic maps of the LA/RA were created in sinus rhythm using the CARTO 
(Biosense Webster) mapping system as previously published. This carried out using A 3.5-
mm tip catheter (Navistar, Biosense Webster, Diamond Bar, California). The accuracy of the 
sensor position has been previously validated to 0.8 mm and 5o. Briefly, the system records 
the surface ECG and bipolar electrograms filtered at 30 to 400 Hz from the mapping and 
reference catheters. Endocardial contact during point acquisition was facilitated by 
electrogram stability, fluoroscopy, and the catheter icon on the CARTO system. Points were 
acquired in the auto-freeze mode if they met the stability criteria in space (≤6 mm) and local 
activation time (LAT; ≤5 ms). Mapping was performed with an equal distribution of points 
using a fill-threshold of 15 mm. Collected points were edited offline. LAT was manually 
annotated to the peak of the largest amplitude deflection on bipolar electrograms. In the 
presence of double potentials, the LAT was annotated at the largest potential. If the bipolar 
electrogram displayed equivalent maximum positive and negative deflections, the maximum 
negative deflection on the simultaneously acquired unipolar electrogram was used to annotate 
the LAT. 
Each point was binned according to location (region), fractionation (presence or 
absence), scar (presence or absence), and bipolar voltage amplitude to allow analysis in a 
mixed-effects model. Regional atrial bipolar voltage and conduction velocity were analysed 
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offline. The LA/RA maps were segmented for analysis, and the following parameters were 
assessed as previously described: 
1. Atrial conduction velocity: To determine conduction velocity (CV), isochronal 
activation maps (5-ms interval) of the atria were created and regional CV measured in 
the direction of the wave-front propagation (i.e., least isochronal crowding). This was 
then assessed by averaging the distance between 3 to 5 pairs of points as a function of 
the difference in LAT. CV was measured in the following regions: 1) RA upper 
lateral wall; 2) RA lower lateral wall; 3) RA septal wall; 4) LA posterior wall; 5) LA 
inferior wall; and 6) LA lateral wall. 
2. Complex electrogram fractionation: Electrograms with a duration ≥50 ms and 3 or 
more deflections crossing baseline were considered complex fractionated 
electrograms; and double potentials were potentials separated by an isoelectric 
interval and with a total electrogram duration ≥50 ms. For analysis, a fraction of the 
total number of fractionated/double points was utilized. 
3. Atrial voltage: Low-voltage areas were defined as 3 contiguous points with a bipolar 
voltage <0.5 mV. Electrically silent areas (scar) were defined as 3 contiguous points 
with an absence of recordable activity or bipolar voltage amplitude <0.05 mV. 
 
4.2.7 Statistical Analysis  
Data were tested for normality using Shapiro-Wilk tests. Normally distributed continuous 
data were expressed as mean plus or minus standard deviation (SD) and analysed with 
ANOVA across groups (controls, obese and weight fluctuation). Skewed distributions were 
expressed as median and interquartile range (IQR) and medians tested using Mann-Whitney 
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U-tests, or Kruskal-Wallis tests. Nominal data was analysed by Chi-square tests of 
independence. Next, we fitted mixed-effect models to the data in order to compare 
conduction velocity and atrial refractory period across regions, chambers, and groups 
(control, obese and weight fluctuation), with two fixed effects at a time. To investigate LA 
regional patterns in both approaches, region (posterior LA, inferior LA and LA appendage) 
and group (control, obese and weight fluctuation) were modelled as fixed effects with an 
interaction term (region x group). RA regional patterns were similarly investigated. If a 
significant interaction was present, mixed-effects post-hoc test p-values were reported (with 
Sidak adjustment of alpha level). To determine the correlation of electrical remodelling with 
epicardial fat, we fitted bivariate linear regression and estimated Pearson coefficient (r) and 
r2. Two-sided p-values ≤0.05 were considered statistically significant. All analyses were 
performed using SPSS version 25 (IBM SPSS Statistics, Chicago, Illinois) and GraphPad 
Prism version 7.0d (GraphPad Software, La Jolla, CA, USA). 
 
4.3 RESULTS 
4.3.1 Group Characteristics  
The obese state was achieved over 80 weeks, with the obese group reaching peak weight 
(109.1±7.1 kg.m-2) by the 40th week and sustained at the achieved weight for another 40 
weeks. The weight fluctuation group reached obese state by 20 weeks; after this, they lost 
weight for 20 weeks, with obesity re-induced for another 20 weeks before finally undergoing 
another round of weight loss reaching a weight of 77.2±4.5 kg.m-2. The control group 
maintained lean weight (76.1±4.5) over the 80-week period. By the end of 80 weeks, the 
obese sheep significantly increased their baseline weight to almost twice the control and 
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weight fluctuation levels ([p<0.001 for both] Table 1). The final weights of the controls and 
the weight fluctuation sheep were not significantly different from each other (p>0.05). The 
Electrolyte, acid-base, and glucose levels remained within their normal ranges throughout the 
over feeding process. 
 
4.3.2 Electrophysiological Remodelling  
Table 1 shows summary of electrical findings due to chronic weight gain and fluctuation.  
 
4.3.2.1 Effective Refractory Period 
Obesity resulted in reduction in mean atrial refractoriness compared to controls (p<0.001) 
and weight fluctuation (p=0.003), Table 1. There was no significant change in mean atrial 
ERP between fluctuating weight group and controls. Interestingly, ERP did not change 
significantly between the groups across all sites evaluated, except at right atrial appendage, 
where ERP in the obese animals was significantly abbreviated compared to controls 
([130.1±37.6 ms vs. 169.3±53.1 ms], p=0.03) and weight fluctuation ([130.1±37.6 ms vs. 
170.8±50.0 ms], p=0.02), see Figure 1.  
 
4.3.2.2 Atrial Conduction 
Figure 2 shows the endocardial CV across left and right atrial sites. In the left atrium, there 
was a significant reduction in the mean endocardial CV in the obese sheep compared to 
controls ([0.97±0.1 m/s vs. 1.26±0.1 m/s], p<0.001). This was found in LA posterior wall 
(LAPW: p=0.036), LA inferior wall (LAIF: p<0.001), and LA lateral wall (LALW: p<0.001). 
Similarly, obesity demonstrated significant reduction of endocardial CV in the right atrium. 
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The mean endocardial CV was reduced by 23% following sustained weight gain compared to 
maintaining baseline weight ([0.96±0.1 m/s vs. 1.24±0.1 m/s], p<0.001). Obesity also 
demonstrated regional conduction slowing in the RA, including RA upper lateral (RAUL: 
p<0.001), lower lateral (RALL: p=0.008), and septal walls (RASW: p<0.001), respectively. 
When weight fluctuation was compared to lean controls, fluctuating weight was 
associated with significant persistent reduction in CV across both chambers. In the LA, mean 
CV was slower by 0.20 m/s ([1.06±0.1 m/s vs. 1.26±0.1 m/s], p<0.001) in the weight 
fluctuation cohort compared to controls. CV changes were seen across the posterior and 
inferior walls ([LAPW: p=0.024] and [LAIF: p=0.002]) but not in the lateral wall (LALW: 
p=0.328). In the RA, there was a 0.15 m/s reduction in mean CV in the weight fluctuation 
compared to controls ([1.09±0.1 m/s vs. 1.24±0.1 m/s], p<0.001). Regionally, slowed 
conduction was seen in the lower lateral and septal walls ([RALL: p=0.0158] and [RASW: 
p=0.0145]). In the upper lateral wall, conduction trended towards significant slowing with 
fluctuating weight (p=0.063).  
Importantly, final weight loss in the weight fluctuation cohort resulted in mean CV 
being mildly increased in both the LA and RA. Regionally, while CV was comparable in the 
posterior and inferior LA, CV was greater in the lateral wall in the weight fluctuation 
compared to obese sheep. Regional CV was reduced in the upper lateral and septal walls of 
the RA in obese animals compared to weight fluctuation ([RAUL: p<0.001] and [RASW: 
p<0.001]). However, the lower lateral wall had similar CV in both groups (p=0.963). 
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4.3.2.3 Electrogram Fractionation 
Obesity resulted in doubling of LA electrogram fractionation compared to controls ([24.7±3.6 
mm vs. 12.1±2.9 mm], p<0.001), see Table 1 and Figure 3A. With fluctuation in weight, LA 
fractionation was persistently increased compared to lean weight controls ([18.2±3.7 mm vs. 
12.1±2.9 mm], p=0.006). Fractionated electrograms were found be 50.4% higher in the 
weight fluctuation group. On the other hand, when compared to stable obesity, weight 
fluctuation was associated with 26.3% lower fractionated electrograms in the LA ([24.7±3.6 
mm vs. 18.2±3.7 mm], p=0.002).   
 
4.3.2.4 LA voltage  
See Table 1 and Figure 3B for a summary of LA voltages in all three groups. The mean LA 
voltage in the obese sheep was 6.5±1.1 mV. In the controls, we found similar results 
(6.5±0.8), with no significant difference between the two groups (p=1.0). The mean LA 
voltage was slightly reduced in the weight fluctuation group compared to lean controls 
(5.8±1.1 mV vs. 6.5±0.8 mV). However, this was not significantly different between the two 
(p=0.387). Similarly, weight fluctuation did not result in significant reduction in LA voltage 
compared to stable obesity in the sheep models ([5.8±1.1 mV vs. 6.5±1.1], p=0.387).  
 
4.3.3 Epicardial Adipose Tissue Remodelling  
See Table 1 and Figure 4 for summary of epicardial adipose tissue (EAT) quantified by 
cardiac MRI. In relation to the atria, epicardial adipose tissue was distributed adjacent to the 
LA posterior wall and atrioventricular groove (Figure 4A). Total cardiac EAT was greater in 
obese group compared to controls (p=0.037) and weight fluctuation (p=0.039). There was no 
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significant difference in total cardiac EAT depot between weight fluctuation and control 
groups (p=0.98). For the total atrial depot, there was slight increase in fat volume in obese 
group compared to controls but did not reach significance (p=0.2). The volume of total atrial 
EAT increased in obesity than did weight fluctuation group (p=0.02). No significant 
difference in LA EAT was noted for all groups. For RA EAT, depot volume did not 
significantly change between obese or weight fluctuation group and controls; however, obese 
animals showed almost 2-fold higher fat volume compared to weight fluctuation groups. 
 
4.3.3.1 Relationship of Epicardial Fat with Electrical Remodelling  
Table 2 and Figures 5 to 7 summarise the linear regression results of epicardial fat and 
electrical substrates. We noted weak correlation between total cardiac EAT and LA voltage 
and electrogram fractionation, which did not reach statistical significance (p>0.05 for both). 
Again, there was no significant correlation between total EAT and CV and ERP (p>0.05 for 
both). Chamber-based sub-analysis did reveal any significant relation between EAT and any 
electrical parameters (see Figure 5-7).  
 
4.4 DISCUSSION 
4.4.1 Major Findings 
The present study provides new mechanistic insights into the nature of fibro-fatty infiltrations 
as an evolving substrate for AF obesity and in fluctuating weight. Using a chronic ovine 
sheep model:  
Compared to reference controls, atrial substrate due to chronic obesity was characterized by: 
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1. 23% significant reduction in atrial endocardial conduction velocities 
2. More than 2-fold increased fractionated electrograms 
3. 14% abbreviated mean atrial refractoriness 
4. Nonsignificant change in left atrial voltage  
5. 46% significantly expanded total cardiac epicardial fat volume 
 
Compared to reference controls, atrial substrate due to weight fluctuation was characterised 
by: 
1. 12% to 16% significant reduction in conduction velocities in the atria 
2. 50.4% greater fractionated electrograms in left atrium 
3. Non-significant changes in mean refractoriness and left atrial voltage 
4. Nonsignificant change in total cardiac epicardial fat depots. 
 
Compared to stable obesity, final weight loss in weight fluctuation was characterised by: 
1. Significant weight reduction 
2. Significant reductions of right atrial (48%), total atrial (35%), and total cardiac 
epicardial (29%) fat depots 
3. 26.3% reduced fractionated electrograms 
4. Mildly increased conduction velocity 
5. 13% increased mean atrial ERP 
6. Nonsignificant change in LA EAT, regional ERPs, and LA voltage  
In summary, despite achieving weight loss, weight fluctuation during weight loss resulted in 
persistent atrial remodelling despite comparable volumes of epicardial fat depots as lean 
weight and showed similar atrial substrate to obesity, albeit to a lesser extent. These findings 
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are consistent with the clinical findings in the LEGACY study associated with weight 
fluctuation.345 
 
4.4.2 Pro-arrhythmic Substrate Due to Obesity  
Obesity is reported to associate with an increased risk of atrial arrhythmias in several 
epidemiological studies.261, 416 Indeed, intensive research is underway to delineate the 
mechanisms that may mediate this sinister clinical link. Given the low-grade inflammation, 
neurohumoral activations, and autonomic imbalance seen during chronic obesity, it is likely 
that they might drive the formation of AF substrate in obesity.181, 340 Consistent with this, in 
an earlier model of short-term obesity, we showed significant atrial enlargement, induction of 
fibrosis, and inflammatory infiltrates.181 Obesity was associated with greater expressions of 
pro-fibrotic markers, including endothelin (ET)-1, ET receptors (ETAR & ETBR), 
transforming growth factor-beta 1 and platelet-derived growth factor in dose-dependent 
fashions. Mahajan et al182 corroborated these findings by demonstrating LA enlargement, 
increased interstitial fibrosis with accompanying pro-fibrotic TGF-b1 expression using a 
sustained model of obesity, induced by high-calorie feeding for 72 weeks.  
Impairment in electrophysiological properties of the atrium is an important further 
requisite for AF substrate formation.11 We previously reported global biatrial endocardial 
remodelling characterized by conduction abnormalities, fractionated electrograms, and 
increased propensity for AF during sustained weight gain, highlighting that obesity could 
induce electrical remodelling.182 This is well in line with current findings. Nonetheless, 
unlike previous studies, we failed to see association of obesity with reduced posterior LA 
endocardial voltage, which we speculate could be blunted by chronic age of our models. 
 




4.4.3 Epicardial Fat and Pro-arrhythmic Substrate  
Epicardial fat expansion is an important factor involved in the pro-arrhythmic substrate 
formation. Experimental studies have shown cardiac MRI assessed EAT expansion as a 
common consequence of obesity, which underscores its role in explaining the clinical link 
between obesity and AF.181, 182 In the present study, we found significantly higher total 
cardiac fat depot but comparable atrial depots with controls. This is in line the findings of 
Wong et al263, reporting non-significant association between peri-atrial EAT and AF burden 
and risk of recurrence after catheter ablation. The author did note, however, that the AF 
burden or recurrence is driven by periventricular depots.263 Furthermore, we showed that 
weight fluctuation is associated with reduction of EAT depots as compared to obesity. 
 
4.4.4 Weight Fluctuation and AF Substrate 
In multiple lines of clinical reports, weight loss has been associated with changes in hormonal 
balance in patients.343, 344 This is postulated to impact both physiological and 
pathophysiological changes.419 These compensatory mechanisms were investigated by 
Sumithran et al344 in a population of postmenopausal women (BMI: 27-40 kg.m-2). After 
weight loss induced by calorie restriction, there was significant increase in appetite regulating 
factors, such ghrelin, gastric inhibitory polypeptide, and pancreatic polypeptide. One year 
after weight reduction, the changes did not return normal value at baseline, thus it highlights 
that the compensatory changes in these factors could cause weight relapse. Hypothetically, 
abnormal release of adipokines like leptin could both directly and indirectly pose great 
arrhythmogenic risk. Importantly, our current data sheds light on the potential nature of the 
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atrial substrate due to periodic fluxes in weight, a common clinical finding in patients.344 
Despite having comparable weights with reference controls, weight fluctuation sheep 
demonstrated LA enlargement, and abnormal atrial conduction and fractionated electrograms, 
without change in atrial endocardial voltage or refractoriness. More importantly, we noted 
that the electro-structural remodelling during weight fluctuation is less severe as compared to 
stable obesity. We believe these observations may explain the findings in the LEGACY 
study.  
 
4.4.5 Study Limitations 
Several limitations are worth noting in the current study. First, there was no segmentation 
performed for atrial EAT due to the limited resolution of CMR. We believe that this could 
have hidden important details on the regional distribution of EAT, which may have prevented 
conclusion on regions that may of important clinical relevance. Segmentation of EAT, as 
reported by Nagashima et al302, would have allowed us to determine EAT location that most 
likely mediate the observed elecro-structural substrate seen therein. It should be noted that 
those investigators used computed tomography as their imaging modality, which 
demonstrates much higher resolution.  
 
4.4.6 Potential Clinical Implications 
These findings provide a mechanistic basis for the clinical associations reported between 
expansion of epicardial fat and AF. EAT may represent a useful risk marker to identify 
patients at an increased AF risk which could allow a more personalized risk stratification. 
EAT could be a promising target for atrial fibrillation, a concept recently tested in patients 
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who underwent pulmonary vein isolation wherein treatment with atorvastatin led to reduction 
in EAT volume. Furthermore, these results provide mechanistic basis for the perils of 
periodic weight fluctuation often encountered in clinical settings. Although weight loss is 
likely to reduce EAT, fluxes in weight could remodel patients’ atria by induction of fibro-
fatty infiltrations and pathologic modulation of contractile units in myocytes. Further studies 
are warranted to explore potential therapies targeting intramyocardial fat cell depositions and 
to determine whether their modulation could constitute a treatment target for primary and 
secondary prevention of AF. 
 
4.5 CONCLUSIONS  
The findings herein demonstrate that chronic obesity induces significant reduction of 
endocardial CV remodelling, doubling of electrogram fractionation, abbreviation of 
refractoriness, and expansion of epicardial fat, without significant change in LA voltage. 
Despite comparable weight with controls, weight fluctuation was associated with significant 
conduction slowing and LA electrogram fractionation, without any significant change in 
mean refractoriness, LA voltage, or total cardiac fat depots. Compared to stable obesity, 
sheep with weight fluctuation showed significant weight loss, lower RA and atrial EAT, 
mildly greater endocardial CV, and increased mean atrial ERP, without significant change in 
LA EAT and LA voltage. This data demonstrates that weight fluctuation results in residual 








Table 1. Anthropometric, and Structural and Electrophysiological Characteristics of Obese, Weight Fluctuation and Control Sheep 
Parameter Control Obese Weight fluctuation 
p-value 
Obese vs. controls 
Weight fluctuation vs. 
controls 
Obese vs. weight 
fluctuation 
Weight (kg) 76.1±4.5 109.1±7.1 77.2±4.5 <0.001 0.960 <0.001 
LA EAT (mL) 4.3±1.3 5.0±2.0 4.2±1.1 0.666 0.987 0.556 
RA EAT (mL) 5.1±1.1 6.9±2.9 3.6±0.9 0.174 0.262 0.006 
Total atrial EAT (mL) 9.5±1.3 12.0±4.5 7.8±1.3 0.228 0.490 0.023 
Total cardiac EAT (mL) 163.5±22.1 238.4±77.1 169.4±47.7 0.037 0.980 0.039 
LA voltage (mV) 6.5±0.8 6.5±1.1 5.8±1.1 1.000 0.387 0.387 
CV, LA (m/s) 1.26±0.11 0.97±0.08 1.06±0.13 <0.001 <0.001 0.026 
CV, RA (m/s) 1.24±0.10 0.96±0.09 1.09±0.11 <0.001 <0.001 <0.001 
ERP mean (ms) 178.6±38.1 153.4±32.7 173.1±31.5 <0.001 0.640 0.003 
ERP, LA (ms) 162.0±33.2 140.0±21.8 161.0±23.5 0.140 0.929 0.074 
ERP, RA (ms) 179.0±22.8 157.0±31.7 180.0±15.9 0.165 0.911 0.081 
ERP, CS (ms) 199.0±40.8 171.0±23.5 182.0±41.1 0.115 0.438 0.490 
LA fractionation (mm)  12.1±2.9 24.7±3.6 18.2±3.7 <0.001 0.006 0.002 
LV ejection fraction (%) 41.6 (8.7) 44.9 (8.3) 45.1 (10.2) 0.710 0.336 0.694 
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Table 2. Relationship Between Total Cardiac Epicardial Fat and Structural and Electrical Substrates  
Parameter Pearson r r2 p-value 
LA voltage (mV) 0.262 0.069 0.251 
CV, LA (m/s) -0.141 0.020 0.542 
CV, RA (m/s)) -0.236 0.056 0.331 
ERP mean, LA (ms) -0.217 0.047 0.345 
ERP mean, RA (ms) -0.216 0.047 0.347 
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4.7 FIGURE LEGENDS 
Figure 1. Distribution of Effective Refractory Periods Across Atrial Sites and Animal 
Groups 
ERP was not changed as results of obesity or weight fluctuation across atrial chambes and 
regions, except in right atrial appendage. LAPW, left atrial posterior wall; LAIF, left atrial 
inferior wall; LAA, left atrial appendage; RAUL, right atrial upper lateral wall; RALL, right 
atrial lower lateral wall; RAA, right atrial appendage; Prox CS; proximal coronary sinus; Dist 
CS; distal coronary sinus; CN, controls; OB, obese; WF, weight fluctuation.  
Figure 2. Changes in Conduction and Conduction Heterogeneity Caused by Weight 
Fluctuation 
Panel A: Endocardial conduction velocity measured six atrial sites. Panel B: Epicardial 
conduction velocity measured across two corners in control, obese and weight fluctuation sheep. 
Panel C: Mean conduction heterogeneity indices of control, obese and weight fluctuation sheep 
measured across two epicardial plaque corners. LAPW, left atrial posterior wall; LAIF, left 
atrial inferior wall; LALW, left atrial lateral wall; RAUL, right atrial upper lateral wall; RALL, 
right atrial lower lateral wall; RASW, right atrial septal wall; C1; corner 1; C2; corner 2; CN, 
controls; OB, obese; WF, weight fluctuation; CHI, conduction heterogeneity index; ns, p>0.05. 
Figure 3. Left Atrial Voltage and Electrogram Fractionation Changes Induced by Weight 
Fluctuation 
Panel A: Left atrial electrogram fractionation of control, obese and weight fluctuation animals. 
Panel B: Left atrial voltage. #, p<0.05: obese vs. controls; &, p<0.05: obese vs. weight 
fluctuation; *, p<0.05: weight fluctuation vs. controls; CN, controls; OB, obese; WF, weight 
fluctuation. 
Figure 4. Epicardial Fat Volume Quantified by Cardiac MRI 
Panel A: Distribution of fat on freshly harvested sheep heart. Fat is mostly abundant around the 
atrioventricular groove and interventricular sulcus. Adipose could also be observed around the 
atrial appendages (white arrowhead showing the left appendage). Panel B: Representative CMR 
images in long-axis view, demonstrating the distribution of epicardial adipose tissue in the three 
study groups; atrial EAT depots are highlighted with contours. Panel C: Box and Whisker charts 
 
   
 
151 
demonstrating quantified volumes of EAT from the four cardiac chambers; showing total 
cardiac, total peri-atrial, left and right atrial EAT volumes, respectively. CN, controls; OB, 
obese; WF, weight fluctuation. 
Figure 5. Relationship Between Epicardial Fat and Effective Refractory Period 
Panel A: Correlation between total peri-atrial epicardial fat and mean left atrial ERP. Panel B: 
Correlations between right atrial EAT and right atrial ERP.  
Figure 6. Relationship Between Epicardial Fat and Atrial Conduction 
Panel A: Correlation between total epicardial fat and conduction velocity in the left atrium. 
Panel B: Correlations between epicardial fat and conduction velocity in the right atrium. 
Figure 7. Relationship Between Epicardial Fat and Fractionated Electrogram and Atrial 
Voltage 
Panel A: Correlation between total epicardial fat and electrogram fractionation in left atrium. 
Panel B: Correlations between epicardial fat and voltage in the left atrium. 
  
 
   
 
152 





















   
 
153 




























































   
 
154 

































B Atrial Voltage across Groups
Atrial Electrogram Fractionation across Groups
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5. Chapter Five 
Cellular Mechanisms of Epicardial Fat in Obesity and 
Weight Fluctuation – Fibrofatty Infiltrations, 
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5.1 INTRODUCTION  
Epicardial adipose tissue (EAT) has emerged as an important factor for formation of the atrial 
pro-arrhythmic substrate. EAT expansion, which occurs during weight gain, predicts increased 
risk of atrial fibrillation (AF)182, poorer outcomes following catheter ablation263 and bypass 
grafting409, and correlates with greater risk of thromboembolic events304, 305, 420. Moreover, this 
association is reported to be independent of traditional measures of obesity, indicating that EAT 
can influence AF risk independently of obesity. 
 Recent advances have implicated epicardial fat in ectopic focal mechanisms and re-
entrant substrates requisite for the initiation and perpetuation of AF.11, 35, 119, 122, 128, 137 EAT has 
been associated with structural abnormalities promoting AF, such as induction of atrial 
fibrosis278, atrial enlargement/stretch181, 182, and inflammation271, 272, 388. We have also 
demonstrated relations between the ectopic fat and electrical substrate in a clinical model of 
obesity. Nonetheless, there is great paucity of data characterising the cellular and ultrastructural 
changes that may mediate EAT-induced atrial remodelling.  
Consequently, therapeutic recourses targeting adiposity and limiting expansion of EAT 
are exciting research endeavours. In fact, weight loss has been established to reduce the burden 
of AF, with dose-dependent effects reported.334, 345 However, recent clinical evidence has 
challenged this notion given that obese individuals often experience oscillation in weight.344 For 
example, weight fluctuation was shown to offset the beneficial effects of weight loss, with more 
than 5% weight fluctuation in associated with twofold greater risk of arrhythmia recurrence after 
ablation.345 The puzzling question remains as to what constitute the atrial substrate due to these 
fluxes in weight. We hypothesised that the periodic weight gains during weight fluctuation will 
result in fibrofatty infiltrations similar to obesity but that the degree of EAT remodelling may not 
be as severe.   
In the present study, we aimed to characterise ultrastructural changes responsible for 
EAT-induced atrial remodelling; spatial distribution of lipids due to weight fluctuation and 








5.2.1 Animals  
Twenty-four Merino Cross Wethers sheep (Ovis aries) were studied in accordance with 
guidelines outlined in the “Australian Code for the Responsible Conduct of Research, 2007 (the 
2007 Code)” adopted jointly by the National Health and Medical Research Council, the 
Australian Research Council and Universities Australia. The protocol and animals used herein 
were approved by both the animal research ethics committees of the University of Adelaide and 
the South Australian Health and Medical Research Institute, Adelaide, Australia, which adhere to 
the Guidelines for the Care and Use of Animals for Research Purposes. 
 
5.2.2 Obese Ovine Model  
Obesity was induced in 8 sheep using a previously well characterised protocol. In brief, sheep 
were commenced on a high-calorie diet for a period of 40 weeks and maintained in this state for 
another 40 weeks. Obesity induction was started at baseline, whereby healthy sheep with normal 
weight were put on a diet consisting of energy-dense soy-bean oil (2.2%) and molasses-fortified 
grain and maintenance hay with weekly weight measurement. Excess voluntary intake was 
predominantly of grass alfalfa silage and hay. Pellets were gradually introduced at 8% excess 
basal energy requirements and rationed to 70% of total dry-matter intake. Blood samples were 
periodically collected to ensure electrolyte and acid-base homeostasis.  
 
5.2.3 Weight Fluctuation Model 
Another group of 8 sheep was maintained as the weight fluctuation animal and were commenced 
on a four 20-week cycles of weight gain/weight loss. All animals were commenced on a high-
calorie diet similar to obese sheep for a period of 20 weeks. Thereafter, sheep were maintained 
on high quality hay for another 20 weeks to induce weight loss, with energy-dense pellets 
rationed at just 0.75% of body weight. At the end of the 20 weeks, the cycle was repeated again. 
Blood samples were periodically collected to ensure electrolyte and acid-base homeostasis.  
 
 
   
 
162 
5.2.4 Lean Control Model  
Eight age-matched sheep were maintained as controls at their baseline weight. To do this, high-
quality hay was provided ad libitum, while energy-dense pellets were rationed at 0.75% of body 
weight. The nutritional content of food and housing conditions were identical for all three 
groups, with only the amount of food intake varying. 
 
5.2.5 Animal Preparation 
Animals were pre-acclimatized for at least 1 week before any surgery. Shorn weight was 
recorded immediately before surgery. 
 
5.2.6 PROTOCOL 
5.2.6.1 Body Composition  
Dual-energy x-ray absorptiometry scans were performed to accurately determine total body fat in 
the animals. 
 
5.2.6.2 Haemodynamic Assessment  
Invasive blood pressure (BP) monitoring was performed during the electrophysiology study. Left 
atrial (LA) and right atrial (RA) pressures were recorded. 
 
5.2.6.3 Cardiac MRI  
Before open chest surgery, animals underwent cardiac MRI using 1.5 Tesla (Siemens Sonata, 
MR Imaging Systems, Siemens Medical Solutions, Erlangen, Germany) with 10-mm slices 
through the ventricles without interslice gaps. To do this, animals were securely placed in the 
dorsal recumbent position for scanning. Mechanical ventilation was maintained, facilitating 
electrocardiogram-gated image acquisition with periodic breath holding. Analyses were 
performed offline by blinded operators by using the proprietary software QMass MR (Medis 
medical imaging systems, Leiden, The Netherlands). The following parameters were measured 
as previously described: Left ventricular chamber mass; LV ejection fraction (LVEF); Left atrial 
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end-systolic volume (LA-ESv); LA end-diastolic volume (LA-EDv); and right atrial end-systolic 
volume (RA-ESv). 
 
5.2.6.4 STRUCTURAL CHARACTERISATION 
Following the electrophysiological study, the sheep were maintained under general anaesthetic. 
Thereafter, they were euthanised by lethal dose of phentobarbitone injection, with samples taken 
for detailed histological and ultrastructural analyses.  
 
5.2.6.4.1 Histological Assessment 
Following euthanasia, atrial tissues were isolated from the LAA and RAA, perfusion-fixed with 
4% paraformaldehyde and immersed in 10% buffered formalin. Tissue sections were processed 
and embedded in paraffin wax. Fixed blocks were cut into 5-µm serial sections and stained with 
haematoxylin and eosin (H&E) and Periodic Acid Schiff (PAS), respectively.  
 
5.2.6.4.1.1 Fibrofatty Infiltration Assessment 
The fibrofatty infiltration of the atria by was confirmed in Oil O Red preparations and H&E 
stained sections, and assessed on Masson’s Trichrome stained sections as previously published. 
Slides were scanned by NanoZoomer digital image scanner and viewed on NDP.view 2 
(Hamamatsu Photonics K.K., Japan). 6 sections were photographed at 100 µm (20x) 
magnification and processed in ImageJ (National Institutes of Health, USA). The following 
parameters were assessed: 
1. Grade infiltration: Fatty infiltrates were graded by the extensive nature of the infiltration 
using scoring algorithm modified from previously published protocol (Figure 1). The 
algorithm ran on 1- to 4-point grade scale. Grading was done for the most severe infiltrate 
per section and repeated for obese, weight fluctuation and control sheep. The grades of 6 
sections were taken and averaged (presented as mean per animal and number of sections 
per grade).  
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2. Percent infiltration: The percent area covered by all fibrofatty infiltrates per sections was 
measured and expressed as percentage of the total section area. This was done by manual 
segmentation, which was defined in the region of interest (ROI) manager of ImageJ. 
3. Total area of infiltration: The total area of fibrofatty infiltrate was assessed by manual 
segmentation (ROI manager). This was done for the same subset of infiltrate used for 
determining grade infiltration. 
4. Number of adipocyte infiltrates: The largest infiltrate (same used for grade infiltration 
and area of fibrofatty infiltration) was used to determine the number of adipocytes per 
infiltrate per section. This was determined in 6 to 10 sections and averaged. 
5. Adipocyte size: Individual adipocyte characteristics were assessed by manual 
segmentation in the ROI manager (ImageJ). The following parameters were determined: 
the average area of adipocytes (pixel2); the average thickness of adipocytes per infiltrate 
measured by Ferret’s diameter (pixel); and perimeter of each adipocyte (pixel). The 
Ferret’s diameter was determined as the longitudinal distance across each adipocyte – 
longest distance between two points across the adipocyte. 
6. Collagen area in infiltrate: The amount of collagen in infiltrate was determined to show 
the extent fibrotic remodelling of the infiltrate. The collagen fibres were traced by manual 
segmentation in ROI manager (ImageJ) and measured in pixel. 
 
5.2.6.4.1.2 Myolysis Assessment and Glycogen Accumulation 
To quantify the degree of myolysis (sarcomere loss), 5-µm sections were stained with periodic 
acid Schiff (PAS). This was with the understanding that the loss of sarcomeric myofibrils results 
in gradual accumulation of the cytoplasmic space by glycogen molecules, which stain with a 
magenta colour on PAS against a toluidine blue background. Fifteen image sections per site were 
photographed at 25 µm distance (80x magnification) for a total of 8 animals per group. 
Assessment of myolysis was only done by counting number of myocytes with intact nucleus in 
the plane of the section. The grading of myolysis was performed as previously published122 but 
with modification, as follows: 
§ Myocytes with <10% glycogen accumulation of the cytosol were considered to have no 
myolysis 
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§ Myocytes with 10% to 25% glycogen accumulation were considered to be mildly 
myolytic  
§ Myocytes with >25% to 50% glycogen accumulation were considered to be moderately 
myolytic 
§ Myocytes with >50% glycogen accumulation were considered to be severely myolytic 
The percentage of total myolysis was expressed as: (Number of myocytes with >10% glycogen 
accumulation/Total myocyte count) x 100%. 
 
5.2.6.5 Matrix-Assisted Laser Desorption Ionization Imaging Mass 
Spectrometry  
Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry imaging (MALDI 
MSI) was used to determine spatial distribution of lipids in the atrial tissues in obesity and 
weight fluctuation. Following non-survival experiments, hearts were harvested and dissected and 
snap-frozen in liquid nitrogen and stored in -80˚C until further use.10-µm thick sections were cut 
at -20. To assist with desorption and ionisation, tissue sections were coated with 3 mg of α-
cyano-4-hydroxycinnamic acid (αCHCA) matrix by sublimation. A laser was used to ionise the 
lipids and electric field was applied until they reached the detector. The laser set to an intensity 
of 150 a.u. and fired for 1.5 seconds per location at a repetition rate of 200 Hz. A spatial 
resolution of 60 µm was selected and a mass range of m/z 50-990 was acquired. MALDI Images 
were obtained using a MALDI Synapt HDMS Mass Spectrometer (Waters Corporation) in MS 
mode. Images were visualised using Biomap (Novartis). 
 
5.2.7 Statistical Analysis  
Data were tested for normality using Shapiro-Wilk tests. Normally distributed continuous data 
were expressed as mean plus or minus standard deviation (SD) and analysed with ANOVA 
across groups (controls, obese and weight fluctuation). Skewed distributions were expressed as 
median and interquartile range (IQR) and medians tested using Mann-Whitney U-tests, or 
Kruskal-Wallis tests. Nominal data was analysed by Chi-square tests of independence. In the 
case of skewed distribution (i.e., total myolysis assessment with PAS staining), data were log-
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transformed before further analysis. To determine the correlation of myolysis with structural 
substrates, we fitted bivariate linear regression and estimated Pearson correlation coefficient (r) 
and r2. Two-sided p-values ≤0.05 were considered statistically significant. All analyses were 
performed using SPSS version 25 (IBM SPSS Statistics, Chicago, Illinois) and GraphPad Prism 
version 7.0d (GraphPad Software, La Jolla, CA, USA). 
 
5.3 RESULTS 
5.3.1 Group Characteristics  
After 80 weeks of high-calorie feeding, the obese group demonstrated significant weight gain 
compared to controls (109.1±7.1 kg.m-2 vs. 76.1±4.5 kg.m-2), see Table 1. The weight 
fluctuation group reached obese state by 20 weeks; after this, they lost weight for 20 weeks, with 
obesity re-induced for another 20 weeks before finally undergoing another round of weight loss 
reaching a weight of 77.2±4.5 kg.m-2. The final weights of the controls and the weight 
fluctuation sheep were not significantly different from each other (p>0.05). The Electrolyte, 
acid-base, and glucose levels remained within their normal ranges throughout the over feeding 
process. 
 
5.3.2 Structural, Functional and Haemodynamic Remodelling 
Blood Pressure 
Changes in systolic BP are presented in Table 1, respectively. Obesity resulted in significant 
increase BP compared to controls (BP [93.2±14.3 vs. 79.4±5.0], p=0.034). Systolic BP changes 
were comparable in the weight fluctuation and lean controls (BP [80.8±10.1 vs. 79.4±5.0], p=ns). 
We observed higher systolic BP in the obese groups as compared to weight fluctuation 
(93.2±14.3 vs. 80.8±10.1), which trended towards significance (p=0.053).  
 
5.3.2.1 Atrial Volume 
Tables 1 & 2 provide summary of chamber characteristics of the study groups. The volume of 
the left atrium (LA) was increased (p=0.001) by 32% (53.6±5.8 cm3 vs.40.6±3.0 cm3) during 
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sustained obesity. Similarly, weight fluctuation resulted in significant increase in left atrial 
volume compared to controls (LA Volume [48.5±6.6 cm3 vs. 40.6±3.0 cm3], p=0.025). We found 
the change LA volume to weight fluctuation to be less severe than stable obesity (LA volume 
[53.6±5.8 cm3 vs. 48.5±6.6 cm3], p<0.001). In the RA, we observed significant difference in 
chamber volumes across the three groups (p>0.05). Furthermore, there was no significant change 
between obese and controls in volumes at the end of diastole or systole in all comparisons 
(p>0.05 for all). The same was true for weight fluctuation (p>0.05). We also did not find any 
significant change in LV ejection fractions across all groups(p>0.05). 
 
5.3.2.2 Atrial Pressure 
Table 1 and Figure 2 provide summary of haemodynamic characteristics of the study groups. 
Both obesity and weight fluctuation caused elevation in LA pressure. We observed more than 2-
fold increased mean LA pressure compared to controls (Pressure [8.5±1.9 mm Hg vs. 3.7±0.9 
mm Hg], p<0.001). With weight fluctuation, the sheep demonstrated 1.5 times higher mean LA 
pressure than lean controls (Pressure [5.7±1.8 mm Hg vs. 3.7±0.9 mm Hg], p=0.02), though this 
was less severe than in stable obesity (Pressure [8.5±1.9 mm Hg vs. 5.7±1.8 mm Hg], p=0.02). 
We further explored diastolic and systolic pressure changes, see Figure 2A. Obesity resulted in 
increased LA systolic and diastolic pressures compared to control (systolic [11.1±2.0 mm Hg vs. 
6.7±0.9 mm Hg], p=0.002; diastolic [6.0±1.8 mm Hg vs. 2.1±1.1 mm Hg], p<0.001) or weight 
fluctuation groups (systolic [11.1±2.0 mm Hg vs. 7.7±3.0 mm Hg], p=0.015; diastolic [6.0±1.8 
mm Hg vs. 3.6±1.0 mm Hg], p=0.007). On the other hand, LA systolic and diastolic pressures 
did not significantly change with weight fluctuation compared to lean controls (systolic [7.7±3.0 
mm Hg vs. 6.7±0.9 mm Hg], p=0.002; diastolic [3.6±1.0 mm Hg vs. 2.1±1.1 mm Hg], p<0.001). 
In the right atrium, obesity resulted in more than 2-fold greater mean right atrial (RA) 
pressure and lean controls (p<0.01), Table 1. Similarly, higher mean RA pressure was noted in 
the obese group compared to weight fluctuation group (p=0.048). We found RA systolic and 
diastolic pressure to be higher in obese sheep compared to controls and animals with weight 
fluctuation, see Figure 2B. Compared with controls, weight fluctuation did not result in greater 
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mean RA pressure (p<0.05 for all). Additionally, the systolic and diastolic pressures were 
significantly changed weight fluctuation in comparison to lean controls.  
 
5.3.3 Fibrofatty Infiltration  
Results for the fibrofatty infiltrations are summarised in Table 2 and Figures 3 & 4. Due to 
chronic age of our model, the controls did show some appreciable infiltration of atrial 
myocardium by fat cells (Figure 3A, left inset). However, with obesity and weight fluctuation, 
the animals demonstrated extensive and widespread fatty infiltrations (Figure 3A, mid & right). 
The most severe infiltrates were characterised by excessive presence of adipocytes and 
inflammatory cells (Figure 3B, arrowheads). More intriguingly, there were presence of giant 
syncytia-looking fat cells likely indicative of cell fusions, which were more common in weight 
fluctuation group (Figure 3C, arrowheads). Both the obese group and weight fluctuation had 
greater average grade infiltrations compared to controls (p<0.05, Figure 4A). There was 
progressive increase in the number of obese and weight fluctuation animals as the infiltrate 
becomes more severe (p = 0.001, Figure 4B). There was no significant difference between obese 
and weight fluctuation groups (p >0.05 Figure 4A). The findings were consistent across both 
atrial chambers. When the region of infiltration was studied more comprehensively, only weight 
fluctuation was associated with significant greater adipocyte number than controls (Figure 4D). 
In the LA, collagen content of the infiltrate was not different between obese and controls (p = 
0.16) but was significantly greater in weight fluctuation group compared to controls (p = 0.042). 
In the RA, there was greater collagen deposition in the infiltrates in the obese group than controls 
(p = 0.05, Figure 4C). 
 
5.3.3.1 Fibrofatty Infiltrations and Electrical Remodelling  
See Table 3 and Figure 5-7 for the summary of the linear regression of fibrofatty infiltrations 
and electrical substrate. Mean atrial fibro-fatty infiltration was correlated with LA and RA CV’s 
and LA electrogram fractionations ([LA CV: r2 = 0.35, p = 0.006], [RA CV: r2 = 0.52, p = 0.001] 
and [fractionated electrogram: r2 = 0.50, p <0.001] Table 3), but not LA voltage or ERP (p > 
0.05 for both). We further evaluated chamber-based correlations. Consistent with results for 
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mean atrial infiltration, LA mean infiltration was correlated with LA fractionated electrograms 
and LA CV but not LA voltage (p >0.05, Figure 7C) or LA mean ERP (p >0.05, Figure 5D). 
The correlation was better with fractionated electrograms than with LA CV ([LA fractionation: r2 
= 0.51, p <0.001], [r2 = 0.38, p = 0.004] Figures 6A & 7A). RA mean infiltration was also 
correlated with RA CV (r2 = 0.45, p = 0.003, Figure 7), but like atrial mean atrial infiltration, it 
did not correlate with RA mean ERP (p = 0.37, Figure 7). 
 
5.3.3.2 Myolysis  
As can be seen in Figure 8 panel A, most myocytes in the control group maintained their 
sarcomeric architecture as indicated by low cytosolic glycogen; only few had mild to moderate 
myolysis. With sustained obesity, the animals showed signs of extensive deterioration of 
myofibres and replacement of the contractile units by glycogen. Weight fluctuation exhibited 
similar impairment of contractile units, albeit to a lesser extent. In the LA, the percent total 
myolysis (mild + moderate + severe) increased in the obese group to more than 2.5-fold those in 
the control group (95.8±2.0% vs. 38.3±16.3%, p <0.001) and by 30% of the weight fluctuation 
group (95.8±2.0 vs. 70.2±9.3%, p = 0.001), Table 2 and Figure 8 panel B. The total myolysis in 
weight fluctuation groups increased to almost twice those in the controls (70.2±9.3% vs. 
38.3±16.3%, p = 0.012), Table 2 and Figure 8 panel B. In the RA, both obese and weight 
fluctuation animals showed greater total myolysis than controls (p = 0.001 for both), but 
comparable myolysis between both groups (p = 0.92), see Table 2 and Figure 8 panel B.  
Furthermore, there were observations of progressive severity of myolysis in the obese 
and weight fluctuation animals, see Figure 9. Myocytes with severe myolysis (>50% of cytosol 
covered by glycogen) were very few in the reference control group but greatly increased in both 
obese and weight fluctuation groups. Myocytes with less severe degree of myolysis became more 
prevalent in the controls and less so in the stable obesity and weight fluctuation groups. 
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5.3.3.3 Association of Myolysis with Structural and Functional 
Substrates  
 See Table 4 and Figure 10-11 for the summary of the linear regression of fibrofatty infiltrations 
and structural and functional substrates. Mean atrial myolysis was positively correlated with: 
body weight (r2=0.39, p=0.025); atrial volume ([LA: r2=0.37, p=0.009], [not with RA: r2 = 0.09, 
p=0.23]; atrial pressures ([LA: r2=0.40, p<0.01], [RA: r2=0.28, p=0.03]); but not with systolic BP 
nor LV ejection fraction (p>0.05). We further evaluated chamber-based correlations. Consistent 
with results for mean atrial myolysis, both LA and RA myolysis did not correlate with systolic 
BP (p= 0.1 and 0.09). LA myolysis showed strong positive correlation with LA volume (r2=0.51, 
p<0.01), meanwhile a negative correlation was found with RA myolysis and RA volume, though 
this was not significant (p=0.09). Additionally, both LA and RA myolysis were correlated with 
left and right atrial pressures ([LA: r2=0.47, p=0.007] and [RA: r2=0.26, p=0.04]), but not with 
LVEF (p>0.05), Figures 12 & 13.  
 
5.3.3.4 Lipid Remodelling by Matrix-Assisted Laser Desorption 
Ionization Imaging Mass Spectrometry 
Please refer to Figure 14 for the lipid maps. We identified five lipid groups that had the most 
abundant spectral peaks: 184.06, 205.99, 760.57, 264.25, and 454.36, respectively (Figure 14 
panel B). The m/z of 184.06, which corresponds to phosphatidylcholine (PC)/sphingomyelin 
headgroup, was abundant in the myocardium but not in epicardial layer, with most intensity seen 
in controls. Similar findings were observed for m/z of 760.57 (PC 34:1). m/z of 205.99, which 
could not be identified in the present pilot study, was more associated with fat regions. 
Differential expression and abundance were also noted for the m/z of 454.36, which again could 
not be identified, and was only observed in the obese myocardium. No further quantitative 
analysis was done due to the pilot nature of the present study, which was aimed to investigate the 
potential usefulness of MALDI imaging as a tool for mapping fibro-fatty lipid substrate.  
 
 




5.4.1 Major Findings 
The present study provides new mechanistic insights into the nature of fibro-fatty infiltrations as 
an evolving substrate for AF obesity and in fluctuating weight. Using a chronic ovine sheep 
model:  
Compared to reference controls, atrial substrate due to chronic obesity was characterized by: 
1. 13.8 mm Hg greater systolic blood pressure 
2. 32% increased left atrial volume 
3. 2-fold greater left and right atrial pressures 
4. Significant fibrofatty infiltrations characterised by excessive presence of adipocytes, 
collagen and inflammatory infiltrates 
5. 2.5-fold extensive myolysis and deterioration of myocyte contractile apparatus  
6. Nonsignificant change in right atrial dimension 
 
Atrial substrate due to weight fluctuation was characterised by: 
1. Increased left atrial size compared to controls, but less severe compared to stable obesity 
2. Nonsignificant change in right atrial volume compared to controls or to stable obesity 
3. 1.5 times higher left atrial pressure compared to controls, but less severe than in obesity 
4. Nonsignificant change in right atrial pressure compared to controls, but reduced in 
comparison to obesity 
5. Significant fibrofatty infiltrations characterised by excessive adipocytes, collagen 
deposits and inflammatory infiltrates, but comparable to stable obesity 
6. 2-fold significant and progression of myolysis of myocytes, but 30% less severe than in 
stable obesity 
7. Characteristic profile and abundance of lipid species in the atrial myocardium 
8. Nonsignificant change in systolic blood pressure 
  
In three groups, atrial substrate is characterised by: 
1. Significant negative correlation between mean grade infiltration and conduction velocity 
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2. Significant positive correlation between mean grade infiltration and electrogram 
fractionation 
3. Significant correlation of grade infiltration with left atrial volume, but no correlation with 
right atrial volume 
4. Nonsignificant correlations of infiltrations with left atrial voltage nor refractoriness 
5. Significant correlations of myolysis with: 
a. Body weight 
b. Left atrial volume 
c. Left and right atrial pressures 
6. Nonsignificant correlations between myolysis and systolic blood pressure and right atrial 
volume 
In summary, weight fluctuation demonstrated an established pathological atrial remodelling 
despite comparable volumes of epicardial fat depots as lean weight and showed similar atrial 
substrate to obesity, albeit to a lesser extent.  
 
5.4.2 Pro-arrhythmic Substrate Due to Obesity  
Obesity is reported to associate with an increased risk of atrial arrhythmias in several 
epidemiological studies.416, 421 Indeed, intensive research is underway to delineate the 
mechanisms that may mediate this sinister clinical link. Given the low-grade inflammation, 
neurohumoral activations, and autonomic imbalance seen during chronic obesity, it is likely that 
they might drive the formation of AF substrate in obesity.181, 340 Consistent with this, in an earlier 
model of short-term obesity, we showed significant atrial enlargement, induction of fibrosis, and 
inflammatory infiltrates.181 Obesity was associated with greater expressions of pro-fibrotic 
markers, including endothelin (ET)-1, ET receptors (ETAR & ETBR), transforming growth 
factor-beta 1 and platelet-derived growth factor in dose-dependent fashions. Mahajan et al.182 
corroborated these findings by demonstrating LA enlargement, increased interstitial fibrosis with 
accompanying pro-fibrotic TGF-b1 expression using a sustained model of obesity, induced by 
high-calorie feeding for 72 weeks. Interestingly, in the present study involving a very chronic 
model of obesity, we showed both abnormal atrial dimensions and haemodynamics.  
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Impairment in electrophysiological properties of the atrial is an important further 
requisite for AF substrate formation.11 We previously reported global biatrial endocardial 
remodelling characterized by conduction abnormalities, fractionated electrograms, and increased 
propensity for AF during sustained weight gain, highlighting that obesity could induce electrical 
remodelling.182 This is well in line with current findings. Nonetheless, unlike previous studies, 
we failed to association of obesity with reduced posterior LA endocardial voltage, which we 
speculate could be blunted by chronic age of our models. 
 
5.4.3 Epicardial Fat and Pro-arrhythmic Substrate  
Epicardial fat expansion is an important factor involved in the pro-arrhythmic substrate 
formation. In clinical reports, EAT is shown to predict greater risk for AF presence, severity and 
recurrence after ablation.263, 265, 266 When compared to traditional markers of adiposity, such as 
BMI and waist circumference, EAT demonstrates superior risk prediction for AF. The link 
between EAT and AF has been further demonstrated several preclinical models. For example, 
experimental studies have shown that cardiac MRI assessed EAT expansion occurs as a common 
consequence of obesity and that it may explain the clinical link between obesity and AF.181, 182 
Additionally, EAT secretome is shown to promote fibrosis, alteration of pro-fibrotic signalling, 
myocyte electrical properties. 
 
5.4.4 Epicardial Fat-mediated Ultrastructural Remodelling 
According to the prevailing hypothesis, induction of fat cell infiltration could occur as a 
consequence of epicardial fat expansion, further adding to the substrate due to obesity.182, 280, 388, 
412 This was recently confirmed in an experimental study by Mahajan et al182, which 
demonstrated significant invasion of contiguous posterior left atrial myocardial walls by 
epicardial fat cells following long-term weight gain. In the current study, we noted substantial 
presence of infiltrated intramyocardial fat cells. When we studied this a bit more in-depth, we 
discovered that these fatty infiltrates were more extensive and severe in chronic obesity and 
weight fluctuation, which were characterised by increased presence of fibrotic scar tissue and 
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inflammatory infiltrates. The adipocytes exhibited signs of cell fusion more characteristics of 
syncytia formation rather than hypertrophic growth. 
Myocardial fibro-fatty infiltrations represent more than just an epiphenomenon. The 
electrical inertness or lack of heat conductivity of fat is a long-established concept281, 422 and 
could, indeed, underlie sinister pro-fibrillatory mechanisms.11, 120 Consistent with this, our data 
showed significant correlation of fibro-fatty infiltrates with complex electrogram fractionations, 
which serve as cardinal signs of complexity in fibrillatory circuitry.11 We propose that these non-
excitable cells could promote reduction in cell–cell coupling and increased local conduction 
blocks that can promote re-entry, electrical dissociation, and wave breakthrough.  
Furthermore, the presence of fatty infiltrates in the microenvironment of myocytes may 
aggravate the paracrine effects of the EAT secretome. This could permit a more direct 
modulating effect on the cardiac myocytes by secreting myriad cytokines with ability to alter the 
functional and structural properties of the atrial myocytes.11, 120, 282 It is intriguing that, in the 
present study, our results demonstrated extensive myofibrillar remodelling, highlighting that 
increased adiposity leads to ultrastructural changes in the myocytes. Additionally, the extent of 
myofibrillar remodelling was correlated with atrial enlargement and haemodynamic 
impairments. This was observed in both the obese and weight fluctuation models, thus implying 
that fluctuating could promote ultrastructural change akin to obesity. It is likely that subcellular 
changes like myolysis and perturbation of lipid signature occur early on before overt AF 
substrate. This concept is well supported by other reports, which have shown that changes at 
subcellular levels, occurring early on in the time of structural remodelling (1 to 3 weeks), 
contribute to AF pathogenesis. Additionally, it could allow for closer and direct cellular crosstalk 
between fat cells and intramyocardial fibroblasts, increasing the likelihood of the latter to 
transmogrify into aggressive collagen-depositing myofibroblasts.388 It is intriguing that the 
results reported herein demonstrated extensive fibrotic scare formation with progressive severity 
of fibro-fatty infiltrates.   
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5.4.5 Atrial Substrate in Weight Fluctuation 
Obesity relapse remains one major bottleneck in weight management programs. Data from 
several trials have implicated compensatory mechanisms, such as reduced energy expenditure, 
changes in adipogenic (i.e., leptin) and appetite regulating hormones, as likely culprits.343, 344, 419 
Potential cardiomodulatory effect of weight fluctuation was recently demonstrated by us. In a 
long-term follow-up study, we showed worsening of benefits of weight loss with more than 5% 
fluctuation in weight of patients.345 We speculate that the changing adipokines following 
fluctuating weight may modulate atrial electrophysiology and predispose to AF. Indeed, recent 
data suggest that leptin may mediate angiotensin-II-423 and high-fat-diet-induced424 atrial fibrosis 
and induction of AF. It is notable that, in the present study, demonstrated residual areas of atrial 
enlargement and atrial pressure increases, which could mediate diastolic dysfunction and AF 
substrate. More importantly, we noted significant fibrofatty infiltrations and myolysis, which 
correlated strongly with structural and haemodynamic remodelling during in weight fluctuation. 
We believe this data may plausible explanation to the results of the LEGACY study. Taken 
together, it is possible that stable obesity and WF promote atrial remodelling via alternate 
upstream mechanisms, the EAT-trigger and compensatory adipokine (EAT-independent) 
pathways, respectively. 
 
5.4.6 Study Limitations 
Several limitations are worth noting in the current study. First, there was no segmentation 
performed for atrial EAT due to the limited resolution of CMR. We believe that this could have 
hidden important details on the regional distribution of EAT, which may have prevented 
conclusion on regions that may of important clinical relevance. Segmentation of EAT, as 
reported by Nagashima et al302, would have allowed us to determine EAT location that most 
likely mediate the observed elecro-structural substrate seen therein. It should be noted that those 
investigators used computed tomography as their imaging modality, which demonstrates much 
higher resolution.  
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5.4.7 Potential Clinical Implications 
These findings provide a mechanistic basis for the clinical associations reported between 
expansion of epicardial fat and AF. EAT may represent a useful risk marker to identify patients 
at an increased AF risk which could allow a more personalized risk stratification. EAT could be 
a promising target for atrial fibrillation, a concept recently tested in patients who underwent 
pulmonary vein isolation wherein treatment with artovastatin led to reduction in EAT volume. 
Furthermore, these results provide mechanistic basis for the perils of periodic weight fluctuation 
often encountered in clinical settings. Although weight loss is likely to reduce EAT, fluxes in 
weight could remodel patients’ atria by induction of fibro-fatty infiltrations and pathologic 
modulation of contractile units in myocytes. Further studies are warranted to explore potential 
therapies targeting intramyocardial fat cell depositions and to determine whether their 
modulation could constitute a treatment target for primary and secondary prevention of AF. 
 
5.5 CONCLUSIONS  
The findings herein demonstrate that chronic obesity induces fibro-fatty replacement of atrial 
myocytes and deterioration of myocyte contractile apparatus, which may drive impairments of 
atrial electrical properties. Weight fluctuation induces similar but less severe changes to those 
seen during stable obesity and this may explain the increased risk of atrial arrhythmias during 
periodic fluxes in weight. Fibro-fatty infiltrations underlie important substrate for the 
pathogenesis of atrial fibrillation, which necessitate therapies targeting intramyocardial fat cell 
depositions. 
 




Table 1. Anthropometric and Haemodynamic Characteristics 
Parameter Control Obese Weight fluctuation 
p-value 
Obese vs. controls 
Weight fluctuation vs. 
controls 
Obese vs. weight 
fluctuation 
Weight (kg) 76.1±4.5 109.1±7.1 77.2±4.5 <0.001 0.960 <0.001 
Systolic BP (mmHg) 79.4±5.0 93.2±14.3 80.8±10.1 0.034 NS 0.053 
LA pressure (mmHg) 3.7±0.9 8.5±1.9 5.7±1.8 <0.001 0.02 0.009 
RA pressure (mmHg) 2.9±0.9 7.2±2.5 4.6±2.7 <0.002 NS 0.048 
LA-EDv (mL) 34.2±5.2 43.3±6.6 33.0±6.6 0.239 0.884 0.086 
LA-ESv (mL) 23.5±3.9 28.8±3.6 23.5±1.4 0.687 0.773 0.28 
RA-EDv (mL) 34.1±4.8 47.9±5.3 35.0±13.2 0.247 0.962 0.318 
RA-ESv (mL) 22.3±4.1 32.8±4.2 25.1±9.1 0.462 0.972 0.551 
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Table 2. Structural, Fibro-fatty Infiltrations, Myofibrillar Remodelling of Obese, Weight Fluctuation and Controls 
Parameter Control Obese Weight fluctuation 
p-value 
Obese vs. controls 
Weight fluctuation 
vs. controls 
Obese vs. weight 
fluctuation 
LA volume (cm3) 40.6±3.0 53.6±5.8 48.5±6.6 0.001 0.025 <0.001 
RA volume (cm3) 71.5±12.2 74.1±7.0 63.7±7.6 0.841 0.224 0.067 
Fibrofatty infiltration 
grade, LA 
1.54±0.29 2.51±0.41 2.35±0.42 0.001 0.004 0.710 
Fibrofatty infiltration 
grade, RA 
1.81±0.25 2.85±0.44 2.85±0.44 0.002 0.047 0.249 
Total myolysis, LA (%) 38.3±16.3 95.8±2.0 70.2±9.3 <0.001 <0.001 0.012 
Total myolysis, RA (%) 40.0±19.6 92.3±10.1 82.5±11.0 0.001 0.001 0.920 
Severe myolysis, LA 
(%) 
5.7±4.9 42.7±5.1 17.2±9.5 <0.001 0.042 <0.001 
Severe myolysis, RA 
(%) 
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Table 3. Relationship Between Mean Grade Fibrofatty Infiltration and Electro-structural Substrates  
Parameter Pearson r r2 p-value 
LA pressure (mm Hg) 0.620 0.384 0.005 
RA pressure (mm Hg) 0.315 0.099 0.175 
LA voltage (mV) -0.076 0.006 0.756 
CV, LA (m/s) -0.592 0.350 0.006 
CV, RA (m/s) -0.721 0.520 0.001 
ERP mean, LA (ms) -0.102 0.010 0.679 
ERP mean, RA (ms) -0.078 0.006 0.749 
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Table 4. Relationship Between Mean Atrial Myolysis and Atrial Structural Substrates  
Parameter Pearson r r2 p-value 
Body weight (kg) 0.540 0.392 0.025 
Systolic BP (mm Hg) 0.443 0.196 0.07 
LA volume (cm3) 0.612 0.374 0.009 
RA volume (cm3) -0.308 0.095 0.228 
LA pressure (mm Hg) 0.633 0.40 0.008 
RA pressure (mm Hg) 0.532 0.283 0.028 
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5.7 FIGURE LEGENDS 
Figure 1. Scoring Algorithm for Classifying Fibrofatty Infiltrations 
Figure 2. Changes in Atrial Pressure  
Panel A: Left atrial pressure demonstrating significantly increased diastolic and systolic 
pressure measurements caused by stable obesity and weight fluctuation.  Panel B: Right 
atrial pressure demonstrating significant diastolic and systolic pressure changes due to 
obesity; chamber pressure increased caused by weight fluctuation trended towards 
significance. CN, controls; OB, obese group; WF, weight fluctuation group. 
Figure 3. Fibro-fatty Remodelling of the Atrial Myocardium due to Obesity and Weight 
Fluctuation 
Panel A: Representative Masson’s Trichrome-stained images of the atrial myocardial tissue 
of control, obese and weight fluctuation animals (x0.6 mag, 2.5 mm); inset, showing fibrotic 
remodelling (arrowheads) of infiltrates in obese and weight fluctuation (x20 mag, 100 µm). 
Panel B: Characteristic hyperplastic nature of fibro-fatty infiltrations in obese and weight 
fluctuation animals; arrowheads pointing to inflammatory cells in the infiltrates (x20 mag, 
100 µm). Panel C: Demonstrations of fat cell fusions in obese and weight fluctuation 
animals.; arrowheads pointing to giant syncytiated adipocytes. CN, controls; OB, obese; WF, 
weight fluctuation; mag, magnification 
Figure 4. Characterisation of Fibro-fatty Infiltrations 
Panel A: Average fibro-fatty infiltration grades of the left and right atrial tissues from 
controls, obese and weight fluctuation sheep. Panel B: Association of obesity and weight 
fluctuation with progressive severity in fibro-fatty infiltrations. Panel C: Collagen content of 
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infiltrates. Panel D: Average number of adipocytes per infiltrate. LA, left atrial wall; and 
RA, right atrial wall.  
Figure 5. Relationship Between Fibrofatty Infiltration and Effective Refractory Period 
Panel A: Linear regression results demonstrating no correlation between grade infiltration 
and ERP in the left atrium. Panel B: Correlations between grade infiltration and ERP in the 
left atrium. ERP, effective refractory period; LA, left atrial; RA, right atrial. 
Figure 6. Relationship Between Fibrofatty Infiltration and Conduction Velocity 
Panel A: Linear regression results demonstrating negative correlation between grade 
infiltration and CV in the left atrium. Panel B: Strong positive correlations between grade 
infiltration and conduction velocity in the right atrium. CV, conduction velocity; LA, left 
atrial; RA, right atrial. 
Figure 7. Relationship Between Fibrofatty Infiltration and Fractionated Electrogram 
and Voltage 
Panel A: Linear regression results demonstrating strong positive correlation between grade 
infiltration and electrogram fractionation in the left atrium. Panel B: No correlation between 
grade infiltration and voltage in the left atrium. LA, left atrial; RA, right atrial. 
Figure 8. Remodelling of the Myofibrillar Contractile Units 
Panel A: Representative periodic acid Schiff stained images, demonstrating replacement of 
the myofibrillar units (myolysis) of atrial myocytes (x80 mag, 25 µm). Panel B: Percent total 
myolysis in controls, obese and weight fluctuation groups in the left and right atrial 
chambers. CN, controls; LA, left atrial; OB, obese; RA, right atrial; WF, weight fluctuation.  
Figure 9. Progressive Remodelling of Myofibrillar Contractile Units 
Progressive severity of myolysis because of stable obesity and weight fluctuation, proportion 
of mocytes with no myolysis (Panel A); mild myolysis (Panel C); moderate myolysis (Panel 
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C); and severe myolysis (Panel D). CN, controls; LA, left atrial; OB, obese; RA, right atrial; 
WF, weight fluctuation.  
Figure 10. Relationship Between Myofibrillar Remodelling and Systolic Blood Pressure 
Panel A: Linear regression results showing non-significant weak correlation of myolysis in 
the left atrium with systolic blood pressure. Panel B: Regression results showing weak and 
non-significant correlation of myolysis in the right atrium and systolic blood pressure. BP, 
blood pressure; LA, left atrial; RA, right atrial. 
Figure 11. Relationship Between Myofibrillar Remodelling and Chamber Volumes 
Panel A: Linear regression results showing strong, significant positive correlation of 
myolysis with chamber volume in left atrium. Panel B: Regression results showing non-
significant negative correlation with chamber volume in the right atrium. BP, blood pressure; 
LA, left atrial; RA, right atrial. 
Figure 12. Relationship Between Myofibrillar Remodelling and Atrial Haemodynamics 
Panel A: Linear regression results showing significant positive correlation of myolysis with 
pressure in the left atrium. Panel B: Regression results showing significant positive 
correlation with pressure in the right atrium. LA, left atrial; RA, right atrial. 
Figure 13. Correlation of LV Ejection Fraction with Atrial Myofibrillar Remodelling 
Panel A: Linear regression results showing no correlation of left atrial myolysis with left 
ventricular ejection fraction (x100). Panel B: Regression results showing no correlation of 
right atrial myolysis with left ventricular ejection fraction. LA, left atrial; RA, right atrial. 
Figure 14. Spectral Distribution of Most Abundant Peaks of Matrix-assisted Laser 
Desorption Ionization Images 
Panel A: Representative H & E staining images and orientation (epicardium to endocardium) 
of sheep posterior left atrial tissue showing distribution of fatty infiltrations. Panel B: 
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MALDI images of lipid with the most abundant peaks. The identified lipids are indicated at 
the top; m/z values are shown above the images. The intensity of each pixel reflects the 
abundance in the tissue.  
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Small area of adipocytes, limited or no fibrosis, 
no inflammation
2
Fat cell infiltration plus increased fibrosis, no 
inflammation
3
Increased infiltrated adipocytes plus increased 
fibrosis plus inflammatory infiltrates
4
Extensive infiltrated adipocytes, fibrotic 
scarring and inflammatory infiltrates
A B
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Figure 14. Spectral Distribution of Most Abundant Peaks of Matrix-assisted Laser 
Desorption Ionization Images 
184.06 205.99 760.57 264.25 454.36m/z:
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6. Chapter Six 
Obesity and Sudden Cardiac Death: A Meta-
Analysis of 1.4 Million Individuals 
  
 




Sudden cardiac death (SCD) is responsible for 50% of total cardiovascular (CV) mortality 
and potential-life lost to CV disease.307, 309, 425  According to recent epidemiological findings, 
while the overall burden of cardiac deaths has been gradually declining, the incidence of SCD 
has demonstrated a steady increase over the same period.314, 426, 427  In the United States 
alone, SCD from out-of-hospital sudden cardiac arrest (OSCA) is reported to affect between 
170,000 to 450,000, with incidence rates of 234 deaths per 100,000 person-years.14, 309, 314, 426, 
427  
Despite this, the true burden of SCD is likely to be inaccurately estimated due in part 
to the confusion in what constitutes sudden death. According to the most recent consensus 
documents, SCD is temporally defined as a natural death from “sudden” cardiac arrest (SCA) 
in patients without known cardiac abnormality, occurring within an hour of onset of symptom 
(witnessed) or 24 hours in an unwitnessed case; with cardiac arrest entailing the cessation of 
mechanical function or activity of the heart, evidenced by termination of both 
cardiopulmonary and systemic circulations.309 Importantly, this takes into account three key 
elements of SCD: natural, rapid, and unexpected nature of the death.  
Mechanistically, SCD is shown to be caused predominantly arrhythmic in origin322, 
often precipitated by ischaemic heart disease317, 318. It is also precipitated by other 
pathological conditions, such as cardiomyopathies and inherited channelopathies.312, 318 
However, data from the general population demonstrate that half the crude rates of SCD 
occur in patients without apparent high-risk features or impaired heart function.307, 331 Why 
this is the case remains unknown. Moreover, left ventricular dysfunction, the dominant 
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determinant for primary prevention implantable defibrillator (ICD), has been reported to only 
occur in the minority of SCD patients, thus highlighting the need for novel risk markers.331  
The prevalence of overweight and obesity has more than doubled since the 1970’s, 
with current projections estimating that up to 90% of middle-aged individuals will be either 
overweight or obese by 2025.1, 3 Importantly, the rise of the obesity epidemic has culminated 
in rise of primary CV morbidities and primary risk factors for SCD.1 Obesity, measured as 
body mass index (BMI), has been reported to show a graded and highly significant 
association with myocardial infarction in community-based studies.335 There is also evidence 
suggesting that increasing adiposity may contribute to the pathogenesis of sudden death337, 
with both moderate and severe obesity reported to associate with higher risk of pulseless 
ventricular tachyarrhythmia’s and late potentials.428, 429  
In this study, we aimed to undertake a systematic review of the literature and provide 
a meta-analytic assessment of the link between obesity and SCD. Our objectives were to 
evaluate the association between SCD and: 1) BMI as a categorical variable, and 2) BMI on a 








6.2.1 Literature Search Strategy and Selection Criteria 
The present study was conducted in accordance with the guidelines given by the Meta-
analysis of Observational Studies in Epidemiology (MOOSE) statement430 and was registered 
on PROSPERO (ID: CRD42018104848). 
We searched the medical literature using the online databases PubMed, EMBASE, 
Ovid MEDLINE, using the key words: 
PubMed: (Overweight [MH] or Overweight [TW] OR Obesity [TW] OR Obesity [MH] OR 
body mass index [TW] OR BMI [TW]) AND (Sudden cardiac death [TW] OR Sudden 
Cardiac Death [MH] OR Sudden Cardiac Arrest [TW] OR Sudden Cardiac Arrest [MH] OR 
Sudden Arrhythmic Death [TW] OR SCD [TW] OR Out-of-Hospital Sudden Cardiac Arrest 
[TW] OR OSCA [TW]) 
EMBASE: ('Obesity'/EXP OR Obesity OR ‘Obesity’/SYN OR 'BMI'/EXP OR ‘BMI’/SYN 
OR 'Body Mass'/EXP OR ‘BODY MASS’/SYN) AND ('Sudden Cardiac Death'/EXP OR 
'Sudden Cardiac Death'/SYN OR 'Out of Hospital Cardiac Arrest'/EXP OR 'Out of Hospital 
Cardiac Arrest'/SYN OR 'Sudden Cardiac Arrest'/EXP OR 'Sudden Cardiac Arrest'/SYN) 
The Core Collection of Web of Science: (Overweight OR Obesity OR “body mass index” 
OR BMI) AND ("Sudden Cardiac Death" OR “SCD” OR “Cardiac Arrest” OR “Out-of-
Hospital Cardiac Arrest” OR “Sudden Cardiac Arrest” OR “OSCA” OR “SCA”) 
Ovide MEDLINE: (body mass index.mp. OR BMI.mp. OR Body Mass Index/ OR 
overweight.mp. OR Overweight/ OR obesity.mp. OR Obesity, Morbid/ OR Obesity/) AND 
(sudden cardiac arrest.mp. OR Death, Sudden, Cardiac/ OR SCD.mp. OR SCA.mp.) 
 
   
 
203 
Studies published in English were retrieved and exported to and sorted in EndNote 
8.2 software. We screened the retrieved papers based upon the titles followed by the scrutiny 
of their abstracts and full texts, thereafter, and excluded: 1), conference reports and case 
reports; 2), abstracts not yet published, editorials and letters to the editor; 3), studies reporting 
only all-cause mortality and/or non-sudden cardiac mortality; 4), and studies that did not 
address study objectives. Review articles were searched for original papers and were later 
excluded. Finally, we included studies if they met the following criteria: 1), reported sudden 
cardiac death as an endpoint; 2), used BMI or WHR as the measure of obesity; and 3), 
conducted an adjusted multivariable risk estimation.  
 
6.2.2 Data Extraction and Quality Assessment  
Data extraction and study quality assessment were done by two investigators (Agbaedeng 
TA, TAA, and Munawar DA, DAM) independently, using an a priori determined set of 
guidelines, and with disagreements resolved by consensus. We extracted the following data: 
1) The incidence of SCD/all-cause mortality/non-SCD; 2), Age; 3), Body mass index (BMI) 
and/or waist-to-hip ratio (WHR); 4), Risk estimates; 5), Follow-up; 6), Study endpoints; 7), 
Study design; 8), Participants. Methodological quality assessment was done via the 
“Newcastle-Ottawa Scale for Cohort Studies.”  
 
6.2.3 Data Analysis 
A random effects meta-analysis was conducted on the pooled results from the various 
citations using the RevMan 5.3 (The Cochrane Collaboration,Copenhagen), with the effect 
size presented as risk ratio or relative risk (RR). RRs were pooled from studies that 
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conducted multivariable analysis. Meta-analyses involving RR were done to show 
independent association with SCD.  
Analysis was conducted on a categorical or continuous BMI, measured as kilogram 
per metre squared (kg.m-2). BMI categories were defined as per World Health Organisation 
guidelines: <18.5 kg.m-2 as underweight; 18.5 kg.m-2 to 24.9 kg.m-2 as normal weight; 25 
kg.m-2 to 29.9 kg.m-2 as overweight; and ≥30 kg.m-2 as obesity. The degree of heterogeneity 
of effect size estimates across the studies was assessed by examination of forest plots, chi-
squared (X2, or Chi2) test and I-squared (I2) statistic. The latter two provide numerical values 
for an assessment of heterogeneity, with a high Chi2 relative to the degree freedom suggestive 
of variations in effect estimates and I2 greater than 75% indicative of a considerable amount 
of heterogeneity (p<0.1 defined as the cut-off). 
  
6.3 RESULTS  
6.3.1 Literature Searching Results 
Our online database searches on MEDLINE, Embase and the Cochrane Library resulted in a 
total of one hundred and ninety references, which were screened for eligibility. This was 
supplemented with hand-searching of the retrieved citations and searches done on sources 
like Google Scholar, thus, resulting in a total of 3925 references. Upon applying the 
exclusion and inclusion criteria (Figure 1), 22 studies were finally chosen for inclusion. Of 
these, five were further excluded for incomplete data reporting, leaving a total of 17 studies. 
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6.3.2 Study Characteristics 
A full description of the characteristics of the included studies are provided in Tables 1 and 
2, including study designs, quality scores, demographics, methodology, study endpoints, 
follow-up, and participants.  
The 17 included studies had a total of 1,481,604 participants (586,641 [39.6%] males 
and 89,4963 [60.4%] females) from 5 countries (1 study from Canada431, 5 from Finland432-
436, 3 from France437-439, 2 from Japan440, 441, 1 from Sweden333 and 5 studies from the 
USA337, 338, 442-444). There were male- or female-only participants in 9 studies each. Three of 
the studies were multi-centre studies including individuals from multiple sites, including 2 
studies performed in USA and 1 from France; there was no description of centres used in the 
rest of the studies. The follow-up period ranged from 8 years, in Albert et al337 to as long as 
56 years, in Cuddy et al431 27% of the studies had incident SCD/SCA as the primary 
outcome; 18.2% had both SCD and cardiovascular disease (CVD) or myocardial infarction 
(MI) as composite endpoints; 9% had coronary heart disease (CHD) as the endpoint; and in 
45.5%, there was no indication that SCD was or not the primary outcome. 
There was a total of 10,825 cardiac deaths reported in the studies, 8,151 (75%) of 
which were SCD, corresponding to an incidence rate of 5.50 deaths per 1,000 (8,151 SCD 
events/1,481,604 participants). SCD was adjudicated by a combination of review of medical 
records and autopsy reports, coroner, and by next-of-kin.  
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6.3.3 Study Quality 
We assessed the methodological study quality using the Newcastle-Ottawa Quality 
Assessment Scale for cohort studies. Overall, the included studies earned NOS scores ranging 
from 5 to 9 (7.2±0.1), see Tables 1 & 2. 
 
6.3.4 Clinical Characteristics 
Patients diagnosed with SCD were older than event-free subjects (p=0.01) and had higher 
BMI (p<0.01), Table 3. Hypertension was the most prevalent condition in SCD subjects at 
55%. SCD patients were 11 times more likely to have congestive heart failure than disease-
free participants (p<0.01). Diabetes was prevalent among 22% SCD subjects compared to 
4.4% in those without SCD (p<0.01).  24.1% and 16.0% of SCD diagnosed patients had a 
history of coronary heart disease and myocardial infarction, as compared to only 6.5% and 
2.3% in SCD free patients (p<0.01 in all). Atrial fibrillation was also more common in SCD 
patients than in individuals without SCD ([6.3% vs. 3.9%, p<0.01], Table 3). 
 
6.3.5 META-ANALYSIS 
6.3.5.1 Incremental BMI and SCD 
As shown in Table 3, BMI was significantly higher in patients with SCD than in those 
without sudden death. Seven studies including 50,552 individuals reported the association 
between increment in BMI and SCD risk.333, 432-434, 437, 438, 440 Four population cohorts were 
reported in Lahtinen et al433, thereby contributing a total of four risk estimates. The individual 
studies corrected for the following variables: alcohol, sex, cholesterol, age, systolic blood 
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pressure, prevalent CHD, smoking, diabetes, hypertension, left ventricular ejection fraction, 
triglycerides, fibrinogen, parental SCD, parental MI, and heart rate. In the pooled analysis, 
we found significant and independent association between BMI and SCD, such that 1-unit 
increase in BMI predicted more than 6% elevated risk of SCD (RR [95% CI]: 1.06 [1.02-
1.10]; p=0.006), Figure 2. 
 
6.3.5.2 Underweight BMI and SCD 
Four studies reporting on underweight BMI and SCD in a total of 1,097,968 participants.338, 
436, 443, 444 Underweight BMI category was defined as BMI <18.5 kg.m-2, except in Chiuve et 
al338 and Eranti et al436, where it was defined as 18.5 to 20.9 kg.m-2 and <20 kg.m-2, 
respectively. We pooled only the adjusted risk ratios from the individual studies in our 
analysis. Interestingly, an independent association of underweight with risk of SCD was only 
reported by Chiuve et al338, but not shown for others. However, in our pooled analysis, this 
was significant and independent of traditional risk factors, such as: age, gender, smoking 
status, cholesterol, alcohol, family history of MI, diabetes, hypertension, prevalent CHD, 
prevalent HF, ECG variables. We found that the underweight predicted 33% increased risk of 
developing SCD (RR [95% CI]: 1.33 [1.00-1.78]; p=0.05), see Figure 3. 
 
6.3.5.3 Overweight and SCD 
We identified a total of 6 studies evaluating the relationship between the overweight state and 
the risk of SCD, and they had 1,381,477 participants.337, 338, 435, 436, 442-444 Adabag et al443 
reported 2 sub-analyses, risk of SCD in individuals with and without a smoking history; 
therefore, we had a total of 7 risk estimates contributing to our meta-analysis. Overweight 
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was defined as BMI of 25 to 29.9 kg.m-2. Other than in Chiuve et al338 and Eranti et al436, the 
rest of the studies did not show any significant association after adjusting for traditional risk 
factors. Accordingly, when we pooled these adjusted RR’s in our meta-analysis, we found no 
significant association of the overweight BMI with SCD (RR: 1.13; 95% CI: 0.94 to 1.35; 
p=0.20), see Figure 4. 
 
6.3.5.4 Obesity and SCD 
We found a total of 10 studies providing data on the relationship of obesity and SCD, 
equating to 1,438,131 participants.337, 338, 431, 435, 436, 439, 441-444 Given that Adabag et al443 had 
two subgroup analyses, we had a total of 11 risk estimates that we pooled in our meta-
analysis. After correcting for traditional risk factors, Adabag et al443 (both in smokers & non-
smokers), Bertoia et al442 and Chiuve et al338 did not find significant association between 
obesity and SCD. Overall, the included studies adjusted for: age, gender, smoking status, 
cholesterol, alcohol, family history of MI, diabetes, hypertension, prevalent CHD, prevalent 
HF, ECG variables. In our pooled analysis, obesity significantly associated with sudden 
death, predicting 44% elevated risk after correcting for covariates (RR: 1.44; 95% CI: 1.21 to 
1.71; p<0.01), see Figure 5. Eranti et al436 contributed the most to the weight of the estimates 
at 15.3%, with Chei et al441 contributing the least at 1.2%. Given the unconventional 
definition of obesity by Empana et al439 (BMI: 28.5 to 46.7 kg.m-2), we excluded this study 
and still found a significant association (RR of 1.41 (95% CI: 1.18 to 1.68; p<0.01).  
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6.3.5.5 Waist-to-Hip Ratio and SCD 
A total of 2 studies also looked at central adiposity measures as composite measures of 
obesity, including waist circumference and waist-to-hip ratio. Unfortunately, waist 
circumference was reported by only Bertoia et al442, and WHR was grouped differently in the 
2 studies that evaluated this, so no further analysis could be done. 
 
6.3.6 Heterogeneity and Sensitivity Analysis 
We evaluated statistical heterogeneity in the studies using Chi2 and I2 statistics. The pooled 
analysis for underweight BMI and SCD showed no evidence of inconsistency in effect size 
estimates (Chi2: 2.04, df: 3, p=0.56; I2: 0%), Figure 3. However, found moderate to 








6.4.1 Major Findings 
Obesity has been implicated in the risk of cardiovascular disease and is currently being 
investigated in the development of sudden cardiac death. In this meta-analysis, we explore 
the relationship between obesity and SCD, demonstrating that: 
1. For every 1-SD increase in BMI significantly and independently associates with a 6% 
elevated risk of developing SCD, even after correcting for baseline covariates. 
2. Underweight status (BMI <18.5 kg.m-2) predicted 33% increased risk of SCD, 
independent of traditional risk factors. 
3. Overweight (BMI 25 to 29.9 kg.m-2) does not show significant association with SCD 
after baseline comorbidities are adjusted for, and. 
4. Finally, obesity (BMI ≥30 kg.m-2) was associated with higher risk of SCD. Even after 
correcting for traditional correlates, obesity still predicted 44% increased risk of the 
disease.  
 
6.4.2 SCD and underweight: is undernutrition or excess 
weight loss to blame? 
In the present study, we showed that underweight is associated with 33% greater risk of SCD 
compared to normal BMI. Indeed, our data is consistent with previously published reports.  
For example, Chiuve et al338 demonstrated up to 58% increased risk of SCD for BMI <21 
kg/m2 in comparison with normal BMI. In another study involving first-time ICD recipients, 
underweight patients demonstrated ~2-fold greater odds of in-hospital death compared to 
 
   
 
211 
normal weight patients.445 Taken together, these data show that low body weight may be 
detrimental in the context of SCD. It is notable that this comes at odds with the established 
benefits of weight loss for cardiac health. Moreover, the precise mechanism driving 
formation of SCD substrate in this cohort of patients remains evasive. Nevertheless, there are 
some data to suggest undernutrition or excessive weight loss may drive SCD risk 
modification.446 Future research should aim to explore these questions in more detail. 
 
6.4.3 Obesity and SCD 
Sudden cardiac death is a major public health burden attributed to about 360,000 annual 
deaths (with estimates ranging from 180,000 individuals to as high as 450,0000 individuals) 
in the US alone, and a crude estimate at a staggering 5 million globally, making it the most 
significant cause of cardiovascular death worldwide.14, 308, 309 More recently, high lifetime 
risk has been estimated for SCD, putting men at 10.9% and women at 2.8% at age of 45 
years, and this is associated with higher aggregate burden of cardiac comorbidities.314  
Obesity is strongly associated with increased prevalence of traditional risk modifiers of 
SCD. For example, in a prospective multicentre registry of individuals without CAD referred 
for coronary computed tomography angiography, higher BMI was positively associated with 
prevalence of any CAD and obstructive CAD.332 Moreover, incident HF is overrepresented 
among obese individuals compared to people with normal BMI, and obesity was 
demonstrated recently as an independent predictor of HF with preserved ejection (HFpEF) as 
against HFrEF.447 In the present meta-analysis, we show that obesity (defined as BMI ≥30 
kg.m-2) is associated with 44% increased risk of SCD, persistence even after correcting 
traditional risk factors, such as HF and CAD. It notable that, despite the obesity paradox 
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often reported in HF-related mortality448, we did not observe this conundrum in the obesity 
and SCD relation. Furthermore, BMI on a categorical scale demonstrated a J-curve relation, 
with the best outcomes seen with normal weight and overweight status, respectively, see Take 
home figure. Our meta-analysis provides robust evidence for obesity and SCD risk. First, we 
provide a comprehensive evaluation of SCD risk in obesity. Second, the overall number of 
participants in this meta-analysis was very large. Third, the average follow-up period was 
long, ranging from at least 8 years to 56 years. Taken together, our data show that obesity 
may drive SCD independently of CAD/HF axis. 
 
6.4.4 SCD Substrate in Obesity 
Whether obesity is directly involved as a potential modifiable risk factor in SCD 
pathogenesis or a mere risk marker is not well described. Obesity has been correlated with 
changes in cardiac electrophysiological properties such as late potentials429, signifying 
delayed activation in diseased myocardium and known marker for SCD, and shown to 
independently predict ventricular tachycardia/fibrillation (VT/VF)428, 449.  
The substrate for SCD in obesity is probably complex and multifactorial. Several 
structural and functional changes that have been described in obese hearts, such as: increased 
left ventricular diameters and mass, eccentric hypertrophy, diastolic dysfunction, and 
repolarisation abnormalities.450-452 Moreover, QRS fragmentation (fQRS), representing 
heterogenous conduction and thereby fibrotic scars453, is a common observation in obesity 
and obese patients dying from SCD454. Both fQRS and fibrosis are shown to predict SCD 
independently of reduced ejection fraction, highlighting the potential mechanism of 
ventricular remodelling in the obese with HFpEF.455, 456  
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Further, obesity is associated with volume overload and haemodynamic impairment, 
which may cause abnormal neurohumoral activations, leading to pro-fibrotic and 
inflammatory signalling.457 Additionally, there may be several ways that obesity can lead to 
SCD. Obesity could impact SCD substrate by promoting traditional risk factors, coronary 
artery disease, and through direct cardiac effects. 
 
6.4.5 Limitations 
The amount of heterogeneity in some of the subgroup analyses is worth noting. Although this 
was significant, we believe that the level of heterogeneity, where it was found, was not 
critical, and may not have affected our risk estimates. The use of overwhelmingly non-
randomised trials is an important drawback and may have introduced bias in the analyses. 
Notwithstanding this limitation, the methodology quality of these studies was moderately 
high, attesting to their internal validity. Finally, the disproportionately low number of males 
(37.3%) in the subjects is another limitation of our meta-analysis. It is well accepted that 
SCD has a male bias. In fact, the latest modelling study puts the life-time risk of SCD at 1 in 








The present meta-analysis demonstrates an independent association between obesity and 
SCD. BMI is greatly increased in patients who die suddenly than non-SCD individuals, with 
1-unit increment in BMI associated with greater risk for SCD. Further studies are warranted 
to delineate the mechanisms underlying this association and to explore the role of weight 
management in reducing the premature death due to SCD. 
  
 




Table 1. Characteristics of Studies Evaluating Obesity on a Continuous Body Mass Index Scale 















France Prospective cohort 8 23 years 
Hard CHD 
Major CHD event 
Independent medical committee (ICD code 798.1) 7,079 (100) 603 (19.6) 25.4±3.3 
Laukkanen 










7 20 years CV events Registry, discharge records and death certificates 2,361 (75.9) 363 (100) 27.5±1.1 
Lahtinen et 
al. 2012 
Finland Population cohort 9 5 years SCD Independent physician reviews 27,629 (47.2) 494 (100) 26.7±0.4 
Benchimol 
et al. 2000 
France Prospective 5 8.1±1.6 years 
SCD & 
MI 
ND 319 (85.9) 34 (74) 26.0±3.0 
Laukkanen 




7 17.6 years ND 
Autopsy reports, interviews and Independent events 
committee 
1,606 (100) 76 (100) 26.7±3.1 
Kataoka et 
al. 2004 
Japan ND 7 6.5±4.8 years SCD Death certificates 8,917 (55.4) 56 (100) 23.6±3.2 
TOTAL   7.3±1.3 15.7±6.7   50,552 (62.1) 1,816 (72.8) 26.1±1.3 
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Table 2. Characteristics of Studies Evaluating Obesity on a Categorical Body Mass Index Scale 
Study ID Country Design Risk Score Follow-up Period Study 
Endpoint 





Cuddy et al. 2006 Canada Prospective, longitudinal 6 56 years ND ND 3,983 (100) 171 (100) 
Overweight 
Obesity 
Eranti et al. 2016 Finland Population cohort 9 35-41 year ND 
Review by 2 
experienced 
cardiologists 





Albert et al. 2003 United States Prospective multiple-source surveillance 6 8 years Incident SCA 
Review by 2 

















Class I obesity 
Class II obesity 




Chei et al. 2008 Japan Prospective, population cohort 7 9.7±2.5 years CHD Medical records 43235 (100) 65 (100) 
Normal 
Obese 











Class II obesity 
Bertoia et al. 2012 United States 
Multi-centre 
Mixed: 3 RCT’s & 
observational 
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Table 3. Summary Baseline Clinical Characteristics 
Co-variate Incident SCD SCD Free Effects Estimate (95% CI) p-value 
Age, year 57.7±9.2 55.7±8.6 1.94 [0.38-3.50] 0.01 
Diabetes 22.05% 4.4% 2.39 [1.46-3.90] <0.001 
Hypertension 55.06% 25.7% 1.99 [1.86-2.14] <0.001 
Body mass index, kg.m-2 28.3±1.1 27.2±1.2 1.22 [0.88-1.56] <0.001 
Myocardial infarction 16.9% 2.3% 5.37 [3.08-9.35] <0.001 
Congestive heart failure 14.3% 1.3% 3.89 [2.03-7.44] <0.001 
Coronary heart disease 24.1% 6.5% 4.95 [2.32-10.57] <0.001 
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6.7 FIGURE LEGEND 
Figure 1. A CONSORT Diagram of the Search Methodology 
Figure 2. Risk of Sudden Death with Incremental BMI 
This analysis evaluates the risk of SCD per 1-unit increase in body mass index (BMI) by 
pooling the multivariate adjusted risk ratios (RR) from the included studies. Adjustment was 
made for: hypertension; type diabetes; coronary heart disease; myocardial infarction; atrial 
fibrillation; sex; age; obstructive sleep apnoea; heart failure; and valvular heart disease. BMI 
was measured in kilogram per square metre (kg.m-2). 
Figure 3. Risk of Sudden Death in Underweight Subjects 
This analysis evaluates the association of underweight BMI and the risk of sudden cardiac 
death (SCD). Please refer to figure 2 for factors adjusted for in the included studies. 
Underweight BMI was categorised as <18.5 kg.m-2 or <20 kg.m-2. 
Figure 4. Risk of Sudden Death in the Overweight Subjects.  
This analysis evaluates the association of overweight BMI and the risk of SCD. overweight 
BMI was defined as 25-29.9 kg.m-2. Please refer to figure 2 for factors adjusted for. 
Figure 5. Risk of Sudden Death in the Obese Subjects.  
This analysis looks at the association of obesity with the risk of SCD. Obese BMI was 
defined as ≥30 kg.m-2. 
Take home figure. Schematic of SCD risks in different weight subclasses 
The top schema shows the progressive development of substrates for ventricular arrhythmias 
and SCD. Bottom chart shows J-curve relation between BMI subgroups and the risk of AF, 
with the best outcomes seen in the normal weight and overweight groups, respectively.  
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Figure 1. A CONSORT Diagram of the Search Methodology 
 











§ Case series and reports 
§ Conference abstracts and 
editorials
§ Animal, in vitro & ex vivo studies
§ Reviews and meta-analysis
§ Articles not addressing study 
questions






















   
 
220 




   
 
221 




   
 
222 






   
 
223 




   
 
224 
Take home figure. Schematic of SCD risks in different weight subclasses 
 
  
Relative Risk of SCD as a Function of BMI Class
The Obesity Epidemic
Development of substrate for ventricular arrhythmias & SCD
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7. Chapter Seven 
Epicardial Fat and Fibro-fatty Infiltration of the 
Ventricle: Implications for Sudden Cardiac Death 
Substrate in Obesity  
  
 




Sudden cardiac death (SCD) is a major health conundrum worldwide, accounting for more 
than 50% of all cardiac deaths.309, 310, 312, 425 Notably, very little has changed in the outcomes 
after SCD over the last few decades. Although there has been a gradual reduction in overall 
cardiac deaths, SCD-attributable cardiovascular death has demonstrated a steady increase.14, 
458 In the US alone, SCD has been shown to cause 180,000 to 450,000 events and is estimated 
at 50 to 100 per 100,000 individuals in both North America and Europe.14, 316  
A large proportion of SCD events are attributed to ischaemic heart disease, 
cardiomyopathies (CMP) and inherited channelopathies.459, 460 Indeed, SCD can be the first 
manifestation of ischaemic heart disease.426 Despite the declining burden of some of these 
predisposing conditions, deaths due to SCD has remain unchanged or, in some areas, is 
rising.427, 461-463 Moreover, in many suffering an SCD episode, there are no salient high-risk 
features to have prompted a preventative strategy.331, 425  
In parallel, there is the growing global obesity epidemic, which poses a huge socio-
economic challenge and a significant disease-attributable public health burden.1 Recent 
clinical reports have demonstrated obesity as a strong independent predictor of greater risk 
for SCD.464, 465 A body mass index (BMI) >30 kg.m-2 has been associated with late potentials 
on signal-averaged ECG and an increased risk for developing ventricular arrhythmias.449 It is 
likely that obesity drives the development of SCD independent of myocardial ischemia. In 
fact, a recent study has implicated obesity-mediated CMP as an important non-ischaemic 
cause of SCD.339 However, the mechanism by which obesity predisposes to SCD remains 
poorly understood. We hypothesize that obesity results in structural change within the 
ventricle to account for the mechanistic link between obesity and SCD. The aim of the 
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current study was to characterise the molecular and structural ventricular remodelling that 
occurs due to chronic obesity. 
 
7.2 METHODOLOGY 
7.2.1 Study Animals  
The study comprised sixteen 1-year old Merino Cross Wethers (Ovis aries) studied in 
accordance with guidelines outlined in the “Australian Code for the Responsible Conduct of 
Research, 2007 (the 2007 Code)” adopted jointly by the National Health and Medical 
Research Council, the Australian Research Council and Universities Australia. Study 
protocol and animals were approved by the animal research ethics committees of the 
University of Adelaide and the South Australian Health & Medical Research Institute, 
Adelaide, Australia, which adhere to the Guidelines for the Care and Use of Animals for 
Research Purposes. 
 
7.2.2 Obesity Model  
Obesity was induced in 16 sheep using a previously well characterised protocol.181, 182 In 
brief, sheep were commenced on a high-calorie diet for a period of 36 weeks and maintained 
in this state for another 36 weeks. Obesity induction was started at baseline, whereby healthy 
sheep with normal weight were put on a diet consisting of energy-dense soy-bean oil (2.2%) 
and molasses-fortified grain and maintenance hay with weekly weight measurement. Excess 
voluntary intake was predominantly of grass alfalfa silage and hay. Pellets were gradually 
introduced at 8% excess basal energy requirements and rationed to 70% of total dry-matter 
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intake. Blood samples were periodically collected to ensure electrolyte and acid-base 
homeostasis.  
 
7.2.3 Lean Controls  
Another 8 age-matched sheep were maintained as controls by providing high-quality hay ad 
libitum. Baseline weight was maintained by ensuring a very low level of energy-dense 
pellets, which were rationed at 0.75% of body weight. Except for the difference in amount of 
food intake, the nutritional content of food and housing conditions were identical for both the 
obese and control groups. 
 
7.2.4 Animal Preparation  
Animals were pre-acclimatized for at least 1 week before any surgery. Shorn weight was 
recorded immediately before surgery. Noteworthy, we could not continue with the 
electrophysiology studies after initial observations of high mortality rates in the obese group 
(half died due to sudden deaths). 
 
7.2.5 STUDY PROTOCOL 
7.2.5.1 Structural and Functional Evaluations 
The obese and the control groups underwent the following investigations: 
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7.2.5.1.1 Body Composition  
The total body fat was quantified using the dual-energy X-ray absorptiometry (DEXA) 
scanning protocol under sedation. 
 
7.2.5.1.2 Haemodynamic Assessment 
Invasive blood pressure (BP) monitoring was performed during the electrophysiology study. 
Left atrial (LA), right atrial (RA), and pulmonary artery (PA) pressures were recorded, 
respectively. 
 
7.2.5.1.3 Cardiac MRI  
Before open chest surgery, animals underwent cardiac MRI using 1.5 Tesla (Siemens Sonata, 
MR Imaging Systems, Siemens Medical Solutions, Erlangen, Germany) with 10-mm slices 
through the ventricles without interslice gaps. To do this, animals were securely placed in the 
dorsal recumbent position for scanning. Mechanical ventilation was maintained, facilitating 
electrocardiogram-gated image acquisition with periodic breath holding. Analyses were 
performed offline by blinded operators by using the proprietary software QMass MR (Medis 
medical imaging systems, Leiden, The Netherlands). The following parameters were 
measured as previously described: Left ventricular chamber mass; LV ejection fraction 
(LVEF); LV end diastolic volume (LVEDV); and epicardial fat volumes. 
Quantification of EAT: Epicardial fat volumes were quantified using previously validated 
protocol.413 Briefly, a 3D model was constructed from consecutive end-diastolic short-axis 
images using semi-automated software. Regions of adipose tissue were marked in each slice 
followed by linear interpolation of pixel intensities in spaces between consecutive image 
 
   
 
230 
slices. Periatrial and periventricular fat were defined as any pericardial fat subtending the 
atria and ventricles and below the visceral pericardium, respectively. Total volume of adipose 
tissue was calculated as a total volume of the 3D model and the mass estimated from volume 
measurements. The Intra-observer and inter-observer reproducibility demonstrated a 
coefficient of variation 8.3% to 10.7% for atrial EAT, and 6.6% to 7.4% for ventricular EAT, 
and 5.5% to 7.2% for total EAT, respectively. 
 
7.2.5.1.4 Transthoracic Echocardiography  
Echocardiogram was performed with Acuson Aspen (Siemens Healthcare, Malvern, 
Pennsylvania) under general anaesthesia. The LV dimensions were determined in the M-
mode in the parasternal long-axis view at the level of the mitral leaflet tips. Using the 
Teicholz formula, we measured global LV function from the LV dimensions. 
 
7.2.5.2 Morphological Evaluations 
Following the imaging studies, the sheep were maintained under general anaesthetic. 
Thereafter, they were then euthanised by lethal dose of phentobarbitone injection and 
removal of the heart, with samples taken for detailed histological and ultrastructural analyses. 
Confirmation of death was done via visual inspection of a lack of heartbeat. 
 
7.2.5.2.1 Histomorphometric Assessment 
 The animals were euthanised and the hearts tissue was preserved in 10% (w/w) 
formaldehyde. Tissue sections were taken from the right and left ventricular free walls and 
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embedded in paraffin wax. Fixed tissue blocks were cut in 5-µm serial sections and stained 
with haematoxylin and eosin (H & E) and Masson Trichrome stains, respectively.  
 
7.2.5.2.1.1 Assessment of Ventricular Fatty Infiltration 
The fat cell infiltration of the ventricles by the epicardial fat was confirmed in Oil O Red 
preparations and assessed in H & E stained sections. Slides were scanned by NanoZoomer 
digital image scanner and viewed on NDP.view 2 (Hamamatsu Photonics K.K., Japan). 
Evaluation of infiltration was done at low-power (1.2x) magnification and with grading 
algorithm developed differently for the LV and RV. 
For the LV, infiltrated adipocytes were graded as a function of the distance away in 
millimetre away from the epicardial surface of the myocardium.  
- Grade I: For none or less than 1 mm extension from the epicardial surface of the 
muscle wall. 
- Grade II: For infiltration extending beyond 1 mm but less than 2 mm. 
- Grade III: For infiltration of more than 2 mm but less than 3 mm. 
- Grade IV: For infiltration of 4 mm or more of the wall of the LV. 
For the RV, grading was done by the anatomical landmark of the muscle wall from 1 to 4 as 
follows: 
- Grade I: For no none or focal infiltration of the adjacent outer third of the ventricular 
wall by epicardial adipocytes. 
- Grade II: Coalescent infiltration of the outer third and/or focal infiltration up to the 
middle third of the ventricular layer. 
- Grade III: Coalescent infiltration extending from the epicardial adipose tissue to the 
middle or inner third of the ventricular muscle layer. 
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- Grade IV: For up to the sub-endocardial surface. 
 
7.2.5.2.1.2 Assessment of Ventricular Fibrosis 
5-µm sections of ventricular tissue were stained with Masson’s trichrome and scanned by 
Hamamatsu NanoZoomer digital image scanner. Images were acquired at high-power (6.4x 
magnification) and analysed using purpose-built macros by colour deconvolution in Image J 
software. 20 images taken per sample were analysed from 8 animals per group to determine 
the mean values. 
 
7.2.5.2.2 Immunohistochemistry  
To assess fibrotic pathways, immunohistochemistry was performed. Isolated LV and RV 
tissues were fixed in 10% neutral formaldehyde, embedded in paraffin and cut in 5-µm 
sections. Embedded sections were deparaffinised by heat and subsequent washes in silane 
and absolute ethanol. Endogenous peroxidases were masked by incubation in 0.3% hydrogen 
peroxidase in methanol for 30 minutes. After performing heat-induced epitope retrieval, 
sections were incubated in normal horse serum for non-specific sites block, and incubated 
overnight with the appropriate primary antibodies against:  
1. Anti-angiotensin II receptor subtype 1 (AT1R, Rabbit polyclonal, 1/800 dilution, 
Biorbyt Ltd);  
2. Mineralocorticoid receptor (MCR, mouse monoclonal, 1/800, Abcam);  
3. Endothelin receptor type A (ET-A, Rabbit polyclonal, 1/400, Sapphire Bioscience 
Pty);  
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4. Transforming growth factor beta type 1 receptor (TGF-bR1, Rabbit polyclonal, 1/400, 
Sapphire Bioscience Pty);  
5. Phosphorylated sma and mothers against decapentaplegic homologue protein 3 
(pSMAD3, Rabbit polyclonal, 1/500, Biorbyt);  
6. SMAD6 (Rabbit polyclonal, 1/1000, ThermoFisher Scientific); and  
7. Desmosomal disruption was assessed by evaluation of desmoglein-2 expression 
(DSG2, Rabbit polyclonal, 1/250, Biorbyt Ltd) to understand mechanism of fatty 
infiltration. 
Next, sections were incubated in appropriate biotinylated secondary antibodies (Goat anti-
rabbit/mouse, Abcam) for 30 min at 1/250 dilution, followed by 1-hour incubation in 
streptavidin horseradish peroxidase-conjugated tertiary antibody at 1/1000 dilution. 
Immunoreactivity was evaluated using 3,3’-diaminobenzedine (DAB, Sigma) for 7 min and 
counter stained with Mayer’s Haematoxylin. Sections were scanned using NDP NanZoomer 
digital scanner and viewed on NDP.view 2. Images were captured and exported at 20x 
magnification (100 µm, 100% scale), and semi-quantitatively assessed by colour 
deconvolution in Image J software. 
 
7.2.6 Statistical Analysis 
Normally distributed continuous variables were presented as mean ± SD and analysed using 
2-tailed independent student t-test. Skewed data (such as endothelin A and SMAD6 protein 
expressions) were expressed as median and interquartile ranges and analysed using Mann-
Whitney U tests. Nominal variables (such as infiltration grades) were assessed using Pearson 
X2 tests. Next, we fitted mixed-effect models to the data to compare pro-fibrotic markers and 
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desmoglein-2 across chambers and groups (control and obese). Animal group (control and 
obese) and chamber (RV & LV) were modelled as fixed effects with an interaction term 
(chamber x group). If a significant interaction was present, mixed-effects post-hoc test p-
values were reported (with Sidak adjustment of alpha level). In the case of skewed 
distribution data were log-transformed before further analysis. Statistical significance was 
defined at 2-sided p-value ≤0.05. All data analyses were performed in SPSS software 
package version 25 (IBM SPSS Statistics, Chicago, Illinois, USA) and GraphPad Prism 
version 7.0d (GraphPad Software, La Jolla, CA, USA). 
 
7.3 RESULTS  
7.3.1 Animal Characteristics  
The obese state was achieved over 72 weeks, with the obese group reaching peak weight 
(94.71±6.5 kg) by the 36th week and sustained at the achieved weight for another 36 weeks. 
The control group maintained lean weight (57.4±4.6 kg) over the 72-week period. By the end 
of 72 weeks, the obese sheep significantly increased their baseline weight to almost twice the 
baseline levels (p<0.01). There was over a 3-fold increase in total body fat composition in the 
obese state ([35% of body weight versus 9.9%; p<0.001] Table 1).  
 
7.3.2 Structural and Functional Remodelling  
LV septal dimension was higher in the obese group as compared to controls (p<0.01) without 
any change in LV function between the groups (p=0.11). There was elevation of the left atrial 
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(LA) mean pressure (p=0.01) without change in systolic blood pressure (p=0.5) in the obese 
sheep; suggestive of diastolic dysfunction. 
 
7.3.3 Epicardial Fat Hyperplasia and Fat Cell Infiltration  
With sustained obesity, epicardial fat significantly increased to more than 2.5-fold those of 
the lean controls as determined by CMR (p=0.04). Accordingly, we explored epicardial fatty 
infiltration using H & E staining under low power. As shown in Figure 1 panel A, there was 
clear demarcation between epicardial layer and the muscle layer in the controls; however, 
with sustained obesity, the epicardial adipocytes infiltrated deep within myocardium causing 
dislodgement of the muscle cells. The fatty infiltration was quantified semi-quantitatively. 
There was more extensive infiltration of epicardial adipocytes in the LV of the obese sheep 
than the control group (mean grade: 3.00±0.9 vs 1.66±0.5; p=0.03; Figure 1 panel B). 
Severe (Grade IV) infiltration was seen in the LV of the obese group, with absence of grade 
III infiltration in controls. Similarly, the RV demonstrated greater infiltration by fat cells in 
the obese animals as compared to controls (mean grade: 3.17±1.2 vs 1.83±0.9; p=0.03; 
Figure 1 panel B), with infiltration extending up to the sub-endocardial surface (obese = 
grade III&IV vs control ≤ grade II). 
 
7.3.4 Desmosomal Disruption 
DSG2 expression was assessed with immunohistochemistry. DSG2 expression was 
significantly reduced in the obese group; with 15% reduction in protein levels in both RV and 
LV in obese group as compared to controls (RV:46.6±3 vs 54.1±7, p=0.04; LV: 40.2±1.1 vs 
47.8±4.9%, p=0.02; Figure 2 panels A & B). The expression of DSG-2 demonstrated 
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significant correlation with animal weight and degree of fatty infiltration in linear regression 
models ([weight: R2=0.424, p=0.02] and [fatty infiltration: R2=0.527, p<0.001]; Figure 2 
panel C). Animals with the most severe infiltration demonstrated the most significant 
reduction in DSG2. 
 
7.3.5 Ventricular Fibrosis  
The obese sheep demonstrated induction of diffuse interstitial fibrosis in both chambers 
(Figure 3 panel A). Analysis of the Masson’s trichrome stained sections of the LV showed 
significantly greater percentage fibrosis as compared to the lean sheep (13.2±2.8% versus 
5.2±0.9%, p=0.01; Figure 3 panel B). Comparable findings were seen in the RV 
myocardium, with obese sheep demonstrating a significant 14.8±6.1% global fibrosis as 
compared to 5.9±0.9% induced fibrosis in the control animals (p<0.01).  
 
7.3.6 REMODELLING OF FIBROTIC PATHWAYS  
7.3.6.1 Transforming Growth Factor-Beta (TGF-b) Pathway 
Figure 4 demonstrates the summary data on the assessment of TGF-b pathway, with the 
model signalling pathway shown in panel A. There was an abundant expression of the 
receptor protein of TGF-b1 in both ventricles as shown in panel B. TGF-b type 1 receptor 
(TbR1) expression was significantly increased in the LV of obese sheep, with up to 3-fold 
change as compared to the control lean weight sheep (13.4±7.2% versus 5.6±1.6, p=0.02; 
Figure 4 panel C). Similarly, the expression of TbR1 was upregulated in the RV in the obese 
group as compared to controls (16.9±5.6 vs 4.7±2.0%; p<0.01).  
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Further, we evaluated the downstream signalling of TGF-b. Contextually, TbR1 transmit pro-
fibrotic signals downstream by phosphorylating SMAD (Sma and mothers against 
decapentaplegic homologue) proteins, notably, SMAD3, which ultimately regulates pro-
fibrotic genes and fibrosis (Figure 4 panel A). As can be seen Figure 4 panel C, there was 
no significant alteration of phosphorylated SMAD3 with sustained obesity ([p>0.05 for both 
RV & LV], Figure 4 panel D), indicating that this component of the pathway may not drive 
obesity-induced TGF-b signalling. On the other hand, there was significant remodelling of 
SMAD6, the inhibitor of the SMAD3-independent component of the pathway (Mann 
Whitney p=0.001]; Figure 4 panel E). The control sheep demonstrated abundant expression 
of SMAD6 protein, which exhibited nuclear localisation. Intriguingly, chronic obesity 
resulted in a substantial repression of SMAD6 expression and nuclear localisation in both the 
LV and RV ([RV: 2.6±0.4% versus 6.9±0.9%, p<0.01] and [LV: 1.8±0.3% versus 5.8±1.3%, 
p<0.01]; respectively), Figure 4 panel E.  
 
7.3.6.2 Endothelin 1 Signalling  
Obesity was associated with overexpression of the cognate receptor for endothelin signalling 
(ET-A) in both ventricles (Figure 5 panels A & B). As compared to the lean controls, 
chronic obesity resulted in increased upregulation of ET-A protein to nearly twice the 
baseline levels in both the LV (47.6±6 versus 26.8±6.2; p<0.01) and the RV (52.7±2.5 versus 
30.3±5.8; p<0.01; Figure 5 panel C). 
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7.3.6.3 Aldosterone Signalling  
Mineralocorticoid receptor (MCR) for aldosterone changed appreciably with chronic weight 
gain (Figure 5 panels A & C). This changed from 43.4±6.2% in the lean controls to 
55.0±3.3% in the LV of obese group (p<0.01). Similarly, MCR protein was upregulated in 
the wall of RV (54.4±3.1 versus 41.1±7.6; p<0.01).   
 
7.3.6.4 Angiotensin II Signalling  
The pro-fibrotic type 1 receptor for Ang II (AT1R) was found to be markedly expressed with 
obesity (Figure 5 panels A & D). Obesity resulted in more than 4-fold elevation of AT1R 
protein levels in the LV compared to lean controls (12.1±4.9 versus 3.7±0.6; p<0.01). In the 
LV, significant expression of AT1R was also observed, chronic obesity associated with 




7.4.1 Major Findings  
The present study provides new mechanistic insights into the nature of ventricular substrate 
for SCD in obesity. Using a chronic ovine sheep model, ventricular remodelling due to 
chronic obesity was characterized by: 
1. Expansion ventricular epicardial fat depot (2.5 fold); 
2. Extensive and severe fat cell infiltrations; 
3. Diffuse ventricular interstitial fibrosis; 
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4. Reduction of the expression of ventricular desmosomal cadherin desmoglein-2 (15% 
reduction), with significant negative correlation with degree of fatty infiltration; 
5. Modulation of the TGF-b pathway, with greater expression of TGF-b receptor protein 
(2-4 fold); downregulation of the anti-fibrotic SMAD6; and no significant alteration 
in pSMAD3 levels; 
6. Overexpression of Angiotensin II receptor subtype 1; Aldosterone receptor protein, 
MCR; and endothelin receptor protein, ET-A. 
 
These important structural consequences to the ventricular myocardium may in part 
contribute to the development of SCD in obese individuals. 
 
7.4.2 Obesity and SCD  
Obesity has been shown to predict greater risk for SCD. Both overweight and obese BMI’s 
are reported to contribute from 33% to 79% elevated risk of premature death due to SCD.436 
Sub-analysis of the MADIT II trials showed significant association between obesity and 
ventricular tachycardia/fibrillation, and was shown to persist even after correcting for other 
clinical comorbidities.428 Moreover, BMI >25 kg.m-2 is positively correlated with higher 
incidence of non-sustained VT and 33% higher risk of exercise-induced VTAs independently 
of covariates.428, 466, 467 SCD requires an electrical trigger acting on vulnerable substrates to 
generate lethal ventricular tachyarrhythmias.309, 322, 458 QRS fragmentation (fQRS), which 
represents subtle scarring and myocardial substrate, has been described to be more common 
in obese SCD victims as compared to normal weight groups.454 Similarly, obesity has been 
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correlated with late potentials, signifying delayed activation in diseased myocardium and 
known marker for SCD, on signal-averaged ECGs.429  
 
7.4.3 SCD Substrate in Obesity 
The substrate for ventricular arrhythmias in obesity is not well investigated. In the summary 
Figure 7, a postulate based on the current study and available evidence is provided to suggest 
the mechanisms for the substrate for SCD in obesity.  
Obesity is associated with ventricular remodelling consisting of increased LV 
diameter and mass, eccentric hypertrophy, diastolic dysfunction, and repolarisation 
abnormalities.457 Additionally, LV systolic dysfunction468 and RV diastolic dysfunction457 
have been reported in the severely obese individuals. Furthermore, weight loss has been 
shown to be associated with improvements in diastolic function and LV mass, and RV 
systolic function.451 Our data was in line with previous reports457 and confirmed that severe 
sustained obesity is associated with elevation of left atrial pressure in the absence of systemic 
hypertension.  
Fibrosis plays an important role in the development of arrhythmias and is regarded as 
the histological cornerstone of structural remodelling that creates a substrate for 
arrhythmias.327, 455 Similarly, recent reports suggest significant association of epicardial fat 
expansion with increased frequency of premature ventricular contractions469, VT/VF470 and 
all-cause long-term mortality471 and mortality due to SCD471. The present study demonstrates 
increase in interstitial fibrosis with severe obesity, similar to non-ischemic 
cardiomyopathies.455 Furthermore, we also demonstrate the novel finding of fatty infiltration 
in the ventricles with severe obesity. We hypothesize, that akin to fibrosis, fatty infiltration 
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may predispose to conduction heterogeneity, re-entry and ventricular arrhythmias. Consistent 
with this, Pouliopoulos et al472 reported fibro-fatty interfaces within LV scar borders is 
significantly associated with altered electrophysiological remodelling and abnormal Cx43 
expression and that gradient increase in intramyocardial adiposity correlates with increased 
inducibility of VT following MI. 
Desmosomal mutations have been shown to result in fibro-fatty infiltration of the 
ventricles in arrhythmogenic right ventricular dysplasia (ARVD) by compromising myocyte 
adhesion and loss of further desmosomal proteins.473 In the present study, we observed a 
similar, but to a lesser extent, reduction in the expression of desmoglein-2 (DSG2), a 
desmosomal cadherin whose mutation is found in up a third of ARVD patients474. We 
propose that this reduction in DSG2 expression is the mechanistic link responsible for 
infiltration of ventricular muscle by overlying epicardial adipose tissue. Previous studies have 
shown that the epicardial adipose tissue secretes pro-fibrotic adipokines.278 The fatty 
infiltration could potentially potentiate the paracrine role of the epicardial fat by increasing 
the exposure of the cardiomyocytes to the pro-fibrotic factors.  
 
7.4.4 Molecular Mechanism of Fibro-fatty Infiltration  
The current study demonstrated activation of TGF-b, endothelin and RAAS pro-fibrotic 
pathways in severe obesity. TGF-b signalling is considered a central pathway in 
fibrogenesis.125, 475 The present study demonstrates that activation of the TGF-b pathway with 
associated with downregulation of SMAD6, but not pSMAD3 protein. Based on these 
findings, we propose that obesity-mediated TGF-b signalling is likely to be via SMAD-
independent component of this pathway. The current study also demonstrated activation of 
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the angiotensin II and aldosterone pathways by the overexpression of the pro-fibrotic AT1R 
and MCR. Both Ang II and aldosterone are important effectors of RAAS system and are 
shown to induce interstitial fibrosis and predispose to ventricular tachyarrhythmic events.475-
477 Previous studies have shown that aldosterone can also act independent of this system, with 
the activation of cardiac MCR resulting in hypertrophy, fibrosis, and heart failure 
independent of blood pressure levels.478 It is important to highlight the prime role of MCR, 
insofar as emerging data from human and in vivo animal studies report induction of cardiac 
fibrosis by the aldosterone/MCR pathway without concomitant increase in MCR ligand levels 
but only in receptor expression.475, 478 Furthermore, there was overexpression of endothelin 
receptor subtype A (ET-A), the receptor for the vasoconstricting endothelin 1 (ET-1). ET-
1/ET-A acts a downstream target of TGF-b gene transactivation and angiotensin II-induced 
fibrosis, and as an amplifier of the pro-fibrotic cascade.479  
 
7.4.5 Limitations 
We present strong evidence implicating obesity in ventricular remodelling. However, few 
limitations should be noted. First, our data is limited by its experimental nature. Although 
they have important implication for the understanding of potential mechanism driving SCD 
in obesity, we would need more translational studies to determine the clinical applications. 
Second, there are several methods for assessing molecular remodelling. Here, we were only 
able to evaluate some key receptors and downstream effector proteins due to the availability 
of appropriate reagents. Like downstream effector proteins, receptors are very good 
indicators of local perturbations. They are also better indicators of more chronic changes and 
so will be more useful in assessing effects of chronic obesity. Finally, we were not able to 
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ascertain the electrophysiological consequences of our structural findings. This was largely to 
do with high incidence of sudden cardiac death experienced during the electrophysiological 
study model. About eight of the obese sheep (≥110 kg) experienced several episodes of 
ventricular arrhythmia and subsequently sudden death with handling of the obese heart.  
 
7.4.6 Clinical Implication 
These findings highlight potential mechanisms that may explain the clinical associations 
reported between and obesity and expansion of epicardial fat and SCD. The novel finding of 
fibro-fatty substrates could form a key element in substrate mapping as a guide for ablation of 
lethal ventricular arrhythmias. EAT may represent an interesting risk marker to identify 
patients with increased SCD risk which could allow a more personalized risk stratification. 
Further studies are warranted to improve our understanding of EAT-mediated ventricular 
remodelling and to determine whether its reduction constitutes a treatment target for primary 
and secondary prevention of SCD. 
 
7.5 CONCLUSIONS 
Chronic sustained obesity promotes biventricular remodelling driven by diastolic 
dysfunction, expansion of ventricular epicardial fat depot with resultant fat cell infiltrations 
of the ventricular wall, and diffuse interstitial fibrosis. Molecular assessments suggest that 
these changes due to obesity may be mediated through DSG2 and abnormal SMAD3-
independent TGF-b signalling, Endothelin and RAAS activation respectively. The fibrofatty 
changes in the ventricles may represent a unique substrate for ventricular arrhythmias and 
sudden cardiac death in severe obesity. 
 









TABLE 1. Structural and Functional Characteristics 
 Parameters Controls Obese p-value 
 Body weight, kg 57.4±4.6 94.71±6.5 <0.001 
DEXA Total body fat, % 9.9±2.5 35.1±5.2 <0.001 
CMR Total EAT, ml 128±15 296±48 0.004 
 Ventricular EAT, ml 115.5±12 253.0±53 0.04 
 LVEF, % 67.6±4.5 73.2±5.2 0.11 
 LV mass, g 121.0±21 138.3±18 0.39 
 RVEF, % 52.7±7.5 57.5±5.9 0.422 
TTE LVEF, % 69±3.7 72±4.8 0.31 
 LVSD, mm 6.8±0.4 8.0±0.6 0.003 
 LVESD, mm 22.8±3.7 22.6±3.0 0.91 
 LVEDD, mm 37±4.9 42.8±4.0 0.07 
Haemodynamics  Systolic BP, mm Hg 69.6±12.5 74.5±12.5 0.50 
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Table 2. Myocardial Deformation and Strain 
 Parameters Controls Obese p-value 
LV Longitudinal strain mean 
(%) 
7.4±1.6 8.7±2.1 0.437 
 Radial strain mean (%) 15.0±4.4 17.6±2.9 0.593 
 Circumferential strain 
mean (%) 
12.1±2.5 12.2±2.4 0.994 
RV  Longitudinal strain mean, 
% 
17.6±3.2 15.6±3.1 0.639 
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TABLE 2. Summary of Major Pathomolecular Findings 
Parameters 
Left ventricle Right ventricle 
Control Obese p-value Control Obese p-value 
Fatty infiltration 1.7±0.5 3±0.9 0.03 1.8±0.9 3.2±1.2 0.03 
Desmoglein-2 (DSG-2, %) 47.7±4.9 40.2±1.1 0.02 54.1±7 46.6±3 0.04 
Percent fibrosis, % 5.2±0.9 13.2±2.8 0.002 5.9±0.9 14.8±6.1 0.01 
TGF-b receptor 1 (Tb1R, %) 5.6±1.6 13.4±7.2 0.02 4.7±2 16.9±5.6 0.001 
SMAD3, % 13.5±5.9 21±4.2 0.09 19.9±12 25.2±6.4 0.45 
SMAD6, % 5.8±1.3 1.8±0.3 0.001 6.9±0.9 2.6±0.4 0.001 
Endothelin receptor A (ET-A, %) 26.8±6.2 47.6±6 0.001 30.3±5.8 52.7±2.5 0.001 
Mineralocorticoid receptor (MCR, %) 43.4±6.2 55±3.3 0.002 41.1±7.7 54.4±3.1 0.003 
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7.7 FIGURE LEGEND 
Figure 1. Epicardial Fat Volume by Cardiac MRI 
Panel A: Representative CMR images in short-axis view, demonstrating the distribution of 
epicardial adipose tissue in the three study groups; ventricular EAT depots are highlighted 
with contours. Panel B: Three dimensional (3D) representations of the ventricular chambers 
reconstructed on CMR images. Panel C: Bar charts demonstrating quantified volumes of 
EAT; showing total cardiac, total ventricular, left and right ventricular EAT volumes, 
respectively. 
Figure 2. Fat Cell Infiltration 
Panel A: Representative H&E stained sections of the right ventricle and left ventricle; and 
Panel B: degree of fat cell infiltration of obese and control sheep, respectively. 
Abbreviation: LV, left ventricle; RV, right ventricle. Data: mean±SD. 
Figure 3. Desmosomal Remodelling 
Panels A, B: Relative protein expression of the desmosomal cadherin protein, desmoglein-2 
(DSG2) by immunostaining, showing photo-images and semi-quantitative assessment of 
protein expression; and Panel C: showing linear regression of grade infiltration and DSG2 
expression in obese animals, with data pooled from both ventricles. Bar: 100 µm. Data: 
mean±SD. 
Figure 4. Ventricular Fibrosis 
Panel A: Representative Masson’s trichrome stained sections demonstrating collagen 
depositions of the RV and LV. Panel B: Quantitative data showing percent fibrosis in the 
myocardial tissue. Data: mean±SD. 
Figure 5. Remodelling of Transforming Growth Factor Pathway 
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Relative protein expression of members of the TGF-β family by immunostaining, showing 
model signalling of the pathway (Panel A); presentative photo-image (Panel B) and semi-
quantitative assessment of protein expression TGF-β1 receptor (Panel C), phosphorylated 
SMAD3 (Panel D), and SMAD6 protein (Panel E); Bar: 50 µm. Data: mean±SD. 
Abbreviation: pSMAD3, phosphorylated sma and mother against decapentaplegic 
homologue protein 3; SMAD6, SMAD protein 6; TGF-β1, transforming growth factor-beta 
1; TβRI, TGF-β1 receptor subtype 1. 
Figure 6. Remodelling of Further Pro-fibrotic Pathways 
Further remodelling of pro-fibrotic pathways showing relative expression (Panel A) and 
semi-quantitative data for endothelin-1 receptor, (Panel B, ET-A); aldosterone receptor, 
(Panel C, MCR); and angiotensin II receptor, (Panel D, AT1R). Bar: 100 µm. Data: 
mean±SD. Abbreviations: AT1R, angiotensin II receptor type 1; MCR, mineralocorticoid 
receptor; ET-A, endothelin type A receptor 
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8. Chapter Eight 
Final Discussion and Implication 
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8.1 Translational Outlook 
The present thesis has investigated important aspects of the developments of atrial fibrillation 
and sudden cardiac death in obesity, establishing epicardial fat expansion and fibro-fatty 
infiltrations as prerequisite events. It has provided strong clinical evidence to establish 
epicardial fat as an independent risk modifier for atrial fibrillation. The findings further 
highlight obesity as a modifiable risk marker for sudden cardiac death independent of high-
risk traditional factors and conditions. More importantly, the observations provided evidence 
for a mechanistic link between cardiac ectopic fat and arrhythmogenic substrates, which has 
advanced our understanding of the mechanistic predispositions to atrial fibrillation and 
sudden cardiac death in obesity. They have several important implications as they underscore 
the need for therapeutic strategies aimed at prevention and regression of the atrial and 
ventricular substrates. 
 
8.2 Epicardial Fat and Atrial Fibrillation 
Multifactorial aetiological basis for atrial substrate formation is well accepted as an 
explanation for the atrial fibrillation epidemic. It is understood that multiple important 
clinical conditions (including advanced age, hypertension, heart failure, type II diabetes, 
valvular heart disease and obstructive sleep apnoea), electrocardiographic and 
echocardiographic factors, and biomarkers predispose to increased propensity for AF. 
Notably, data also show that AF symptomatic burden increases with increasing number of 
these concomitant conditions in patients, and that they associate with greater risk of 
chronicity of the rhythm disorder. Nevertheless, the current global burden and lifetime risk of 
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atrial fibrillation are more than could be explained by traditional cardiovascular risk factors 
alone, which highlights the need to explore emerging risk modifiers.  
Obesity is implicated in precipitating AF risk and momentum is building to accurately 
characterise this association. Multiple lines of data have reported association of obesity with 
echocardiographic markers of atrial dysfunction and atrial enlargement, and markers of 
cardiac autonomic tone dysfunction and inflammation. Moreover, AF and obesity are parallel 
burgeoning global conditions, persisting even in the wake of declining traditional risk factors. 
Among the factors implicated in this relation is galectin-3, a b-galactoside-binding 
lectin mainly secreted by macrophages and to a lesser extent by adipocytes and fibroblasts.379 
Gal-3 is has been shown to promote structural remodelling in a preclinical model of obesity. 
Herein, our data in Chapter 2 reports on the elegant relationship between Gal-3 and AF in a 
meta-analysis. We show that plasma Gal-3 is increased in patients with pre-existing AF 
compared to those in sinus rhythm. Our findings further demonstrated that high Gal-3 
predicts greater risk of AF, this association persisting even after adjusting for covariates.  
More recently, clinical reports have drawn our focus onto epicardial adipose tissue, an 
ectopic fat depot lying contiguously above the myocardium. It has been postulated to 
promote increased vulnerability to pro-arrhythmic states. Despite this, the relationship 
between epicardial fat and atrial fibrillation has not been properly defined. In chapter 3, the 
clinical associations of epicardial fat and atrial fibrillation, arrhythmia progression, recurrent 
atrial fibrillation following curative catheter ablation, and post-operative atrial fibrillation 
after cardiac surgery are presented in a meta-analysis. The findings demonstrated increased 
expansions of total cardiac and peri-atrial epicardial adipose, with greater risk of atrial 
fibrillation occurrence seen for every unit increment in epicardial fat, which persisted even 
after correcting for traditional cardiovascular risk factors and other measures of obesity. 
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Epicardial was associated with severity of atrial fibrillation, recurrence post-ablation, and de 
novo incidence after cardiac surgery. Further studies are warranted to facilitate the 
understanding of atrial remodelling due to EAT and determine whether its reduction 
constitutes a treatment target. The observations suggest possible mechanistic role for atrial 
fibrillation in obesity, thus warranting an understanding of the atrial substrate due to 
epicardial fat. 
 The pathogenesis of AF is driven by a complex interplay of ectopic foci and re-
entrant mechanisms acting on vulnerable atrial substrates. Evidence from a number of 
seminal studies has identified both structural and electrical abnormalities as requisite 
conditions for the formation of the AF substrates. Chapter 4 & 5 draw conclusions from the 
investigation of the key structural remodelling underpinning epicardial fat and AF 
relationships and how it influences electrical substrates in chronic ovine models of obesity 
and weight fluctuation. It has demonstrated that obesity induces expansion of epicardial fat 
hyperplasia and fibro-fatty replacement of atrial myocytes and deterioration of myocyte 
contractile apparatus, which may drive impairments of atrial electrical properties. It has also 
shown that weight fluctuation induces similar but less severe changes to those seen during 
stable obesity and that this may explain the increased risk of atrial arrhythmias often seen 
with periodic fluxes in weight. Importantly, these chapters have highlighted fibro-fatty 
infiltration as an important substrate for the pathogenesis of atrial fibrillation, which thus 
necessitates therapies targeting intramyocardial fat depositions. Taken together, our data 
strongly support the role of epicardial fat and fibro-fatty infiltrations as important pro-
arrhythmic substrates for atrial fibrillation in obesity. We speculate that, during obesity, Gal-
3 may mediate epicardial fat dysfunction and downstream atrial structural and electrical 
remodelling. Given the deregulation of adipokines during weight fluctuation, it is possible 
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that Gal-3 may be involved in the formation of atrial substrate; perhaps, by acting to via 
leptin signalling pathways.378, 480  
 
8.3 Epicardial Fat and Sudden Cardiac Death 
The premature death due to sudden cardiac death represents a significant public health 
burden. Despite the decline in overall burden of total cardiac mortality, the proportion due to 
sudden cardiac has remained largely unchanged and, in some reports, has demonstrated a 
steady increase overtime. Moreover, population-based epidemiologic data demonstrates that 
half of the crude rates of SCD occur in patients without apparent high-risk features, such as 
myocardial infarction, inherited channelopathies, ischaemic and non-ischaemic 
cardiomyopathies, or impaired heart function. There is growing body of data suggesting that 
this burden of SCD might be driven by the rising prevalence of obesity in the community. 
Chapter 6 reports the findings from a systematic review and meta-analysis undertaking to 
define the association between obesity and sudden cardiac death. In the analysis involving 
over 1.4 million patients, underweight body mass index was associated with an increased risk 
of sudden cardiac death. Importantly, obesity predicted an exaggerated risk for sudden 
cardiac death even after correcting for traditional high-risk features of sudden cardiac death. 
Similarly, unit increment in body mass index was shown to demonstrate a greater risk for 
sudden cardiac death. More crucially, these findings implicate the role of obesity in the risk 
of sudden cardiac death and the possibility of incorporating adiposity measures in SCD risk 
stratification 
   Much akin to atrial fibrillation, sudden cardiac death is driven by abnormal cardiac 
electrical activities. However, the potential mechanistic drivers of the ventricular substrate for 
 
   
 
262 
sudden cardiac death in obesity are not known. In chapter 7, the molecular and structural 
substrates for ventricular arrhythmias that lead to sudden cardiac death in a model of chronic 
obesity are presented. Obesity demonstrated two-and-half-fold expanded ventricular 
epicardial fat depot with a consequent extensive and severe fat cell infiltrations. There was 
significant reduction in ventricular desmosomal cadherin desmoglein-2, which demonstrated 
significant negative correlation with the degree of fatty infiltration. Additionally, obesity was 
associated with induction of diffuse ventricular interstitial fibrosis. The findings further 
demonstrated that obesity results in significant abnormal modulation of fibrotic pathways, 
including an alternative component of the central transforming growth factor-beta 1 pathway, 
angiotensin II, endothelin and aldosterone signalling pathways.  
The observation of epicardial fat expansion is particularly noteworthy as this adds an 
important extra layer to the stratification of patients at risk of sudden cardiac death. Indeed, 
there are few reports showing epicardial fat could predict greater risk for premature 
ventricular complexes, ventricular tachycardia/fibrillation, all-cause long-term mortality, and 
mortality due to sudden cardiac death in stable coronary artery disease.469, 470 Furthermore, 
the novel finding of fibro-fatty substrates in the ventricular myocardium could be sufficient to 
create conduction blocks, leading to re-entrant ventricular tachycardia/fibrillation and sudden 
cardiac death.481 More importantly, the fibro-fatty deposits could form a key element in 
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9. Chapter Nine 
Current Challenges and Future Directions 
  
 
   
 
264 
The findings made during this doctoral thesis have provided crucial understanding of the 
clinical and mechanistic relationships between epicardial fat and cardiac arrhythmias and 
sudden cardiac death. They indeed have far reaching implication for management strategies 
for atrial fibrillation and sudden cardiac death. However, these observations raise some 
important questions, which would need to be addressed in future research. 
 
9.1 Epicardial Fat: Challenges and Concluding 
Remarks 
The findings reported therein have demonstrated expansion of epicardial fat as a prerequisite 
for the development for atrial fibrillation and sudden cardiac death, using a multimodal 
approach involving meta-analysis and animal models. However, the incorporation of this 
ectopic cardiac fat in risk models is likely to be met with challenges, inasmuch as there is 
inconsistency in the literature regarding what constitute epicardial adipose tissue and 
pericardial adipose tissue. As noted in the thesis, whereas epicardial fat pertains to the fat 
lying contiguously with the myocardium, pericardial fat is a loose term used to describe the 
totality of fat depots found around the heart. It incorporates both “epicardial fat” and another 
adipose tissue “paracardial fat”, which is located externally to the parietal pericardial layer or 
membrane.412, 413 As a drawback, ambiguity in distinguishing these fat zones could lead to 
overestimation or underestimation of the reported values of epicardial fat. Therefore, further 
studies are highly warranted to establish consensus on these definitions and clearly evaluate 
the risks associated with each fat depot. 
 Although this thesis robustly implicates mechanistic relationship between epicardial 
fat and sudden cardiac death, evidence for clinical association is very scant. Further studies 
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are warranted to thoroughly define this clinical relations and strategies to improve outcomes 
of patients at risk of sudden cardiac death.  
 
9.2 Fibro-fatty Infiltrations: Opportunities for 
Dynamic Risk Profiling 
This thesis has demonstrated extensive and severe fat cell infiltrations with induction of 
diffuse interstitial fibrosis because of epicardial fat hyperplasia. This represents a uniquely 
novel substrate for cardiac arrhythmias and sudden cardiac death due to obesity.  
Use of fibro-fatty infiltrations for accurate profiling of sudden cardiac death risk in the 
general low-risk communities but with high events rates would make an exciting research 
endeavour. However, with apparent limitations in imaging modalities, clinical and non-
invasive characterisation of zones of fibro-fatty infiltrates would likely be a major challenge. 
Nonetheless, there is some glimmer of hope, with emerging data demonstrating spatial 
overlap VT/VF circuits on electroanatomic maps and reconstructed CT images in the post-MI 
heart. Clinical utility of this approach would require extensive validation studies. 
 
9.3 Obesity Relapse: The Bottleneck in Management 
Strategies 
The benefits of weight loss have been demonstrated in both non-randomised and randomised 
trials. However, long-term sustenance of weight loss remains a major challenge in clinical 
practice.344 We previously reported that 5% or more fluctuation in weight counteracts the 
effects of initial weight loss in reducing the burden of cardiac arrhythmias.345 Importantly, the 
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findings reported in this thesis implicate an underlying remodelling in the myocardial tissue 
of weight fluctuation animals compared to reference controls despite having comparable 
amounts of epicardial fat. These observations highlight a likely induction of unique cytokine 
profiles by the cyclic fluxes in weight. Further research is very needed to clarify this 
bottleneck. More importantly, better strategies are warranted to effectively prevent relapse in 
obesity following weight management regimes.  
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